Clinical Chemistry

International Journal of Laboratory Medicine and Molecular Diagnostics

Volume 42, 1996
AUTHOR INDEX

NOTE: Authors of 1996 Annual Meeting abstracts are indexed in the June Annual Meeting Supplement, pp. S316–S324.

Abendschein, D. R. See Jaffe, A. S.
Ablondi, F. See Denti, L.
Abraham, P. See Richie, J. P. Jr.
Actor, J. K. See Smith, D. F.
Adam, B. W. See Chace, D. H.
Adam, O. See Pussard, E.
Adams, G. A. See Perkins, S. L.
Adams, M. J. See Gunter, E. W.
Adamson, E. See Liu, C.
Adessi, G. L. See Mularoni, A.
Aebi, C. See Grey, V.
Aebi, Y. See Zhang, C.-X.
Aegerter, P. See Muller, F.
Aggarwal, S. K. See Baird, G. S.
Agnani, G. See Mularoni, A.
Aigrain, Y. See Muller, F.
Akcay, F. See Yildiz, L.
Åkerman, K. K.; Jolkkonen, J.; Parviainen, M.; Penttilä, I. (benzodiazepines, HPLC), 1412
Akman, S. A. See Rodriguez, H.
Alba, A. See Martin, A.
Alban, A. See Rodriguez-Segade
Albers, J. J. See Marcovina, S. M.
Albertioni, F.; Rask, C.; Eksborg, S.; Poulsen, J. H.; Pettersson, B.; Beck, O.; Schroeder, H.; Peterson, C. (methotrexate assay evaln.), 39
Alcantarilla, G.; Lozano, M. D. (aminoglycoside absorption), 771
Aleryani, S.; Kabakibi, A.; Cluette-Brown, J.; Laposata, M. (fatty acid ethyl ester synthase), 24
Alexandersen, P. See Overgaard, K.
Allain, J.-P. See Petrik, J.
Allen, E. M. See Pappas, J. B.
Alonsozana, G. L.; Christenson, R. H. (troponin T), 803
Alting, I. H. See Beyer, C.
Altinier, S. See Zaninotto, M.
Amann, D. See Dean, R. A.
Amante, A. J.; Kahan, B. D. (CsA monitoring), 1294
Amino, N. See Yamanishi, H.; See Kimura, S.
Amossé, J. See Ducros, V.
Andreu, L. See Martin, A.
Anguiano, A. See Tseng, R. W.
Annesi, G. See Muglia, M.
Ansell, R. J.; Ramström, O.; Mosbach, K. (artificial Abs), 1506
Antenucci, M. See Forni, F.
Antinozzi, R. See Dittadi, R.
Apple, F. S.; Lowe, M. C.; Googins, M. K.; Kloss, J. (thiocyanate conc. and renal function, letter), 1878
Arakawa, T. See Tominaga, K.
Arbez-Gindre, F. See Mularoni, A.
Ardakani, S. See Gomez, B. Jr.
Arenas, J. See Villena, V.
Arenas Barbero, J.. See Villena, V.
Armijo, J. A. See Sánchez, B. M.
Arribas, C. See Sánchez, B. M.
Arruda, J. C. See Martinelli, R. A.
Artur, Y. See Lecomte, E.
Ash, K. O. (cost cutting impacts), 822
Ashwood, E. R. (book author: Tietz Fundamentals of Clinical Chemistry), 1503
Astion, M. L.; Wener, M. H.; Hutchinson, K.; Olsen, G. B.; Orkand, A. R.; Pagliaro, L. J. (antinuclear Ab), 836
Auerbach, P. S. (point-of-care testing, letter), 2052
Aula, P. See Hietala, M.
Auricchio, S. See Sacchetti, L.
Ausili-Cefaro, G. See Forni, F.
Aveldaño, M. I.; Donnari, D. (adrenoleukodystrophy), 454
Avidor, B.; Zakut, H.; Kerem, B. (CF mutation), 103
Ayar, S. F.; Malone, R. W. (luciferase reporter genes), 1895
Azar, R. See Wu, A. H. B.
Bachorik, P. S. See Kafonek, S. D.
Badia, R. See de la Torre, R.
Baenziger, J. See Forrey, A. W.
Bailey, A. See Martinez, J. J.
—; Martinez, J. J.; Fenwick, R.; Leon, J. A. (fragile X syndrome diag.), 1890
Baird, G. S.; Fitzgerald, R. L.; Aggarwal, S. K.; Herold, D. A. (Pb: GC-MS), 286
Bakan, N. See Yildiz, L.
Baker, A. See Harris, N.
Balch, B. See Mallik, A. K.
Balderson, G. A. See Taylor, P. J.
Baldo, L. See Modenese, A.
Banner, W. Jr. See Pappas, J. B.
Barbas, C. F. III. See Liu, Q.
Barbeito, S. See Slobodianik, N. H.
Barbera, P. See Buttarello, M.
Bargellini, A. See Borella, P.
Barichello, M. See Dittadi, R.
Barioli, P. See Dittadi, R.
Barr, J. R.; Maggio, V. L.; Patterson, D. G. Jr.; Cooper, G. R.; Henderson, L. O.; Turner, W. E.; Smith, S. J.; Hannon, W. H.; Needham, L. L.; Sampson, E. J. (apo-AI: isotope diln.-MS), 1676
Barton, J. K. See Dandliker, P. J.
Bauer, C. R. See Vreman, H. J.
Baum, H. See Braun, S. L.
—; Obst, M.; Huber, U.; Neumeier, D. (troponin T), 474
Baumann, J. See Gonschior, A.-K.
Baxter, L. M. See Vreman, H. J.
Bayer, M. J.; McKay, C. (advances in poison management), 1361
Bayer, P. M. See Hübl, W.
Bean, P. (alcohol abuse detect. by transferrin, letter), 2049
Beaulieu, J. See Hollis, B. W.
Beck, O. See Albertioni, F.; See Helander, A.
Becker, M. M. See Hall, T.; See Matsuda, E.
Beerendonk, C. C. M. See Derkx, F. H. M.
Bellanger, L. See Delage, V.
Bellido, A. L. See Jover Sanz, E.
Ben Cheikh, A. See Matsuda, E.
Bénard, J. Y. See Schellenberg, F.
Benayas, C. G. See Villena, V.
Bender, E. W. See Laurino, J. P.
Bennett, D. See Carpenter, K. M.
Bennett, W. P. See Hruszkewycz, A. M.
Berger, D. M.; Dilly, K. A.; Williams, K. C.; Bustos, S. A. (*M. tuberculosis* and MAC detect. by amplifn.), 1894
Bergmann, P. See Peretz, A.
Bermejo-Barrera, A. See Bermejo-Barrera, P.
Bermejo-Barrera, P.; Moreda-Piñeiro, A.; Romero-Barbieto, T.; Moreda-Piñeiro, J.; Bermejo-Barrera, A. (hair Cd, AAS), 1287
Bermes, E. W. Jr. See Wei, T. Q.
Bernard, A.; Van Houte, G. (Clara cell protein, letter), 1120
Bernard, D. W.; Bowman, R. L.; Grimm, F. A.; Wolf, B. A.; Simson, M. B.; Shaw, L. M. (digoxin monitoring), 45
Berndt, C. See Henke, W.
Bernini, G. P. See Paci, A.
Berti, S. See Clerico, A.
Beyer, C.; Alting, I. H. (creatine in RBCs), 313
Beyne, P.; Letteron, P.; Hervé, C.; Roullet, J.-B.; Delacoux, E. (bilirubin interference, letter), 988
Bhagavan, N. V. See Honda, S. A. A.
Bhat, B. See Sanghvi, Y. S.
Bhatt, R. S. See Spitsbergen, M. P.
Biagini, A. See Clerico, A.
Bialk, P. See Braun, S. L.
Bianchi, G. See Mannello, F.
Bigelow, R. B. See Erali, M.
Biset, B. (software author: Clinical Cases Computer Aided Learning: Thyroid Disorders), 118
Bissbort, S. H. See Ungerer, J. P. J.
Bissé, E.; Renner, F.; Sußmann, S.; Schölmerich, J.; Wieland, H. (hair Fe content), 1270
Bissell, M. G. See James, O. A.
Bittikofer, J. (book reviewer: Clinical Chemistry, 3rd ed.), 1127
Biver, P. See Paci, A.
Bjøro, T. See Torjesen, P. A.
Blank, R. D.; Sklar, C. A.; Martin, M. L. (endocrine neoplasia), 598
Blankenstein, M. A. See van Duijnhoven, H. L. P.
—; van Duijnhoven, H. L. P. (correct PSA concs., letter), 1884
Blaschke, T. See Kastrissios, H.
Blassak, M.; Wick, J.; Mueller, R. (*Cryptosporidium* DNA detect.), 1891
Block, K. J. See Brown, E. N.
Blombäck, M. See Linder, R.
Blomberg, K. See Lövgren, T.
Bloomdahl, J. A. See Gibbs, W.
Bodenmüller, H. See Klein, G.
Boele, S. See Sillekens, P.
Boelens, Y. See van Eijsden, R.
Bohannon, J. A. See Chmielewski, S. A.
Bohner, J.; von Pape, K.-W.; Hannes, W.; Stegmann, T. (false-neg. troponin IA, letter), 2046
Bold, A. M. See Timms, P. M.
Boman, K. See Nilsson, T. K.
Bon, G. G. See van Kamp, G. J.
Bond, C. E.; Hodes, M. E. (*huntingtin* gene amplifn.), 773
Bonde, M.; Fledius, C.; Qvist, P.; Christiansen, C. (RIA: bone resorption), 1639
Bonin, B. See Chantin, C.
Booth, R. E. Jr. See Mariani, B. D.
Borella, P.; Bargellini, A.; Salvioli, S.; Cossarizza, A. (killer cell: AAS), 319
Bortolin, S.; Christopoulos, T. K. (RT-PCR and fluorometry for BCR-ABL mRNA, 1924
Bory, C. See Chantin, C.

Boschetti, N.; Brodbeck, U.; Jensen, S. P.; Koch, C.; Nørgaard-Pedersen, B. (acetylcholinesterase MAbs), 19
Boss, S. See Westgard, J. O.
Bost, M. See Vandenberghe, A.
Bott, M. See Cheung, J.
Boucherat, M. See Vandenberghe, A.
Boulieu, R. See Chantin, C.
Bouman, A. A.; de Ridder, C. M.; Nijhof, J. H.; Netelenbos, J. C.; Delemarre-vd Waal, H. A. (bone ALP: IA comparison), 1970
Bourke, J. See Iqbal, S. J.
Boutière, B. See Houbouyan, L.
Bowers, L. D.; Segura, J. (steroids and athletes), 999
Bowie, L. J. See Reddy, P. L.
Bowman, B. A. See Gunter, E. W.
Bowman, R. L. See Bernard, D. W.
Bowsher, R. R.; See Burge, M. R.
—; Voelker, J. R. (angiotensin, letter), 1501
Boyd, J. C. (book author: Statistical Bases of Reference Values in Laboratory Medicine), 1303
—; Felder, R. A.; Savory, J. (robotics and clin. lab.), 1901
Braganza, J. M. See Schofield, D.
Brancati, C. See Muglia, M.
Brandt, B.; Griwatz, C. (prostate-derived cell enrichment, letter), 1881
Braun, S. L.
—; Baum, H.; Neumeier, D.; Vogt, W. (troponins, letter), 781
—; Pongratz, D. E.; Bialk, P.; Liem, S.; Schlotter, B.; Vogt, W. (cardiac troponins), 2039
Braverman, L. E. (thyroid status in dis.), 174; See Pino, S.
Brenan, J. See Petroziello, J. M.
Brenna, S. See Zoppi, F.
Bridgi, B. See Marquet, P.-Y.
Brill, E. M. See Carville, D. G. M.
Brink, D. S. See Kelley, P. D.
Brock, A. See Petersen, N. E.
Brodbeck, U. See Boschetti, N.
Bronstein, I.; Martin, C. S.; Fortin, J. J.; Olesen, C. E. M.; Voyta, J. C. (chemilum., reporter gene assay), 1542
Brooks, K. E.; Smith, N. B. (lactate, GC), 1111
Brosnihan, K. B. See Chappell, M. C.
Brown, E. N.; McDermott, T. J.; Block, K. J.; McCollum, A. D. (IA, analyte), 893
Brown, J. F. Jr. See Silkworth, J. B.
Brunie, G. See Gérard, B.
Bruns, D. E. (Clin. Chem. journal new look), 5; See Pelkey, T. J.
Brux, B. See Jung, K.
Bryan, R. See Spitsbergen, M. P.
Budillon, G. See Castaldo, G.
Budker, O. See Levenson, C.
Bulian, P. See Buttarello, M.
Bures, K. See Suh, D. D.
Burge, M. R.; McLeod, J.; Bowsher, R. R.; Schade, D. S. (Coat-A-Count insulin, letter), 777
Burke-Payne, J. See Smith, D. F.
Burlingame, A. L. (book editor: Mass Spectrometry in the Biological Sciences), 1728
Burnett, L. See Chesher, D.
—; Hegedus, G.; Chesher, D.; Burnett, J.; Costaganna, G. (quality control), 2035
Burnett, J. See Burnett, L.
Burns, B. F. See Donnelly, J. G.
Burns, J. See Cheung, J.
Burritt, M. F. (clin. chem. in uncertain climate), 6
Burtis, C. A. (impact of converging technologies), 1735; (book author: Tietz Fundamentals of Clinical Chemistry), 1503
Burton, P. See Kastrissios, H.
Bussières, L. See Muller, F.
Bustos, S. A. See Berger, D. M.
Butler, I. J. See Tseng, B. S.
Butler, R. See Miki, K.
Butt, A. See Semra, Y.
Buttarello, M.; Bulian, P.; De Prà, M.; Barbera, P.; Rizzotti, P. (reticulocyte quant.), 1930
Cabanas, D. See Cheung, J.
Cacès, E. See Schellenberg, F.
Calcagno, G. See Castaldo, G.
Calzolari, C. See Rama, D.
Camiña, M. F. See Rodriguez-Segade
Candal, D. See Luo, C. C.
Candan, G. See Seven, A.
Cannon, D. J. (book reviewer: Cost Containment in the Clinical Laboratory), 1127
Cantero, M.; Conejo, J. R.; Jiménez, A. (lipemia interference, letter), 987
Capitanio, G. See Dittadi, R.
Capon, F. See Novelli, G.
Caputo, G. See Della Ciana, L.
Caratsch, T. See DiDomenico, N.
Carlson, J. See Cheung, J.
Carnero, A. See Rodriguez-Segade
Caro, J. F. See Considine, R. V.
Carobene, A. See Modenese, A.
Carpenter, K. M.; Durrant, L. G.; Morgan, K.; Bennett, D.; Hardcastle, J. D.; Kalsheker, N. A. (K-*ras* Val-12 mutation), 904
Carr, S. A. (book editor: Mass Spectrometry in the Biological Sciences), 1728
Carraro, P. See Zaninotto, M.
Caruthers, M. H. See Graff Yoerg, D. A.
Carville, D. G. M.; Dimitrijevic, N.; Walsh, M.; Digirolamo, T.; Brill, E. M.; Drew, N.; Gargan, P. E. (thrombus precursor protein), 1537
Casella, E. See Slobodianik, N. H.
Caspary, W. F. See Stein, J.
Castaldo, G.
—; Intrieri, M.; Calcagno, G.; Cimino, L.; Budillon, G.; Sacchetti, L.; Salvatore, F. (pseudouridine discrimination of ascites), 1843
—; Oriani, G.; Lofrano, M. M.; Cimino, L.; Topa, M.; Budillon, G.; Salvatore, F.; Sacchetti, L. (hepatocellular cancer and cirrhosis differentiation), 1263
Castellani, W. J. (software reviewer: Astute Statistics Add-in for Microsoft Excel for Windows), 1887
Cate, J. C. IV. See Papadea, C.
Caudill, S. P. See Gunter, E. W.
Cavé, H. See Gérard, B.
Cavicchini, A. See Novelli, G.
Cazurro, A. M. See Jover Sanz, E.
Cazzolato, G. See Dittadi, R.
Cazzuola, F. See Clerico, A.
Cecco, S. A. See Rehak, N. N.
Ceriotti, F. See Modenese, A.
Cesati, R.; Dolci, A. (Au overstaining in urine electrophoresis), 1293
Chabner, B. A. See Treon, S. P.
Chace, D. H.; Hillman, S. L.; Millington, D. S.; Kahler, S. G.; Adam, B. W.; Levy, H. L. (homocystinuria, MS-MS), 349
Chaing, S. H. See Rohlfs, E. M.
Chakraborty, J. See Frost, S. J.
Chamberlain, R. T. (clin. toxicologist role in court), 1337
Chan, S. See Patel, R.
Chan, S. D. H. See Gibbs, W.
Chang, J. See Laurino, J. P.
Chang, S. See Mate, K.
Chantin, C.; Bonin, B.; Boulieu, R.; Bory, C. (purine metab.), 326
Chapius-Cellier, C. See Poupon-Fleuret, C.
Chapkin, R. S. See Jiang, Y.-H.
Chapman, J. F. See Rohlfs, E. M.
Chapon, F. See Vandenberghe, A.
Chappell, M. C.; Brosnihan, K. B.; Ferrario, C. M. (angiotensin, letter), 1500
Charles, L. See Forrey, A. W.
Chaturvedi, P. See Natowicz, M. R.
Chauplannaz, G. See Vandenberghe, A.
Chazot, G. See Vandenberghe, A.
Cheesmar, R. (software author: Clinical Cases Computer Aided Learning: Thyroid Disorders), 118
Chemelli, B. See Nabbe, A.
Chen, F.-T. A. See Liu, M.-S.
Chen, H. See Levin, B. C.
Chen, Z.; Prestigiacomo, A.; Stamey, T. A. (PSA-ACT, letter), 1297
Chern, M.-S. See Wu, J. H.
Chesher, D. See Burnett, L.
—; Burnett, L. (Shewhart *p* control charts, lab. performance), 1478
Cheung, J.; Bott, M.; Burns, J.; Cabanas, D.; Carlson, J.; Clark, K.; McLaughlin, B.; Tran, L.; Vacquier, J. (*Chlamydia trachomatis* assay), 1890
Cheung, K.-L. See Law, L.-K.
Chien, C.-S. See Liu, C.-Y.
Chikamori, K. See Okabayashi, T. See Okabayashi, T.
Chikura, Y. See Eto, A.
Chmielewski, S. A.; Kurtock, D. K.; Jennings, S. A.; Bohannon, J. A.; Taylor, K. A.; McMannis, J. L.; Miller, E. E. (glucose monitoring, letter), 115
Chou, D. (Internet), 827; (software reviewer: Mosby's Diagnostic and Laboratory Test Infobase), 118
Chowdrey, P. E. See Stone, M. J.
Chretien, P. See Reddy, P. L.
Christenson, R. H. See Alonsozana, G. L.
Christians, U. See Streit, F.; See Gonschior, A.-K.
Christiansen, C. See Overgaard, K.; See Bonde, M.
Christopoulos, T. K. See Bortolin, S.
Chua, L.-H. See Lee, B.-L.
Cianflone, K. See Sniderman, A. D.
Ciarimboli, G. See Paci, A.
Cimino, L. See Castaldo, G.
Clark, K. See Cheung, J.
Clayton, S. S. See James, O. A.
Clerico, A.; Iervasi, G.; Grazia del Chicca, M.; Maffei, S.; Berti, S.; Sabatino, L.; Turchi, S.; Cazzuola, F.; Manfredi, C.; Biagini, A. (IRMA kit: natriuretic peptides), 1627
Cluette-Brown, J. See Aleryani, S.; See Hallaq, Y.
Cocco, G. See Dittadi, R.
Cody, L. See Honda, S. A. A.
Cohen, L. F.; Mohabeer, A. J.; Keffer, J. H.; Jialal, I. (troponin I), 1494
Coia, G.; Dolezal, O.; Hillyard, C. J.; Hudson, P. J.; Lilley, G. G. (HIV epitope tails, agglutination reagents), 1566
Cole, D. E. C.; Evrovski, J. (sulfite oxidase, letter), 654
Colin, A. A. See Rifai, N.
Collier, J.; Maguire, S.; Kyne, F. (Sarstedt Monovettes increase Ca results, letter), 1722
Comby, S. See Pittet, J.-L.
Comeau, F. See Merel, P.
Comhaire, F. See Schoonjans, F.
Conejo, J. R. See Cantero, M.
Conforti, F. L. See Muglia, M.
Considine, R. V.; Caro, J. F. (leptins), 843
Contant, G. See Houbouyan, L.
Contois, J. H. See Wu, A. H. B.
—; McNamara, J. R.; Lammi-Keefe, C. J.; Wilson, P. W. F.; Massov, T.; Schaefer, E. J. (apo A-1 ref. interval), 507
—; McNamara, J. R.; Lammi-Keefe, C. J.; Wilson, P. W. F.; Massov, T.; Schaefer, E. J. (apo B ref. interval), 515
Cooke, R. R.; McIntosh, J. E. A.; Murray-McIntosh, R. P. (cortisol), 249
Coombs, J. See Radike, E.; See Meixell, G.
Cooper, G. R. See Barr, J. R.
Copeland, B. E. See De, B. K.
Copeland, K. R. See Loun, B.
Copinschi, G. See L'Hermite-Balériaux, M.
Cornelis, R. See Zhang, X.
Cornillie, F. See Hompes, P. G. A.
Cortellini, P. See Denti, L.
Cortés, L. F. López. See Ruiz, M. Cruz
Cossarizza, A. See Borella, P.
Cosson, E. See Piketty, M.-L.
Costaganna, G. See Burnett, L.
Court, D. A. See Mulder, T. P. J.
Couttenye, M.-M.; Jurgens, A.; Lamberts, L. V.; Verpooten, G. A.; D'Haese, P. C.; De Broe, M. E. (Ca, storage sample), 468
Couvent, S. See Moreau, E.
Coyne, R. V. See Lin, M.-J.
Craig, W. Y.; Davis, A. E.; Poulin, S. E. (ELISA for autoAbs against LDL), 1709
Créminon, C. See Grassi, J.
Crifasi, J. See Long, C.
Crooks, R. See Dudman, N. P. B.
Croos, P. See Wheeler, M. J.
Cuny, C.; Pham, L.; Kramp, W.; Sharp, T.; Soriano, T. F. (PSA, IRMA), 1243
Custer, L. J. See Franke, A. A.
Cuypers, Th. See Sillekens, P.

Czarnecki, M. See Fuith, L. C.
Dafforn, A. See Ullman, E. F.; See Patel, R.
Dallapiccola, B. See Novelli, G.
Damen. M. See Sillekens, P.
Dandliker, P. J.; Holmlin, R. E.; Barton, J. K. (thymine dimer repair), 1898
Dandliker, W. B. See Walker, G. T.
Darnige, L. See Guillerm, C.
Datta, P.; Xu, L.; Malik, S.; Landicho, D.; Ferreri, L.; Halverson, K.; Roby, P. V.; Zebelman, A. M.; Kenny, M. A. (digoxin IAs), 373
D'Auriol, L. See Gérard, B.
Dautzenberg, M. D. See Houbouyan, L.
Davalian, D. See Ullman, E. F.
Davé, S. J. See Euler, D. E.
Daver, A. See Marquet, P.-Y.
Davidson, G. See Miki, K.
Davidson, L. A. See Jiang, Y.-H.
Davie, M. W. J. See Sharp, C. A.
Davis, A. E. See Graig, W. Y.
De, B. K.; Karr, B. A.; Ghosn, S.; Copeland, B. E. (NIST SRM 909a vial accuracy), 1832
De Abreu, R. A. See Keuzenkamp-Jansen, C. W.
De Biasi, F. See Dittadi, R.
De Broe, M. E. See Couttenye, M.-M.
de Bruin, R. J. A. See Derkx, F. H. M.
De Buyzere, M. See Langlois, M.
De Cos, M. A. See Sánchez, B. M.
De Cubber, A. See Zhang, X.
de Fries, R. See Miura, Y.
De Giorgi, E. See Modenese, A.
de Jong, J. G. N. See Keuzenkamp-Jansen, C. W.
de Keijzer, M. H.; Korf, H.; Kusters, R. (ethanol stick meas., letter), 985
De Kimpe, J. See Zhang, X.
de la Torre, R.; Domingo-Salvany, A.; Badia, R.; Gonzàlez, G.; McFarlane, D.; San, L.; Torrens, M. (abused drug device testing), 1433
De Leenheer, A. P. See Stöckl, D.; See Thienpont, L. M.
De Moerloose, P. See Pittet, J.-L.
De Prà, M. See Buttarello, M.
de Ridder, C. M. See Bouman, A. A.
de Rijke, Y. B. See Demacker, P. N. M.
Dean, R. A.; Thomasson, H. R.; Dumaual, N.; Amann, D.; Li, T.-K. (ethanol, GC-MS), 367
DeBari, V. A. See Erickson, E. N. Jr.
Delacoux, E. See Beyne, P.
Delage, V.; Teulon, J.-M.; Bellanger, L.; Seguin, P.; Descotes, F.; Saez, S. (estrogen receptor), 1955
Delanghe, J. R. See Langlois, M. R.
Delemarre-vd Waal, H. A. See Bouman, A. A.
Delgado, R. M. See Hruszkewycz, A. M.
Della Ciana, L.; Caputo, G. (biosensor, urea), 1079
Delvecchio, V. G. See Petroziello, J. M.; See Singh, N. P.
Delves, H. T. (Pb screening, letter), 983
Demacker, P. N. M.; Toenhake-Dijkstra, H.; de Rijke, Y. B.; Stalenhoef, A. F. H.; Stuyt, P. M. J.; Willems, H. L. (triglyceremia, Friedewald formula), 1491
Demedts, P. See Maes, M.
Demers, L. M. (thyroid-function testing), 119
DeMoor, G. See Forrey, A. W.
Denamur, E. See Gérard, B.
Denti, L.; Pasolini, G.; Cortellini, P.; Ferretti, S.; Sanfelici, L.; Ablondi, F.; Valenti, G. (Lp(a), lipid metab. in prostate cancer), 1176
Depuydt, C. See Schoonjans, F.
Derkx, F. H. M.; de Bruin, R. J. A.; van Gool, J. M. G.; van den Hoek, M.-J.; Beerendonk, C. C. M.; Rosmalen, F.; Haima, P.; Schalekamp, M. A. D. H. (renin and prorenin), 1051
Descotes, F. See Delage, V.
Desnyder, R. See Maes, M.
Dessi, J. L. See Self, C. H.
Detraz, C. See Levenson, C.
Deuser, S. M. See Parvin, C. A.
Devaraj, S. See Jialal, I.
Devlin, R. F. See Walker, G. T.
D'Haese, P. C. See Couttenye, M.-M.
d'Herbomez, M. See Piketty, M.-L.
Diagle, F. See Letellier, M.
Diamandi, A. See Khosravi, M. J.
Diamandis, E. P. (molec. diagnostics automation), 7; See Hoffman, B. R.; See Randell, E. W.; See Zarghami, N.; See Ferguson, R. A.; See Melegos, D. N.
—; Yu, H.; Melegos, D. N. (PSA assays), 853
Dibbelt, L.; Vierke, G.; Wünsche, W. (PSA acty. and breast cancer, letter), 1721
DiDomenico, N.; Link, H.; Knobel, R.; Caratsch, T.; Weschler, W.; Loewy, Z. G.; Rosenstraus, M. (COBAS AMPLICOR for PCR), 1915
Digirolamo, T. See Carville, D. G. M.
Dilly, K. A. See Berger, D. M.
Dilouya, A. See Piketty, M.-L.
Dimitrijevic, N. See Carville, D. G. M.
Dimock, S. See Sanghvi, Y. S.
Dittadi, R.; Barioli, P.; Gion, M.; Mione, R.; Barichello, M.; Capitanio, G.; Cocco, G.; Cazzolato, G.; De Biasi, F.; Praturlon, S.; Antinozzi, R.; Gianneo, E. (tumor marker CYFRA21.1 standardization), 1634
Diver, M. J.; Jones, P. J.; Hughes, J. G.; Hipkin, L. J.; West, C. R. (FT_4 and T_3, letter), 1124
Dockter, J.; Kolk, D.; Myers, K.; Yang, Y.; McDonough, S.; Giachetti, C. (HCV RNA detect.), 1891
Dolci, A. See Cesati, R.
Dolezal, O. See Coia, G.
Dombernowsky, P. See Sölétormos, G.
Domingo-Salvany, A. See de la Torre, R.
Dommergues, M. See Muller, F.
Dongxing, Y. See Yaping, Z.
Donnari, D. See Aveldaño, M. I.
Donnelly, J. G.; See Koprowicz, K. T.; See Livesey, J. F.
—; Ooi, D. S.; Burns, B. F.; Goel, R. (lipase), 462
Donovan, L. See Kafonek, S. D.
Donovan, E. F. See Vreman, H. J.
D'Orazio, P. (thiocyanate interference, glucose, letter), 1124
Dorval, I. See Guillerm, C.
Doumas, B. T.; Eckfeldt, J. H. (bilirubin meas.), 845
Dourson, J.-L. See Lessinger, J.-M.
Dowdy, Y. G. See Eder, A. F.
Dowell, B. See Piironen, T.
Drew, N. See Carville, D. G. M.
D'Souza, A. See Wheeler, M. J.
Dubick, M. A. See Wade, C. E.
DuBois, D. See Pasloske, B. L.
Ducros, V.; Peoc'h, M.; Moulin, C.; Ruffieux, D.; Amossé, J.; Favier, A.; Pasquier, B. (Ti identn. by ICP-MS and ICP-OES), 1875
Dudman, N. P. B.; Guo, X. W.; Crooks, R.; Xie, L.; Silberberg, S. (homocysteine calibration), 2028
Duewer, D. L. See Margolis, S. A.
Duez, P.; Kumps, A.; Mardens, Y. (urinary organic acids: GC-MS), 1609
Duggan, R. (vit. D interference, letter), 113
Duhem, C. See Teissier, E.
Dumas, A. See Vandenberghe, A.
Dumaual, N. See Dean, R. A.
Dumez, Y. See Muller, F.
Dumont, A. See Piketty, M.-L.
Duncan, A. See Fleming, S. C.; See Robins, S. P.
Dupin, B. See Merel, P.
Dupuy, G. See Pittet, J.-L.
Durand, C. See Pittet, J.-L.
Duriez, P. See Teissier, E.
Durrant, L. G. See Carpenter, K. M.
Durst, R. A. See Rule, G. S.
Duthel, S. See Vandenberghe, A.
Duvison, M. Hebles. See Ruiz, M. Cruz
Dwivedi, P. See Martinelli, R. A.
Dybkjaer, L. See Rasmussen, K.
Eastman, J. W.; Wong, R.; Liao, C. L.; Morales, D. R. (neonate Hb screening), 704
Echave, J. See Villena, V.
Eckert, B. See Hoyle, N. R.
Eckfeldt, J. H. See Garg, U. C.; See Doumas, B. T.
Eder, A. F.; Dowdy, Y. G.; Gardiner, J. A. M.; Wolf, B. A.; Shaw, L. M. (ethylene glycol interference by LDH), 1489
Eerola, R. See Piironen, T.
Eggers, M. See Mallik, A. K.
Ehrenkranz, R. A. See Vreman, H. J.
Ehrmeyer, S. S. See Olafsdottir, E.
Ekangaki, A. See Mackenzie, I. M. J.
Eksborg, S. See Albertioni, F.
El-Deiry, W. S. See Velculescu, V. E.
El-Kadi, H. S. See Erickson, E. N. Jr.
El-Lamie, K. I. See Mabrouk, G. M.
Elia, M. See Jennings, G.
Elin, R. J. See Niemela, J. E.; See Rehak, N. N.
Elion, J. See Gérard, B.
Ellis, G. See Randell, E. W.
Elsey, T. S. See Taylor, K.
Emrich, R. (book author: Cost Containment in the Clinical Laboratory), 1127
Encuentra, A. L. See Villena, V.
Eppenberger, U. See Schlaeppi, J.-M.
Erali, M.; Bigelow, R. B.; Meikle, A. W. (ELISA, thyroglobulin), 766
Erickson, E. N. Jr.; Najmey, S. S.; Keil, L. B.; El-Kadi, H. S.; DeBari, V. A. (β_2-glycoprotein), 1116
Ericson, M. See Ullman, E. F.
Ernst, L. See Streit, F.
España, F.; Sánchez-Cuenca, J.; Estellés, A.; Gilabert, J.; Griffin, J. H.; Heeb, M. J. (PSA, macroglobulin), 545
Esposito, P. See Sacchetti, L.
Estellés, A. See España, F.
Estey, C. A.; Felder, R. A. (centrifn.), 402
Eswaren, S. See Smith, D. F.
Etienne, E. See Grassi, J.
Eto, A.; Oishi, T.; Nakano, N. I.; Chikura, Y. (g-glutamycltransferase ref. material), 2008
Ettinger, B. See Lin, M.-J.
Euler, D. E.; Davé, S. J.; Guo, H. (smoking: pentane excretion), 303
Evans, B. J. See Gomez, B. Jr.; See Robins, S. P.
Evans, D. (book author: Cost Containment in the Clinical Laboratory), 1127
Evrovski, J. See Cole, D. E. C.
Ezan, E. See Grassi, J.
Ezquieta, B.; Varela, J. M.; Jariego, C.; Oliver, A.; Gracia, R. (*CYP21B* mutation), 1108
Faergeman, O. See Jensen, H. K.
Faix, J. D. (T-uptake, letter), 342
Fallon, K. D. See Olafsdottir, E.
Fanaroff, A. A. See Vreman, H. J.
Fang, S.-L. See Pino, S.
Farley, J. (ALP stds., letter), 481
Favier, A. See Ducros, V.
Fay, J. See Spiehler, V.
Felder, R. A. See Estey, C. A.; See Boyd, J. C.
Feldt-Rasmussen, U. (autoAbs to thyroid), 160
Feng, Y. J. See Wu, A. H. B.
Fenwick, R. G. See Bailey, A.; See Guida, M.; See Wen, L. T.
Férard, G. See Lessinger, J.-M.
Ferguson, R. A.; Yu, H.; Kalyvas, M.; Zammit, S.; Diamandis, E. P. (PSA immunofluorometry), 675
Ferrajolo, A. See Sacchetti, L.
Ferrante, A. See Trnovsky, J.
Ferrario, C. M. See Chappell, M. C.
Ferreri, L. See Datta, P.
Ferrero, C. See Modenese, A.
Ferretti, S. See Denti, L.
Ferzli, C. See Singh, P.
Fields, H. A. See Manak, M. M.
Fiers, T. See Forrey, A. W.
Fievet, P. See Houbouyan, L.
Fiorentino, G. See Forni, F.
Firth, G. B. See Frost, S. J.
Fisher, D. A. (thyroid hormone variation), 135; See Martinez, J. J.
Fisher, M. E.; Watson, R. M. (HCV and HIV RNA target detect.), 1895
Fitzgerald, R. L.; Herold, D. A. (testosterone IA), 749; See Baird, G. S.
Fledius, C. See Bonde, M.
Fleetwood, M. K.; Quinton, L.; Wolfe, J.; Maturani, D.; Spandra, B.; Lebo, R. (PTH assay, letter), 1498
Fleming, S. C.; Duncan, A.; Russell, R. I.; Laker, M. F. (sugar probes), 445
Flückiger, J. See van Kamp, G. J.
Fogerson, R. See Spiehler, V.
Fok, T.-F. See Law, L.-K.

Ford, K. See Schlain, B.
Forni, F.; Zuppi, C.; Antenucci, M.; Ausili-Cefaro, G.; Marmiroli, L.; Fiorentino, G.; Giardina, B. (carboplatin, biochem. markers, letter), 1498
Forrey, A. W.; McDonald, C. J.; DeMoor, G.; Huff, S. M.; Leavelle, D.; Leland, D.; Fiers, T.; Charles, L.; Griffin, B.; Stalling, F.; Tullis, A.; Hutchins, K.; Baenziger, J. (electronic reporting), 81
Forsman, R. W. (lab. and managed care), 813; (book reviewer: Statistical Bases of Reference Values in Laboratory Medicine), 1303
Fortin, J. J. See Bronstein, I.
Franchello, A. See Slobodianik, N. H.
Franck, P.; Sallerin, J.-L.; Schroeder, H.; Gelot, M.-A.; Nabet, P. (fecal fat detn.), 2015
Franke, A. A.; Custer, L. J. (daidzein and genistein), 955
Frantz, D. (book author: Cost Containment in the Clinical Laboratory), 1127
Frantzen, I. See Sillekens, P.
Franz, W. M.; Remppis, A.; Kandolf, R.; Kübler, W.; Katus, H. A. (troponin T, letter), 340
Franzin, M. See Modenese, A.
Franzini, C. See Modenese, A.
French, C. See Passkiewicz, B.
Frengen, J. See Utgaard, J. O.
Frey, J. See Granouillet, R.
Fridlund, C. See Luo, C. C.
Frierson, H. F. Jr. See Pelkey, T. J.
Frobert, Y. See Grassi, J.
Frost, S. J.; Chakraborty, J.; Firth, G. B. (liposome IA), 874
Fruchart, J.-C. See Teissier, E.
Frush, H. See Schlain, B.
Fuchs, D. See Fuith, L. C.
Fuhrman, S. A. See Steffes, M. W.
Fuith, L. C.; Czarnecki, M.; Wachter, H.; Fuchs, D. (neopterin concs. in vagina), 1495
Fujiwara, H. See Seishima, M.
Fumagalli, C. See Zoppi, F.
Furihata, K. See Tozuka, M.
Fushimi, R. See Yamanishi, H.; See Kimura, S.
Gabriele, A. L. See Muglia, M.
Galpchian, V. See Harris, N.; See Rifai, N.
Gambino, R. (Fe status evaln., letter), 2053
Gangadharan, R. See Mallik, A. K.
García-Benayas, C. See Villena, V.
Gardiner, J. A. M. See Eder, A. F.
Garg, U. C.; Hanson, N. Q.; Tsai, M. Y.; Eckfeldt, J. H. (DNA extn.), 647
Gargan, P. E. See Carville, D. G. M.
Garrard, C. S. See Mackenzie, I. M. J.
Garrett, P. E. See Manak, M. M.
Gävert, M. See Kuronen, I.
Gazzanelli, G. See Mannello, F.
Geffroy, F. See Guillerm, C.
Gelot, M.-A. See Franck, P.
Geltman, E. M. See Jaffe, A. S.
Gérard, B.; Peponnet, C.; Brunie, G.; Cavé, H.; Denamur, E.; D'Auriol, L.; Monplaisir, N.; Simon, F.; Elion, J.; Grandchamp, B. (HIV, fluorometry), 696
Ghiara, J. See Liu, Q.
Ghosn, S. See De, B. K.
Giachetti, C. See Dockter, J.
Gianneo, E. See Dittadi, R.
Giardina, B. See Forni, F.
Gibbs, W.; Wada, H. G.; Chan, S. D. H.; Bloomdahl, J. A. (DNA and mRNA detect.), 1896
Giboudeau, J. See Guéchot, J.
Giguère, R. See McCann, M. T.
Gilabert, J. See España, F.
Gillen, J. L. See Steffes, M. W.
Gills, T. E.; May, W. E. (comments on defective NIST SRM 909a vials, letter), 1878
Gingerich, R. L. See Ma, Z.
Ginsburg, G. S. See Harris, N.
Gion, M. See Dittadi, R.
Giorgio, A. See Modenese, A.
Giraudi, V. See Slobodianik, N. H.
Gispen-de Wied, C. C. See Thijssen, J. H. H.
Giudicelli, J.-F. See Pussard, E.
Glass, M. See Radike, E.; See Meixell, G.
Glatz, J. F. C. See Kragten, J. A.
Gleixner, A.; Sauerwein, H.; Meyer, H. H. D. (clenbuterol detect. by HPLC/EIA), 1869
Goel, R. See Donnelly, J. G.
Goepp, J. G. K. (pediatric poisonings), 1356
Goldberger, B. A. (book editor: Handbook of Workplace Drug Testing), 485
Goldberg, D. M. (red wine resveratrol, letter), 113
Goldstein, A. P. See Honda, S. A. A.
Gomez, B. Jr.; Ardakani, S.; Evans, B. J.; Merrell, L. D.; Jenkins, D. K.; Kung, V. T. (pyridinium cross-links, MAb), 1168
Gonschior, A.-K.; Christians, U.; Winkler, M.; Linck, A.; Baumann, J.; Sewing, K.-F. (tacrolimus blood pattern), 1426
Gonzàlez, G. See de la Torre, R.
Gonzalez, J. See O'Malley, B. A.
Gonzalez-Villaseñor, L. I. See Manak, M. M.
—; Wu, K.; Manak, M. M. (*Borrelia burgdorferi* OspA sequence detect.), 1892
Googins, M. K. See Apple, F. S.
Góth, L.; Vitai, M. (hypocatalasemia, letter), 341
Gottfried, J. I. (book author: Cost Containment in the Clinical Laboratory), 1127
Gourmelin, Y. See Houbouyan, L.
Gracia, R. See Ezquieta, B.
Graff Yoerg, D. A.; Caruthers, M. H. (Ab nucleic acid detect.), 1897
Grandchamp, B. See Gérard, B.
Grandinetti, C. See Muglia, M.
Grandjean, P. See Guldager, B.
Granouillet, R.; Rascle, F.; Sicallac, P.; Raby, N.; Frey, J. (analyte detn.), 105
Grant, A. See Letellier, M.
Grassi, J.; Créminon, C.; Frobert, Y.; Etienne, E.; Ezan, E.; Volland, H.; Pradelles, P. (immunometric assay, haptens), 1532
Grazia del Chicca, M. See Clerico, A.
Green, T. R.; Swanson, J. R. (false Li detect., letter), 1302
Gregersen, N. See Jensen, H. K.
Gregory, J. F. III. See Pfeiffer, C. M.
Greiner-Mai, E. See Heinze, T.
Grey, V.; Perlas, M.; Aebi, C. (Hb A_{1c}, letter), 2046
Griffin, B. See Forrey, A. W.
Griffin, J. H. See España, F.
Grimm, F. A. See Bernard, D. W.
Grip, L. See Linder, R.
Griwatz, C. See Brandt, B.
Groome, N. P. See McConnell, D. S.
Gros, P. See Rama, D.
Groß, W. See Siekmeier, R.
Guder, W. G. See Ivandić, M.; See Schmolke, M.
Guéchot, J.; Laudat, A.; Loria, A.; Serfaty, L.; Poupon, R.; Giboudeau, J. (hyaluronan, hepatitis C), 558
Guerin, M. D. See Jenkins, M. A.
Gueron, I. C. See McCann, M. T.
Guida, M.; Fenwick, R. G.; Papp, A. C.; Snyder, P. J.; Sedra, M.; Prior, T. W. (Huntington dis. Southern transfer protocol), 1711
Guigueno, N. See Pussard, E.
Guillerm, C.; Lellouche, F.; Darnige, L.; Schandelong, A.; Geffroy, F.; Dorval, I. (coagulation factor V), 329
Guldager, B.; Jørgensen, P. J.; Grandjean, P. (IV EDTA and metal excretion), 1938
Gunter, E. W.; Bowman, B. A.; Caudill, S. P.; Twite, D. B.; Adams, M. J.; Sampson, E. J. (internatl. round robin for folate), 1689
Guo, H. See Euler, D. E.
Guo, X. W. See Dudman, N. P. B.
Gutman, S. (FDA's impact on lab. performance), 786
Haapiainen, R. See Hedström, J.
Haas, B. See Nauck, M.
Hachiya, T. See Seishima, M.
Haff, L.; Smirnov, I. P. (molec. diagnostics), 1898
Hall, K. S. See Yang, M.
Hall, T.; Nelson, N. C.; Matsuda, E.; Becker, M. M. (base mismatch detect.), 1893
Hallaq, Y.; Szczepiorkowski, Z. M.; Teruya, J.; Cluette-Brown, J. E.; Laposata, M. (fasting and fatty acids), 771
Hallbach, J. See Schmolke, M.
Halverson, K. See Datta, P.
Hamdan, H. See Martinez, J. J.
Hannes, W. See Bohner, J.
Hannon, W. H. See Barr, J. R.
Hansen, P. S. See Jensen, H. K.
Hansen, T. S. See Petersen, N. E.
Hanson, N. Q. See Garg, U. C.
Harbeck, R. (book author: Cost Containment in the Clinical Laboratory), 1127
Hardcastle, J. D. See Carpenter, K. M.
Härkönen, M. See Löfberg, M.
Harris, E. K. (book author: Statistical Bases of Reference Values in Laboratory Medicine), 1303
Harris, N. See Rifai, N.
—; Galpchian, V.; Rifai, N. (HDL methods), 738
—; Neufeld, E. J.; Newburger, J. W.; Ticho, B.; Baker, A.; Ginsburg, G. S.; Rimm, E.; Rifai, N. (LDL-cholesterol, direct assay), 1182
Harris, P. L. See James, O. A.
Hartmann, D. J. See Marquet, P.-Y.
Hase, K. See Kawamura, M.
Hashimoto, K. See Okabayashi, T. See Okabayashi, T.
Hastka, J.; Lasserre, J.-J.; Schwarzbeck, A.; Reiter, A.; Hehlmann, R. (Fe status), 718
Hatemi, H. See Seven, A.
Hatemi, S. See Seven, A.
Haukipuro, K. See Melkko, J.
Hayaishi, O. See Melegos, D. N.
Hayashi, S. See Kimura, S.
Hayashi, T. See Iwata, R.
Hedström, J.; Sainio, V.; Kemppainen, E.; Puolakkainen, P.; Haapiainen, R.; Kivilaakso, E.; Schauman, K.-O.; Stenman, U.-H. (trypsinogen), 685
Heeb, M. J. See España, F.
Heetebrij, R. See van Eijsden, R.
Hegedus, G. See Burnett, L.
Hehlmann, R. See Hastka, J.
Heinemann, G.; Vogt, W. (Va, AAS), 1275
Heinze, T.; Greiner-Mai, E. (CA 72-4), 472
Helal, B. O. See Piketty, M.-L.
Helal, S. A. A. See Mabrouk, G. M.
Helander, A.; Beck, O.; Jones, A. W. (alcohol consumption), 618
Helm, R. A. See Jortani, S. A.
Henderson, L. O. See Barr, J. R.
Hendrie, H. C. See Yang, M.
Henke, W.; See Jung, K.
—; Jung, M.; Jung, K.; Lein, M.; Schlechte, H.; Berndt, C.; Rudolph, B.; Schnorr, D.; Loening, S. A. (PSA, RT-PCR, letter), 1499
Herbeth, B. See Lecomte, E.
Hermens, W. T. See Kragten, J. A.
Hernanz, A. See Jariego, C. M.
Herold, D. A. See Baird, G. S.; See Fitzgerald, R. L.; See Summers, R. H.
Hervé, C. See Beyne, P.
Hickman, P. E. See McWhinney, B. C.
Hicks, J. M. B. (book author: Biochemical Basis of Pediatric Disease), 485
Hidaka, H. See Tozuka, M.
Hietala, M.; Aula, P.; Syvänen, A.-C.; Isoniemi, A.; Peltonen, L.; Palotie, A. (DNA-based carrier screening), 1398
Highsmith, W. E. See Stoerker, J.
—; Silverman, L. (automated molec. diagnostics), 1367
Hillman, S. L. See Chace, D. H.
Hillyard, C. J. See Coia, G.
Hipkin, L. J. See Diver, M. J.
Hobbs, H. H. See Marcovina, S. M.
Hodes, M. E. See Bond, C. E.; See Yang, M.
Hoffman, B. R.; Yu, H.; Diamandis, E. P. (PSA screening), 536
Hofmann, W. See Ivandić, M.
Hogan, C. (book author: Cost Containment in the Clinical Laboratory), 1127
Hogan, M. See Mallik, A. K.
Hoke, C. See Lin, M.-J.
Holcroft, J. W. See Wade, C. E.
Hollis, B. W.; Kamerud, J. Q.; Kurkowski, A.; Beaulieu, J.; Napoli, J. L. (vit. D), 586
Holloway, H. W. See Shetty, H. U
Holmlin, R. E. See Dandliker, P. J.
Holmquist, G. P. See Rodriguez, H.
Hompes, P. G. A.; Koninckx, P. R.; Kennedy, S.;

van Kamp, G. J.; Verstraeten, R. A.; Cornillie, F. (CA-125 marker in endometriosis), 1871
Honda, S. A. A.; Goldstein, A. P.; Morita, T.; Sugiyama, C.; Cody, L.; Rios, C. N.; Bhagavan, N. V. (PSA in acute illness), 1785
Hooper, J. (software author: Clinical Cases Computer Aided Learning: Thyroid Disorders), 118
Hørder, M. See Petersen, N. E.
Horsfall, K. See Werness, P.
Hoshino, H. See Takahashi, M.
Houbouyan, L.; Boutière, B.; Contant, G.; Dautzenberg, M. D.; Fievet, P.; Potron, G.; Vassault, A.; Gourmelin, Y. (anti-Xa meas.), 1223
Howell, R. M. See Manak, M. M.
Hoyle, N. R.; Eckert, B.; Kraiss, S. (electrochemilum.), 1576
Hristova, E. N. See Rehak, N. N.
Hruszkewycz, A. M.; Delgado, R. M.; Khan, M. A.; Bennett, W. P. (K-*ras* detect.), 1717
Hsieh, M.; Tsai, H.-F.; Yang, C.-Y.; Li, S.-Y. (Machado-Joseph dis. gene), 1889
Hu, D. See Luo, C. C.
Hubbs, L. M. See Kaufman, M. S.
Huber, U. See Baum, H.
Hübl, W.; Tlustos, L.; Bayer, P. M. (leukocyte differential), 1068
Hudson, P. J. See Coia, G.
Huff, S. M. See Forrey, A. W.
Hughes, J. G. See Diver, M. J.
Huiqin, C. See Yaping, Z.
Hunter, R. L. See Smith, D. F.
Hurwitz, C. See Stoerker, J.
Hutchins, K. See Forrey, A. W.
Hutchinson, K. See Astion, M. L.
Huthinson, P. See Iqbal, S. J.
Ichikawa, T. See Tozuka, M.
Ichikawa, Y. See Miura, Y.
Iervasi, G. See Clerico, A.
Imbrogno, E. See Muglia, M.
Impivaara, O. See Leino, A.
Inano, K. See Miida, T.
Inoue, T. See Takahashi, M.
Intrieri, M. See Castaldo, G.
Ioannou, P. C. See Lianidou, E. S.
Iqbal, S. J.; Whittaker, P.; Bourke, J.; Mumford, R.; Huthinson, P.; Le Van, L. W. (vit. D interference, letter), 112
Ireland, J. J. See McConnell, D. S.
Irvin, B. R. See Ullman, E. F.
Ishikawa, T. See Miura, Y.
Ishkanian, J. See Ullman, E. F.
Isoniemi, A. See Hietala, M.
Ito, H. See Iwata, R.
Itoh, N. See Ohta, M.
Ivandić, M.; Hofmann, W.; Guder, W. G. (urine protein expert system), 1214
Ivor, L. P. (payment for technologies), 1558
Iwata, R.; Hayashi, T.; Nakao, Y.; Yamaki, M.; Yoshimasa, T.; Ito, H.; Saito, Y.; Mukoyam, M.; Nakao, K. (endothelin-I, chemilum. EIA), 1155
Iyama, S. See Yamanishi, H.; See Kimura, S.
Jacobsen, D. W. (serum and RBC folates), 1579
Jaffe, A. S.; Landt, Y.; Parvin, C. A.; Abendschein, D. R.; Geltman, E. M.; Ladenson, J. H. (troponin I and LDH isoenzyme sensitivity), 1770
James, O. A.; Petersen, J. R.; Bissell, M. G.; Okorodudu, A. O.; Harris, P. L.; Clayton, S. S.; Mohammad, A. A. (sample retrieval time), 1571
Jandreski, M. A. See Wei, T. Q.
Jansen, J. B. M. J. See Mulder, T. P. J.
Jansson, J.-H. See Nilsson, T. K.
Jariego, C. M. See Ezquieta, B.
—; Hernanz, A. (organic acids, electrophoresis), 477
Jelsma, T. See van Eijsden, R.
Jenkins, D. K. See Gomez, B. Jr.
Jenkins, M. A.; Guerin, M. D. (protein sepn. by capillary electrophoresis, letter), 1886
Jennings, G.; Elia, M. (Br^- detn. after deproteinization), 1210
Jennings, S. A. See Chmielewski, S. A.
Jennings, V. See Smith, D. F.
Jensen, H. K.; Jensen, L. G.; Hansen, P. S.; Faergeman, O.; Gregersen, N. (LDL receptor gene validn. by DNA sequencing), 1140
Jensen, L. G. See Jensen, H. K.
Jensen, S. P. See Boschetti, N.
Jette, D. C.; Kreutz, F. T.; Malcolm, B. A.; Wishart, D. S.; Noujaim, A. A.; Suresh, M. R. (PSA epitope mapping), 1961
Jialal, I. See Cohen, L. F.
—; Devaraj, S. (LDL oxidn.), 498; See Li, D.
Jiang, Y.-H.; Davidson, L. A.; Lupton, J. R.; Chapkin, R. S. (PCR, gene expression), 227
JianHua, M.; ShiJue, C.; ZhiYun, N.; Yang, Z.; YongKun, H.; YongPing, L. (retinol-binding protein), 466
Jiménez, A. See Cantero, M.
Jixiang, C. See Yaping, Z.
Johansson, A. See Oroskar, A. A.
John, W. G. (Hb A_{1c} IA), 1874
Joist, J. H. See Kelley, P. D.
Jolkkonen, J. See Åkerman, K. K.
Jones, A. See Taylor, P. J.
Jones, A. W. See Helander, A.
Jones, P. J. See Diver, M. J.
Jørgensen, J. S.; Pedersen, J. B.; Pedersen, S. M. (neural networks), 604
Jørgensen, P. J. See Guldager, B.
Jortani, S. A. See Qazzaz, H. M. A. M.
—; Helm, R. A.; Valdes, R. Jr. (oleandrin inhibition of Na,K- ATPase), 1654
Jover Sanz, E.; Cazurro, A. M.; Bellido, A. L.; López Martín, I. M. (Lp(a), smoking, letter), 479
Jowitt, S.; Longlands, M. G.; Probert, D. E. (K variation with gel separators, letter), 1300
Jukkola, A. See Melkko, J.
Jung, K. See Henke, W.
—; Nowak, L.; Lein, M.; Henke, W.; Schnorr, D.; Loening, S. A. (metalloproteinase inhibitors), 2043
—; Stephan, C.; Lein, M.; Henke, W.; Schnorr, D.; Brux, B.; Schürenkämper, P.; Loening, S. A. (PSA), 1026
Jung, M. See Stein, J.; See Henke, W.
Jurgens, A. See Couttenye, M.-M.
Kabakibi, A. See Aleryani, S.
Kafonek, S. D.; Donovan, L.; Lovejoy, K. L.; Bachorik, P. S. (lipids in fingerstick blood), 2002
Kågedal, B. See Nilsson, L.
Kahan, B. D. See Streit, F.; See Amante, A. J.; See Napoli, K. L.
Kahler, S. G. See Chace, D. H.
Kaitsaari, M. See Leino, A.
Kalnovičová, T. See Kuracka, L.
Kalsheker, N. A. See Carpenter, K. M.
Kalyvas, M. See Ferguson, R. A.
Kamerud, J. Q. See Hollis, B. W.
Kampa, I. (book reviewer: OPSpecs Manual: Operating Specifications for Precision, Accuracy, and Quality Control, Expanded Edition), 990
Kandolf, R. See Franz, W. M.
Kao, J.-T. See Wu, J. H.
Kaplan, B. See Shaw, L. M.
Karhi, K. K. See Tiainen, P.
Karp, M. See Piironen, T.
Karr, B. A. See De, B. K.
Karst, L. See Tenner, K. S.
Kastrissios, H.; Nakano, M.; Burton, P.; Blaschke, T. (zalcitabine), 465
Kates, J. A. See Smith, K. M.
Katsuyama, T. See Tozuka, M.
Katus, H. A. See Franz, W. M.
Kaufman, D. See Shaw, L. M.
Kaufman, M. S.; Hubbs, L. M.; Melander, K. (alum effect on methamphetamine, letter), 1720
Kauppila, S. See Melkko, J.
Kawada, M. See Okabayashi, T. See Okabayashi, T.
Kawamura, M.; Hase, K.; Miyazaki, S. (LDL oxidn.), 644
Kawana, K. See Takahashi, M.
Kaynar, H. See Yildiz, L.
Kazarosyan, M. See Spencer, C. A.
Keffer, J. H. (thyroid-function testing), 125; See Cohen, L. F.; See Li, D.
Keil, L. B. See Erickson, E. N. Jr.
Kelleher, B.; O'Broin, S. (folate, letter), 652
Kelley, P. D.; Brink, D. S.; Joist, J. H.; Ritter, D. (LDH isoenzyme utilzn., letter), 1723
Kempe, T. See Levenson, C.
Kemppainen, E. See Hedström, J.
Kenemans, P. See van Kamp, G. J.
Kennedy, S. See Hompes, P. G. A.
Kenny, M. A. See Datta, P.; See Wu, C.
Kent, M. A. See Nelson, P. S.
Kerem, B. See Avidor, B.
Kernen, K. See O'Malley, B. A.
Kessimian, N. See Laurino, J. P.
Keuzenkamp-Jansen, C. W.; van Baal, J. M.; De Abreu, R. A.; de Jong, J. G. N.; Zuiderent, R.; Trijbels, J. M. F. (6-Mercaptopurine), 380
Khalifa, A. See Mabrouk, G. M.
Khan, M. A. See Hruszkewycz, A. M.
Khosravi, M. J.; Diamandi, A.; Mistry, J.; Lee, P. D. K. (ELISA, insulin-like growth factor-I), 1147
Kieft, K. A. See Krause, B. R.
Kievits, I.; Oudshoorn, P.; Kok, W. (NASBA for HIV-1 RNA), 1889
Kievits, T. See Sillekens, P.; See Nabbe, A.; See Top, B.
Kimura, S.; Iyama, S.; Yamaguchi, Y.; Hayashi, S.; Fushimi, R.; Amino, N. (Ca, enzyme assay), 1202
Kirakossian, H. See Ullman, E. F.
Kitagawa, Y. See Ohta, M.
Kivilaakso, E. See Hedström, J.
Klee, G. G. (T_3 meas.), 155
Klein, G.; Bodenmüller, H. (ALP stds., letter), 480
Klein, S. See Ma, Z.
Kloss, J. See Apple, F. S.
Knobel, R. See DiDomenico, N.
Koay, E. S. C. (book author: Primer of Chemical Pathology), 1887
Kobayashi, K. See Tominaga, K.
Koch, C. See Boschetti, N.
Koch, D. D. (eval. new technologies), 797
Koda, J. E. See Percy, A. J.
Kok, W. See Kievits, I.; See Nabbe, A.
Kolk, D. See Dockter, J.
Koninckx, P. R. See Hompes, P. G. A.
Koprowicz, K. T.; Ooi, D. S.; Donnelly, J. G. (dopamine effect on peroxidase, letter), 1502
Korf, H. See de Keijzer, M. H.
Korones, S. B. See Vreman, H. J.
Kost, G. J. (book author: Handbook of Clinical Automation, Robotics, and Optimization), 1728
Kragten, J. A.; van Nieuwenhoven, F. A.; van Dieijen-Visser, M. P.; Theunissen, P. H. M. H.; Hermens, W. T.; Glatz, J. F. C. (myoglobin, letter), 337
Kraiss, S. See Hoyle, N. R.
Kramp, W. See Cuny, C.
Krause, B. R.; Schork, N. J.; Kieft, K. A.; Smith, M. P.; Maciejko, J. J. (lipoprotein cholesterol assay comparison), 1996
Krause, M. S. Jr. (ISO 9001 benefits and pitfalls), 1561
Krauss, J. S. See Suh, D. D.
Kreutz, F. T. See Jette, D. C.
Kricka, L. J. (book editor: Nonisotopic Probing, Blotting, and Sequencing, 2nd ed.), 1127
Krikau, M. See van Kamp, G. J.
Krueger-Nielsen, S. See Whinna, H. C.
Kubic, V. L. (neonate hemoglobinopathies), 658
Kübler, W. See Franz, W. M.
Kubo, Y. See Okabayashi, T. See Okabayashi, T.
Kumps, A. See Duez, P.
Kung, V. T. See Gomez, B. Jr.
Küng, W. See Schlaeppi, J.-M.
Kuračka, L.; Kalnovičová, T.; Líška, B.; Turčáni, P. (CSF purines), 756
Kurkowski, A. See Hollis, B. W.
Kurn, N. See Patel, R.; See Ullman, E. F.
Kuronen, I.; Savolainen, K.; Gävert, M.; Mononen, I. (Kone Quartus evaln.), 335
Kurtock, D. K. See Chmielewski, S. A.
Kushida, K. See Takahashi, M.
Kusters, R. See de Keijzer, M. H.
Kyne, F. See Collier, J.
Lachin, M. See Zaninotto, M.
Lackner, K. J. See Schlosser, U.
Lacoste, L. See Merel, P.

Ladenson, J. H. See Jaffe, A. S.
Ladenson, P. W. (thyroid hyperplasia), 183
Laguenay, A. See Vandenberghe, A.
Lahoz, C.; Osgood, D.; Wilson, P. W. F.; Schaefer, E. J.; Ordovas, J. M. (apo E phenotype—genotype discrepancies), 1817
Lajarin, F.; Zaragoza, R.; Tovar, I.; Martinez-Hernandez, P. (lipids in anabolic steroids), 970
Laker, M. F. See Fleming, S. C.
Lamberts, L. V. See Couttenye, M.-M.
Lambrechts, A. C. See Top, B.
Lammi-Keefe, C. J. See Contois, J. H.
Landicho, D. See Datta, P.
Landt, M. See Ma, Z.
Landt, Y. See Jaffe, A. S.
Langlois, M. R.
—; Delanghe, J. R. (signif. of haptoglobin polymorphisms), 1589
—; Delanghe, J. R.; De Buyzere, M. (IgA and haptoglobin type relation, letter), 1722
Laposata, M. See Aleryani, S.; See Hallaq, Y.
Laragh, J. H. See Sealey, J. E.
Larsson, R. See Nilsson, L.
Larue, C. See Rama, D.
Lasserre, J.-J. See Hastka, J.
Latour, P. See Vandenberghe, A.
Laudat, A. See Guéchot, J.
Laurino, J. P.; Bender, E. W.; Kessimian, N.; Chang, J.; Pelletier, T.; Usategui, M. (CK-MB2, CK-MB, and myoglobin sensitivities), 1454
Law, L.-K.; Pang, C.-P.; Cheung, K.-L.; Fok, T.-F. (neonatal jaundice: cord biochem.), 1716
Law, T. See Rifai, N.
Le Guillouzic, D. See Piketty, M.-L.
Le Van, L. W. See Iqbal, S. J.
Leavelle, D. See Forrey, A. W.
LeBar, W. D. (*Chlamydia* diag.), 809
Lebo, R. See Fleetwood, M. K.
Lebtahi, R. See Piketty, M.-L.
Lecomte, E.; Herbeth, B.; Paille, F.; Steinmetz, J.; Artur, Y.; Siest, G. (apo and lipoprotein: heart dis.), 1666
Ledda, A. See Paci, A.
Lee, B.-L.; Chua, L.-H.; Ong, H.-Y.; Yang, H. G.; Wu, J.; Ong, C.N. (Al, HPLC), 1405
Lee, C. (interference with free cortisol), 1290
Lee, J. See Sassi, A. P.
Lee, P. D. K. See Khosravi, M. J.
Lee-Thomas, S. See Luo, C. C.
Leikin, J. B. (book author: Poisoning and Toxicology Handbook, 2nd ed.), 2054
Lein, M. See Henke, W.; See Jung, K.
Leino, A.; Impivaara, O.; Kaitsaari, M. (deoxypyridinoline and hydroxyproline monitoring), 2037
Leland, D. See Forrey, A. W.
Lellouche, F. See Guillerm, C.
Lembcke, B. See Stein, J.
Lemieux, B. See McCann, M. T.
Lemke, G. See Zhao, J. J.
Lemons, J. A. See Vreman, H. J.
Leon, J. A. See Martinez, J. J.; See Bailey, A.
Leonard, D. See Werness, P.
Leone, O. See Muglia, M.
Leroux-Roels, G. See Moreau, E.
Lessinger, J.-M.; Dourson, J.-L.; Férard, G. (lipase standardization), 1979
Letellier, M.; Lévesque, A.; Diagle, F.; Grant, A. (Technicon Immuno I evaln.), 1695
Lettéron, P. See Beyne, P.
Leutzinger, Y. See Richie, J. P. Jr.
Levato, C. See Novelli, G.
Levenson, C.
—; Detraz, C.; Budker, O. (oligonucleotide-protein purifn.), 1897
—; Kempe, T. (DNA deprotection), 1898
Lévesque, A. See Letellier, M.
Levin, B. C.; Chen, H.; Reeder, D. J. (mitochondrial DNA ref. std.), 1892
Levinson, S. S.; Maciejko, J. J. (LDL cholesterol, letter), 780
Levy, H. L. See Chace, D. H.
Lewis, L. M. See Parvin, C. A.
L'Hermite-Balériaux, M.; Copinschi, G.; Van Cauter, E. (growth hormone assays), 1789
Li, D.; Jialal, I.; Keffer, J. (troponins in renal dis., letter), 114
Li, S.-Y. See Hsieh, M.
Li, T.-K. See Dean, R. A.
Liang, H. K. (evaln. of poisoned patient), 1350
Lianidou, E. S.; Ioannou, P. C. (PABA and PASA: Tb-sensitized luminescence), 1659
Liao, C. L. See Eastman, J. W.
Libeer, J.-C. See Stöckl, D.
Liem, S. See Braun, S. L.
Lilja, H. See Piironen, T.
Lilley, G. G.See Coia, G.
Lin, M.-J.; Hoke, C.; Ettinger, B.; Coyne, R. V. (fructosamine assay), 244
Lin, S. H. See Singh, P.
Linck, A. See Gonschior, A.-K.; See Streit, F.
Linder, R.; Grip, L.; Olason, E.; Blombäck, M. (heparin monitoring), 1488
Lindmo, T. See Utgaard, J. O.
Link, H. See DiDomenico, N.
Linn, C. P. See Walker, G. T.
Líška, B. See Kuračka, L.
Liu, C.; See Potapova, O.
—; Adamson, E.; Mercola, D. (EGR-1 suppression), 1896
Liu, C.-Y.; Chien, C.-S. (methamphetamine, letter), 338
Liu, M.; Wang, G.-R.; Liu, T.-Z.; Tsai, K.-J. (xanthurenic), 397
Liu, M.-S.; Chen, F.-T. A. (DNA anal., electrophoresis), 1106
Liu, Q.; Ghiara, J.; Barbas, C. F. III (DNA binding proteins), 1893
Liu, R. H. (book editor: Handbook of Workplace Drug Testing), 485
Liu, T.-Z. See Liu, M.
Liu, Y. P. See Patel, R.
Livesey, J. F.; Donnelly, J. G.; Ooi, D. S. (cystinuria: HPLC), 1714
Lo, S. F. See Parvin, C. A.; See Scott, M. G.
Lo, S.-K. See Wu, J. H.
Lockitch, G. (book reviewer: Primer of Chemical Pathology), 1887
Loening, S. A. See Henke, W.; See Jung, K.
Loewy, Z. G. See DiDomenico, N.
Löfberg, M.; Tähtelä, R.; Härkönen, M.; Somer, H. (troponins, letter), 1126
Lofrano, M. M. See Castaldo, G.; See Sacchetti, L.
Logue, J. (federal reimbursements), 817
Loirat, C. See Muller, F.
Lojo, S. See Rodriguez-Segade
Long, C.; Crifasi, J.; Maginn, D. (thioridazine interference of phencyclidine, letter), 1885
Longlands, M. G. See Jowitt, S.
López-Encuentra, A. See Villena, V.
López Martin, I. M. See Jover Sanz, E.
Lorenzo, M. J. See Rodriguez-Segade
Loria, A. See Guéchot, J.
Lortat-Jacob, S. See Muller, F.
Lott, J. A.; Smith, D. A.; Mitchell, L. C.; Moeschberger, M. L. (anal. stability), 888
Loun, B.; Copeland, K. R.; Sedor, F. A. (myoglobin ultracentrifugation), 965
Lovejoy, K. L. See Kafonek, S. D.
Lövgren, J. See Piironen, T.
Lövgren, T. See Meriö, L.; See Piironen, T.
—; Meriö, L.; Mitrunen, K.; Mäkinen, M.-L.; Mäkelä, M.; Blomberg, K.; Palenius, T.; Pettersson, K. (dry reagent IA with fluorescent Eu and fluorometry), 1196
Lowe, M. C. See Apple, F. S.
Lozano, M. D. See Alcantarilla, G.
Luc, G. See Teissier, E.
Lundquist, P. See Nilsson, L.
Lundwall, A. See Piironen, T.
Luo, C. C.; Candal, D.; Hu, D.; Otten, R. A.; Schochetman, G.; Rayfield, M.; Lee-Thomas, S.; Fridlund, C.; Swanson, P.; Respess, R. (HIV-1 subtyping), 1891
Lupski, J. R. (Charcot—Marie—Tooth dis.), 995
Lupton, J. R. See Jiang, Y.-H.
Lynch, D. See van Kamp, G. J.
Lynch, S. V. See Taylor, P. J.
Lyngbak, M. See Rasmussen, K.
Ma, Z.; Gingerich, R. L.; Santiago, J. V.; Klein, S.; Smith, C. H.; Landt, M. (leptin RIA), 942
Mabrouk, G. M.; Helal, S. A. A.; El-Lamie, K. I.; Khalifa, A. (*c-erbB*-2 p185 and p53 EIA), 981
Maciejko, J. J. See Krause, B. R.; See Levinson, S. S.
Mackenzie, I. M. J.; Ekangaki, A.; Young, J. D.; Garrard, C. S. (NO and renals), 440
Mackrell, J. See Singh, N. P.
Maes, M.; Weeckx, S.; Wauters, A.; Neels, H.; Scharpé, S.; Verkerk, R.; Demedts, P.; Desnyder, R. (Vit. E, variability in serum concs.), 1824
Maffei, S. See Clerico, A.
Maggio, V. L. See Barr, J. R.
Maginn, D. See Long, C.
Maguire, G. A. See Taylor, K.
Maguire, S. See Collier, J.
Mäkelä, M. See Lövgren, T.
Mäkinen, M.-L. See Lövgren, T.
Malcolm, B. A. See Jette, D. C.
Malenfant, A.; Shirey, T.; Young, C. C. (thiocyanate interference, letter), 483
Malik, S. See Datta, P.
Mallik, A. K.; Eggers, M.; McMahon, M.; Gangadharan, R.; Powdrill, T.; Hogan, M.; Mendoza, L.; Balch, B. (chemilum. reporters, quant. detect.), 1573
Malmstrom, S. See Radike, E.; See Meixell, G.
Malone, R. W. See Ayar, S. F.
Manak, M. M. See Gonzalez-Villaseñor, L. I.
—; Gonzalez-Villaseñor, L. I.; Howell, R. M.; Weiblen, B. J.; Garrett, P. E.; Fields, H. A.; Schumacher, R. T. (HGV sequence detect.), 1892
Manfredi, C. See Clerico, A.
Mangels, J. I. (book author: Cost Containment in the Clinical Laboratory), 1127
Mannello, F.; Bianchi, G.; Gazzanelli, G. (PSA, saliva), 1110
Mannucci, P. M. See Tripodi, A.
Manzanos, J. A. See Villena, V.
Marconnet, P. See Rama, D.
Marcovina, S. M.; Hobbs, H. H.; Albers, J. J. (apo(a) kringle units), 436
Marcus, F. I. (titrating cardiovascular drugs), 1312
Mardens, Y. See Duez, P.
Margaritis, I. See Rama, D.
Margolis, S. A.; Duewer, D. L. (ascorbic acid in plasma and serum), 1257
Mariani, B. D.; Booth, R. E. Jr; Tuan, R. S. (PCR, orthopedic infections), 1890
Marmiroli, L. See Forni, F.
Marocchi, A. See Zoppi, F.
Marquet, P.-Y.; Daver, A.; Sapin, R.; Bridgi, B.; Muratet, J.-P.; Hartmann, D. J.; Paolucci, F.; Pau, B. (IRMA, thyroglobulin), 258
Marshall, W. J. (book author: Clinical Chemistry, 3rd ed.), 1127
Martin, A.; Andreu, L.; Orti, T.; Alba, A. (CK interference, letter), 1501
Martin, C. S. See Bronstein, I.
Martin, M. See Schellenberg, F.
Martin, M. L. See Blank, R. D.
Martinelli, R. A.; Arruda, J. C.; Dwivedi, P. (CF mutations), 14
Martinez, J. J. See Bailey, A.
—; Bailey, A.; Hamdan, H.; Fisher, D. A.; Leon, J. A. (endocrine neoplasia, gene sequencing), 1890
Martinez-Hernandez, P. See Lajarin, F.
Martiny-Baron, G. See Schlaeppi, J.-M.
März, W. See Nauck, M.; See Siekmeier, R.
Massov, T. See Contois, J. H.
Matadeen, J. See Wheeler, M. J.
Mate, K.; Chang, S.; Parsons, G. (IA simulation system), 1569
Matsuda, E. See Hall, T.
—; Nelson, N. C.; Ben Cheikh, A.; Becker, M. M. (multianalyte detect., chemilum.), 1894
Matsuo, S. See Ohta, M.
Matsuto, T. See Miida, T.
Maturani, D. See Fleetwood, M. K.
May, W. E. See Gills, T. E.
McCann, M. T.; Thompson, M. M : Gueron, I. C.; Lemieux, B.; Giguère, R.; Tucnman, M. (methylmalonic acid, GC-MS), 910
McCollum, A. D. See Brown, E. N.
McConnell, D. S.; Padmanabhan, V.; Pollak, T. B.;

Groome, N. P.; Ireland, J. J.; Midgley, A. R. Jr. (inhibin-A, immunochemilum.), 1159
McCormick, A. See Rosenson, R. S.
McDermott, T. J. See Brown, E. N.
McDonald, C. J. See Forrey, A. W.
McDonough, S. See Dockter, J.
McFarlane, D. See de la Torre, R.
McGlennen, R. C. (mutations pose challenges for molec. diagnostics lab.), 1582
McGrath, P. See Trnovsky, J.
McIntosh, J. E. A. See Cooke, R. R.
McKay, C. See Bayer, M. J.
McLaughlin, B. See Cheung, J.
McLeod, J. See Burge, M. R.
McMahon, M. See Mallik, A. K.
McMannis, J. L. See Chmielewski, S. A.
McNamara, J. R. See Contois, J. H.
—; Schaefer, E. J. (NCEP lipoprotein, letter), 651;
McWhinney, B. C.; Ward, G.; Hickman, P. E. (steroids, HPLC), 979
Mees, L. See Zhang, X.
Mehta, A. See Rama, N.; See Rodrigues, C.
Mehta, H. B.; Vold, B. S.; Minkin, S.; Ullman, E. F. (DELISA, diabetes), 263
Meikle, A. W. See Erali, M.
Meixell, G. See Radike, E.
—; Glass, M.; Malmstrom, S.; Coombs, J.; Slade, L.; Radike, E.; Tautkus, G.; Wu, L. (multianalyte detect.), 1895
Melander, K. See Kaufman, M. S.
Melegos, D. N. See Diamandis, E. P.
—; Diamandis, E. P.; Oda, H.; Urade, Y.; Hayaishi, O. (prostaglandin D synthase assay), 1984
—; Yu, H.; Diamandis, E. P. (prostaglandin, amniotic fluid), 1042
Melkko, J.; Kauppila, S.; Niemi, S.; Risteli, L.; Haukipuro, K.; Jukkola, A.; Risteli, J. (IA, procollagen), 947
Melser, R. See Sillekens, P.
Mendoza, L. See Mallik, A. K.
Menon, S. See Rama, N.; See Rodrigues, C.
Mercola, D. See Potapova, O.; See Liu, C.
Merel, P.; Dupin, B.; Comeau, F.; Lacoste, L.; Vezon, G. (DNA extn.), 1285
Meriö, L. See Lövgren, T.
—; Pettersson, K.; Lövgren, T. (MAb fluorometric assay), 1513
Merrell, L. D. See Gomez, B. Jr.
Meyer, H. H. D. See Gleixner, A.
Miall, P. See Stone, M. J.
Micillo, M. See Sacchetti, L.
Midgley, A. R. Jr. See McConnell, D. S.
Mifflin, T. E. (book reviewer: PCR Essential Data), 1503
Miida, T.; Nakamura, Y.; Inano, K.; Matsuto, T.; Yamaguchi, T.; Tsuda, T.; Okada, M. (preb$_1$-HDL in coronary artery dis.), 1992
Miki, K.; Butler, R.; Moore, D.; Davidson, G. (urine sugars, HPLC), 71
Miller, E. E. See Chmielewski, S. A.
Miller, N. E. See Nanjee, M. N.
Miller, W. G. (usefulness of ref. materials), 1733
Millington, D. S. See Chace, D. H.
Minatoguchi, S. See Seishima, M.
Minkin, S. See Mehta, H. B.
Mione, R. See Dittadi, R.
Mistry, J. See Khosravi, M. J.
Mitchell, L. C. See Lott, J. A.
Mitrunen, K. See Lövgren, T.
Mitsuhashi, M. See Miura, Y.; See Tominaga, K.
Miura, Y. See Tominaga, K.
—; Ichikawa, Y.; Ishikawa, T.; Ogura, M.; de Fries, R.; Shimada, H.; Mitsuhashi, M. (fluorometric detn. of mRNA), 1758
Miyazaki, S. See Kawamura, M.
Modenese, A.; Carobene, A.; Ferrero, C.; Ceriotti, F.; Franzini, C.; De Giorgi, E.; Franzin, M.; Giorgio, A.; Baldo, L. (cholesterol ref. method), 475
Modlin, D. See Werness, P.
Moeschberger, M. L. See Lott, J. A.
Mohabeer, A. J. See Cohen, L. F.
Mohamed-Ali, V.; Nagi, D. K.; Yudkin, J. S. (proinsulin, IRMA), 977
Mohammad, A. A. See James, O. A.
Moll III, F. See Singh, P.
Moller, J. See Rasmussen, K.
Mononen, I. See Kuronen, I.
Monplaisir, N. See Gérard, B.
Montagna, R. A. See Rule, G. S.
Moore, D. See Miki, K.
Moore, M. See Singh, N. P.
Morales, D. R. See Eastman, J. W.
Moran, R. F. (ref. method, letter), 112
Moreau, E.; Philippé, J.; Couvent, S.; Leroux-Roels, G. (TNF receptor interference), 1450
Moreda-Piñeiro, A. See Bermejo-Barrera, P.
Moreda-Piñeiro, J. See Bermejo-Barrera, P.
Morgan, C. L.; Newman, D. J.; Price, C. P. (immunosensors), 193
Morgan, K. See Carpenter, K. M.
Morgan, J. R. See Roth, C. M.
Moris, M. See Peretz, A.
Morita, T. See Honda, S. A. A.
Morland, H.; Smith-Kielland, A. (false-neg. with Emit amphetamine kit, letter), 1726
Morrison, S. (software author: Clinical Cases Computer Aided Learning: Thyroid Disorders), 118
Morrison, S. R. See Tietz, N. W.
Mosbach, K. See Ansell, R. J.
Moulin, C. See Ducros, V.
Mountain, P. J. See Westgard, J. O.
Moyer, T. P. (book reviewer: Handbook of Clinical Automation, Robotics, and Optimization), 1728
Mueller, R. See Blassak, M.
Muglia, M.; Leone, O.; Annesi, G.; Gabriele, A. L.; Imbrogno, E.; Grandinetti, C.; Conforti, F. L.; Naso, F.; Brancati, C. (detect. of $(CAG)_n$ repeats causing Huntington dis.), 1601
Mukoyam, M. See Iwata, R.
Mularoni, A.; Adessi, G. L.; Arbez-Gindre, F.; Agnani, G.; Nicollier, M. (RT-PCR quant. endometrial CFTR mRNA), 1765
Mulder, T. P. J.; Peters, W. H. M.; Court, D. A.; Jansen, J. B. M. J. (glutathione transferase), 416
Muller, F.; Dommergues, M.; Bussières, L.; Lortat-Jacob, S.; Loirat, C.; Oury, J.-F.; Aigrain, Y.; Niaudet, P.; Aegerter, P.; Dumez, Y. (biochem markers, renal function), 1855
Mumford, R. See Iqbal, S. J.
Muratet, J.-P. See Marquet, P.-Y.
Murray, L. M. See Sadler, W. A.
Murray-McIntosh, R. P. See Cooke, R. R.
Muthini, S. See Nelson, P. S.
Myers, K. See Dockter, J.
Nabbe, A.; Verwimp, M.; Oudshoorn, P.; Kok, W.; Chemelli, B.; Pope, L.; Kievits, T. (NASBA nucleic acid extractor), 1896
Nabet, P. See Franck. P.
Nadeau, J. G. See Walker, G. T.
Nagi, D. K. See Mohamed-Ali, V.
Najmey, S. S. See Erickson, E. N. Jr.
Nakamura, S. See Okabayashi, T. See Okabayashi, T.
Nakamura, Y. See Miida, T.
Nakano, K. See Ohta, M.
Nakano, M. See Kastrissios, H.
Nakano, N. I. See Eto, A.
Nakao, K. See Iwata, R.
Nakao, Y. See Iwata, R.
Nanjee, M. N.; Miller, N. E. (lipid microenzymatic assay), 915
Napoli, J. L. See Hollis, B. W.
Napoli, K. L.; Kahan, B. D. (sirolimus monitoring), 1943; See Streit, F.
Naso, F. See Muglia, M.
Natowicz, M. R.; Prence, E. M.; Chaturvedi, P.; Newburg, D. S. (leukodystrophy), 232
Nauck, M.
—; März, W.; Haas, B.; Wieland, H. (HDL), 424
—; März, W.; Wieland, H. (lipoprotein electrophoretic mobility), 1283
Navarro, J. A. See Villena, V.
Navarro-Gonzálvez, J. A. See Villena, V.
Needham, L. L. See Barr, J. R.
Neels, H. See Maes, M.
Nelson, J. C.; Wilcox, R. B. (T_4 assays), 146
Nelson, N. C. See Matsuda, E.; See Hall, T.
Nelson, P. S.; Muthini, S.; Kent, M. A.; Smith, T. H. (3′-terminal labeling), 1896
Netelenbos, J. C. See Bouman, A. A.
Neufeld, E. J. See Harris, N.
Neumeier, D. See Baum, H.; See Braun, S. L.
Newburg, D. S. See Natowicz, M. R.
Newburger, J. W. See Harris, N.
Newman, D. J. See Morgan, C. L.
Newton, C. R. (book author: PCR Essential Data), 1503
Ng, V. (book author: Cost Containment in the Clinical Laboratory), 1127
Niaudet, P. See Muller, F.
Nicollier, M. See Mularoni, A.
Niedbala, R. S. See Spiehler, V.
Nielsen, D. See Sölétormos, G.
Niemela, J. E. See Rehak, N. N.
—; Snader, B. M.; Elin, R. J. (platelet Mg), 744
Niemeyer, D. See Singh, N. P.
Niemi, S. See Melkko, J.
Nijhof, J. H. See Bouman, A. A.
Nilsson, L.; Lundquist, P.; Kågedal, B.; Larsson, R. (renal cyanate, letter), 482
Nilsson, T. K.; Thögersen, A. M.; Jansson, J.-H.; Boman, K. (Willebrand factor), 976
Nishimura, M. See Ohta, M.
Nissen, H. See Petersen, N. E.
Noma, A. See Seishima, M.
Nørgaard-Pedersen, B. See Boschetti, N.
Norris, R. L. G. See Taylor, P. J.
Noujaim, A. A. See Jette, D. C.
Novelli, G.; Capon, F.; Levato, C.; Cavicchini, A.; Dallapiccola, B. (spinal atrophies), 643
Nowak, L. See Jung, K.
Obayashi, H. See Ohta, M.
O'Broin, S. See Kelleher, B.
Obst, M. See Baum, H.
O'Connor, J. (software author: Clinical Cases Computer Aided Learning: Thyroid Disorders), 118
Oda, H. See Melegos, D. N.
Ogura, M. See Miura, Y.
Oh, W. See Vreman, H. J.
Ohta, K. See Ohta, M.
Ohta, M.; Obayashi, H.; Takahashi, K.; Kitagawa, Y.; Nakano, K.; Matsuo, S.; Nishimura, M.; Itoh, N.; Ohta, K. (glutamic acid decarboxylase RIA), 1975
Oishi, T. See Eto, A.
Okabayashi, T.; Takeda, K.; Kawada, M.; Kubo, Y.; Nakamura, S.; Chikamori, K.; Terao, N.; Hashimoto, K. (FT_4: equil. dialysis), 1616
Okada, M. See Miida, T.
O'Kane, D. J. See Tenner, K. S.
Okorodudu, A. O. See James, O. A.
Okumura, N. See Tozuka, M.
Olafsdottir, E.; Westgard, J. O.; Ehrmeyer, S. S.; Fallon, K. D. (Po_2 monitor), 392
Olason, E. See Linder, R.
Olesen, C. E. M. See Bronstein, I.
Oliver, A. See Ezquieta, B.
Ollagnon, E. See Vandenberghe, A.
Olsen, G. B. See Astion, M. L.
Olsen, M. See Smith, D. F.
Olson, E. N. See Tseng, B. S.
Oluwole, O. S. A. See Yang, M.
O'Malley, B. A.; Kernen, K.; Gonzalez, J. (PSA mRNA, RT-PCR), 1892
O'Neal, C. L.; Poklis, A. (lidocaine: HPLC), 330
Ong, C.N. See Lee, B.-L.
Ong, H.-Y. See Lee, B.-L.
Ooi, D. S. See Donnelly, J. G.; See Koprowicz, K. T.; See Livesey, J. F.
Ordovas, J. M. See Lahoz, C.
Oremek, G. M.; Seiffert, U. B. (PSA and exercise), 691
Oriani, G. See Castaldo, G.; See Sacchetti, L.
Orkand, A. R. See Astion, M. L.
Oroskar, A. A.; Rasmussen, S.-E.; Rasmussen, H. N.; Rasmussen, S. R.; Sullivan, B. M.; Johansson, A. (ELISA, amplicons), 1547
Orsetti, A. See Rama, D.
Orti, T. See Martin, A.
Osgood, D. See Lahoz, C.
Osikowicz, G. See Schlain, B.
Otten, R. A. See Luo, C. C.

Ou, C.-N.; Rognerud, C. L. (Hb variants), 774
Oudshoorn, P. See Nabbe, A.; See Kievits, I.
Oury, J.-F. See Muller, F.
Overgaard, K.; Alexandersen, P.; Riis, B. J.; Christiansen, C. (bone ALP), 973
Paci, A.
—; Ciarimboli, G.; Biver, P. (digitalis-like factors, placenta), 270
—; Ledda, A.; Ciarimboli, G.; Biver, P.; Bernini, G. P. (ouabain EIA), 648
Padmanabhan, V. See McConnell, D. S.
Pagana, K. D. (software author: Mosby's Diagnostic and Laboratory Test Infobase), 118
Pagana, T. J. (software author: Mosby's Diagnostic and Laboratory Test Infobase), 118
Pagani, F. See Panteghini, M.
Pagliaro, L. J. See Astion, M. L.
Paille, F. See Lecomte, E.
Palenius, T. See Lövgren, T.
Pallaro, A. See Slobodianik, N. H.
Palotie, A. See Hietala, M.
Paloucek, F. P. (book author: Poisoning and Toxicology Handbook, 2nd ed.), 2054
Pang, C.-P. See Law, L.-K.
Panteghini, M.; Pagani, F. (myoglobin and CK-MB detect.), 1292
Paolucci, F. See Marquet, P.-Y.
Papadea, C.; Cate, J. C. IV (Hbs A, F, G, and C quantd.), 57
Paparo, F. See Sacchetti, L.
Papile, L.-A. See Vreman, H. J.
Papp, A. C. See Guida, M.
Pappas, J. B.; Allen, E. M.; Ross, M.; Banner, W. Jr. (amrinone), 761
Parker, H. L. See Petrik, J.
Parsons, G. See Mate, K.
Partanen, J. See Pastinen. T.
Parviainen, M. See Åkerman, K. K.
Parvin, C. A. See Jaffe, A. S.; See Scott, M. G.
—; Lo, S. F.; Deuser, S. M.; Weaver, L. G.; Lewis, L. M.; Scott, M. G. (point-of-care testing), 711
Pasloske, B. L.; Winkler, M.; DuBois, D. (HIV diagnostics), 1890
Pasolini, G. See Denti, L.
Pasquier, B. See Ducros, V.
Passey, R. B. (book reviewer: Tietz Fundamentals of Clinical Chemistry), 1503
Passkiewicz, B.; French, C. (folate, letter), 654
Pastinen. T.; Partanen, J.; Syvänen, A.-C. (DNA sequence screening), 1391
Patel, R. See Ullman, E. F.
—; Western, L.; Liu, Y. P.; Dafforn, A.; Chan, S.; Rose, S.; Kurn, N.; Ullman, E. F. (bacteria detect., DNA amplifn.), 1894
Patsches, M. See Schectman, G.
Patterson, D. G. Jr. See Barr, J. R.
Pau, B. See Marquet, P.-Y.; See Rama, D.
Paunio, T.; Reima, I.; Syvänen, A.-C. (blastomere DNA diagnosis), 1382
Pearson, G. M. See Petrik, J.
Pease, J. See Ullman, E. F.
Peddecord, K. M. (personnel stds.), 790
Pedersen, A.-M. H. See Rasmussen, K.
Pedersen, J. B. See Pedersen, S. M.; See Jørgensen, J. S.
Pedersen, S. M. See Jørgensen, J. S.
—; Jørgensen, J. S.; Pedersen, J. B.; (neural networks), 613
Pelkey, T. J.; Frierson, H. F. Jr.; Bruns, D. E. (tumor cell and micrometastases detect.), 1369
Pelletier, T. See Laurino, J. P.
Peltonen, L. See Hietala, M.
Pennington, C. See Schlain, B.
Penttilä, I. See Åkerman, K. K.
Peoc'h, D. See Sanghvi, Y. S.
Peoc'h, M. See Ducros, V.
Peponnet, C. See Gérard, B.
Péquériaux, N. C. V. See van Duijnhoven, H. L. P.
Peralta, F. G. See Sánchez, B. M.
Percy, A. J.; Trainor, D. A.; Rittenhouse, J.; Phelps, J.; Koda, J. E. (amylin IA), 576
Perebolte, L. See Top, B.
Peretz, A.; Moris, M.; Willems, D.; Bergmann, P. (bone ALP marker), 102
Perkins, S. L.; Adams, G. A. (Du Pont axial sepn. system), 1467
Perlas, M. See Grey, V.
Perry, C. A. See Wade, C. E.
Peter, J. B. See Robins, T.
Peters, W. H. M. See Mulder, T. P. J.
Petersen, N. E.; Nissen, H.; Hansen, T. S.; Rasmussen, K.; Brock, A.; Hørder, M. (porphyria, hydroxymethylbilane gene), 106
Petersen, J. R. See James, O. A.
Peterson, C. See Albertioni, F.
Petrik, J.; Pearson, G. M.; Parker, H. L.; Allain, J.-P. (HCV/HGBV-C PCR detect.), 1895
Petrick, M. See Reddy, P. L.
Petroziello, J. M.; Singh, N. P.; Scialla, T.; Brenan, J.; Delvecchio, V. G. (p53 gene mutation detect.), 1894
Pettersson, B. See Albertioni, F.
Pettersson, K. See Lövgren, T.; See Piironen, T.; See Meriö, L.
Pfeiffer, C. M.; Gregory, J. F. III (folate, reversed-phase chromatog.), 1847
Pham, L. See Cuny, C.
Phelps, J. See Percy, A. J.
Philippé, J. See Moreau, E.
Phillipov, G. (glucose challenge test), 255
Piga, N. See Pittet, J.-L.
Piironen, T.; Lövgren, J.; Karp, M.; Eerola, R.; Lundwall, A.; Dowell, B.; Lövgren, T.; Lilja, H.; Pettersson, K. (kallikrein), 1034
Piketty, M.-L.; d'Herbomez, M.; Le Guillouzic, D.; Lebtahi, R.; Cosson, E.; Dumont, A.; Dilouya, A.; Helal, B. O. (3 IAs, FT_3), 933
Pino, S.; Fang, S.-L.; Braverman, L. E. (urinary I⁻), 239
Pirio, M. See Ullman, E. F.
Pittet, J.-L.; De Moerloose, P.; Reber, G.; Durand, C.; Villard, C.; Piga, N.; Rolland, D.; Comby, S.; Dupuy, G. (D-dimer, ELISA), 410
Plebani, M. See Zaninotto, M.
Poklis, A. See O'Neal, C. L.
Pollak, T. B. See McConnell, D. S.
Pond, S. M. See Taylor, P. J.
Pongratz, D. E. See Braun, S. L.
Poole, J. M. See Qazzaz, H. M. A. M.
Pope, L. See Nabbe, A.
Porter, W. H. See Yao, H. H.
Potapova, O.; Liu, C.; Mercola, D. (cisplatin sensitizing), 1893
Potron, G. See Houbouyan, L.
Pouget, J. See Vandenberghe, A.
Poulin, S. E. See Graig, W. Y.
Poulsen, J. H. See Albertioni, F.
Poupon, R. See Guéchot, J.
Poupon-Fleuret, C.; Chapius-Cellier, C. (monoclonal Ig interference of PO_4, letter), 1298
Powdrill, T. See Mallik, A. K.
Pradelles, P. See Grassi, J.
Praturlon, S. See Dittadi, R.
Prence, E. M. See Natowicz, M. R.
Prestigiacomo, A. See Chen, Z.
Pretto, C. See Smith, D. F.
Price, C. P. See Morgan, C. L.; See Stone, M. J.
Priebe, M. (triglyceride reagent, letter), 778
Prior, T. W. See Guida, M.
Probert, D. E. See Jowitt, S.
Puolakkainen, P. See Hedström, J.
Purschian, B. See Stein, J.
Pussard, E.; Guigueno, N.; Adam, O.; Giudicelli, J.-F. (serotonin, HPLC), 1086
Puustinen, A. See Tiainen, P.
Qazzaz, H. M. A. M.; Jortani, S. A.; Poole, J. M.; Valdes, R. Jr. (digoxin), 1092
Quijano, F. Recio. See Ruiz, M. Cruz
Quinteiro, C. See Rodriguez-Segade
Quinton, L. See Fleetwood, M. K.
Qvist, P. See Bonde, M.
Raby, N. See Granouillet, R.
Radike, E. See Meixell, G.
—; Coombs, J.; Malmstrom, S.; Glass, M.; Slade, L.; Meixell, G.; Wu, L. (fecal DNA isolation), 1897
Rainey, P. M.; Rogers, K. E.; Roberts, W. L. (phenytoin IA interference), 1645
Raisys, V. See Whinna, H. C.
Rajur, S. B. See Roth, C. M.
Rama, D.; Margaritis, I.; Orsetti, A.; Marconnet, P.; Gros, P.; Larue, C.; Trinquier, S.; Pau, B.; Calzolari, C. (troponin I in athlete), 2033
Rama, N. See Rodrigues, C.
—; Rodrigues, C.; Menon, S.; Mehta, A. (*M.tuberculosis* IS6110 amplifn.), 1895
Ramos, O. See Slobodianik, N. H.
Ramström, O. See Ansell, R. J.
Randell, E. W.; St. Louis, P. (glucose interference), 449
—; Diamandis, E. P.; Ellis, G. (PSA in children), 420
Rascle, F. See Granouillet, R.
Rask, C. See Albertioni, F.
Rasmussen, H. N. See Oroskar, A. A.
Rasmussen, K. See Petersen, N. E.
—; Moller, J.; Lyngbak, M.; Pedersen, A.-M. H.; Dybkjaer, L. (homocysteine ref. intervals), 630
Rasmussen, S.-E. See Oroskar, A. A.
Rasmussen, S. R. See Oroskar, A. A.
Ray, W. A. (drug effects in humans), 1306
Rayfield, M. See Luo, C. C.
Reber, G. See Pittet, J.-L.
Reddy, P. L.; Bowie, L. J.; Chretien, P.; Petrick, M. (a thalassemia sequencing), 1892
Reeder, D. J. See Levin, B. C.
Rehak, N. N.; Cecco, S. A.; Niemela, J. E.; Hristova, E. N.; Elin, R. J. (Mg and Ca electrodes), 880
Reiken, S. R. See Roth, C. M.
Reima, I. See Paunio, T.
Reinauer, H. See Withold, W.; See Stöckl, D.
Reiter, A. See Hastka, J.
Rej, R. (drugs and toxins in clin. lab. practice), 1305
Remaley, A. (book reviewer: Biochemical Basis of Pediatric Disease), 485
Remppis, A. See Franz, W. M.
Renner, F. See Bissé, E.
Respess, R. See Luo, C. C.
Richie, J. P. Jr.
—; Abraham, P.; Leutzinger, Y. (glutathione and cysteine), 1100
—; Skowronski, L.; Abraham, P.; Leutzinger, Y. (glutathione), 64
Ridgway, E. C. (thyroid gland failure), 179
Rifai, N.; Sakamoto, M.; Law, T.; Galpchian, V.; Harris, N.; Colin, A. A. (HPLC for ibuprofen in cystic fibrosis), 1812
Rifai, N. (book author: Biochemical Basis of Pediatric Disease), 485; See Harris, N.
Riis, B. J. See Overgaard, K.
Rimm, E. See Harris, N.
Rinker, A. D. See Tietz, N. W.
Rio, M. E. See Slobodianik, N. H.
Rios, C. N. See Honda, S. A. A.
Risteli, J. See Melkko, J.; See Sharp, C. A.
Risteli, L. See Melkko, J.; See Sharp, C. A.
Rittenhouse, H. See Strobel, S.
Rittenhouse, J. See Percy, A. J.
Ritter, D. See Kelley, P. D.
Rizzotti, P. See Buttarello, M.
Roberts, R. Q. (TLC anal., drugs), 1570
Roberts, W. L. See Rainey, P. M.
Robins, S. P.; Duncan, A.; Wilson, N.; Evans, B. J. (pyridinium crosslinks: biochem. markers), 1621
Robins, T.; Peter, J. B. (HIV drug-resistant mutants), 1891
Roby, P. V. See Datta, P.
Rodenhuis, S. See Top, B.
Rodrigues, C. See Rama, N.
—; Rama, N.; Menon, S.; Mehta, A. (*M.tuberculosis* ISI6110 amplifn.), 1896
Rodriguez, H.; Holmquist, G. P.; Akman, S. A. (ligation-mediated PCR), 1896
Rodriguez-Segade, S.; Camiña, M. F.; Carnero, A.; Lorenzo, M. J.; Alban, A.; Quinteiro, C.; Lojo, S. (IgA in diabetes), 1064
Rogers, K. E. See Rainey, P. M.
Rognerud, C. L. See Ou, C.-N.
Rohlfs, E. M.; Chaing, S. H.; Chapman, J. F. (fetal lung maturation, evaln. of RIMAD), 1861
Rolland, D. See Pittet, J.-L.
Romero-Barbieto, T. See Bermejo-Barrera, P.
Rose, N. C. See Stoerker, J.
Rose, S. See Patel, R.

Rosenberg, P. H. See Tiainen, P.
Rosenson, R. S.; McCormick, A.; Uretz, E. F. (blood viscosity values), 1189
Rosenstraus, M. See DiDomenico, N.
Rosenthal, P. (bilirubin meast. accuracy, letter), 1880
Rosmalen, F.; Haima, P. See Derkx, F. H. M.
Ross, M. See Pappas, J. B.
Roth, C. M.; Rajur, S. B.; Reiken, S. R.; Morgan, J. R.; Yarmush, M. L. (antisense modulation of inflammation), 1893
Roullet, J.-B. See Beyne, P.
Rouse, B. A. (epidemiology of abused drug use), 1330
Rubio, R. Vázquez. See Ruiz, M. Cruz
Rudolph, B. See Henke, W.
Ruffieux, D. See Ducros, V.
Ruibal, A. See van Kamp, G. J.
Ruiz, M. Cruz; Quijano, F. Recio; Cortés, L. F. López; Duvison, M. Hebles; Rubio, R. Vázquez (TNF shelf life), 670
Rule, G. S.; Montagna, R. A.; Durst, R. A. (DNA sequences, tagged liposomes), 1206
Russell, R. I. See Fleming, S. C.
Sabatino, L. See Clerico, A.
Sacchetti, L. See Castaldo, G.
—; Ferrajolo, A.; Salerno, G.; Esposito, P.; Lofrano, M. M.; Oriani, G.; Micillo, M.; Paparo, F.; Troncone, R.; Auricchio, S.; Salvatore, F. (Ab detect. in celiac dis.), 1838
Sacks, D. B. (amylin, diabetes), 494
Sadler, W. A.
—; Murray, L. M.; Turner, J. G. (TSH handling), 593
—; Murray, L. M.; Turner, J. G. (what does "functional sensitivity" mean?, letter), 2051
Saez, S. See Delage, V.
Sahota, A. See Yang, M.
Sainio, V. See Hedström, J.
Saito, K. See Seishima, M.
Saito, Y. See Iwata, R.
Sakamoto, M. See Rifai, N.
Salerno, G. See Sacchetti, L.
Sallerin, J.-L. See Franck, P.
Salvatore, F. See Castaldo, G.; See Sacchetti, L.
Salvioli, S. See Borella, P.
Sampson, E. J. See Gunter, E. W. ; See Barr, J. R.
San, L. See de la Torre, R.
Sánchez, B. M.; De Cos, M. A.; Peralta, F. G.; Arribas, C.; Armijo, J. A. (digoxin-like factor interference), 974
Sánchez-Cuenca, J. See España, F.
Sanfelici, L. See Denti, L.
Sanghvi, Y. S.; Swayze, E. E.; Peoc'h, D.; Bhat, B.; Dimock, S. (MMI linkage), 1897
Sano, H. See Seishima, M.
Santiago, J. V. See Ma, Z.
Sapin, R. See Marquet, P.-Y.
Sasse, E. A. See Schectman, G.
Sassi, A. P.; Yu, J.; Lee, J. (media for PCR fragments), 1897
Sauerwein, H. See Gleixner, A.
Savolainen, K. See Kuronen, I.
Savory, J. See Boyd, J. C.
Schade, D. S. See Burge, M. R.
Schaefer, E. J. See Contois, J. H.; See McNamara, J. R.; J. See Lahoz, C.
Schalekamp, M. A. D. H. See Derkx, F. H. M.
Schandelong, A. See Guillerm, C.
Schänzer, W. (steroid metab.), 1001
Schapiro, M. B. See Shetty, H. U
Scharpé, S. See Maes, M.
Schauman, K.-O. See Hedström, J.
Scheckenhofer, C. See Schlosser, U.
Schectman, G.; Patsches, M.; Sasse, E. A. (cholesterol variability), 732
Schellenberg, F.; Martin, M.; Cacès, E.; Bénard, J. Y.; Weill, J. (transferrin), 551
Schiebel, H.-M. See Streit, F.
Schiöler, V. See Sölétormos, G.
Schlaeppi, J.-M.; Eppenberger, U.; Martiny-Baron, G.; Küng, W. (chemilum. IA for endothelial growth factor), 1777
Schlain, B.; Frush, H.; Pennington, C.; Osikowicz, G.; Ford, K. (random access units), 725
Schlechte, H. See Henke, W.
Schlosser, U.; Lackner, K. J.; Scheckenhofer, C.; Schmitz, G. (calpastatin autoAbs), 1250
Schlotter, B. See Braun, S. L.
Schmid, R. See Utgaard, J. O.
Schmitz, G. See Schlosser, U.
Schmolke, M.; Hallbach, J.; Guder, W. G. (false-pos. for drug IAs in perazine-intoxicated patient, letter), 1725
Schnorr, D. See Henke, W.; See Jung, K.; See Jung, K.
Schochetman, G. See Luo, C. C.
Schoendorfer, D. See Spiehler, V.
Schofield, D.; Braganza, J. M. (antioxidant status of fluids), 1712
Schölmerich, J. See Bissé, E.
Schoonjans, F.; Depuydt, C.; Comhaire, F. (ROC plots, letter), 986
Schork, N. J. See Krause, B. R.
Schroeder, H. See Albertioni, F.; See Franck, P.
Schulte, U. See Withold, W.
Schumacher, R. T. See Manak, M. M.
Schürenkämper, P. See Jung, K.
Schwarzbeck, A. See Hastka, J.
Scialla, T. See Petroziello, J. M.
Scott, M. G. See Parvin, C. A.
—; Lo, S. F.; Parvin, C. A. (point-of-care testing, letter), 2052
Sealey, J. E.; Laragh, J. H. (renin and prorenin), 993
Seckinger, D. (strand displacement amplifn. and fluorescence polarizn., letter), 1720
Sedor, F. A. See Loun, B.
Sedra, M. See Guida, M.
Seely, B. L. See Summers, R. H.
Seguin, P. See Delage, V.
Segura, J. See Bowers, L. D.
Seibel, M. J. See Woitge, H. W.
Seiffert, U. B. See Oremek, G. M.
Seishima, M.; Takemura, M.; Saito, K.; Sano, H.; Minatoguchi, S.; Fujiwara, H.; Hachiya, T.; Noma, A. (ELISA for sol. Fas), 1911
Self, C. H.; Dessi, J. L.; Winger, L. A. (small molecule IAs), 1527
Semra, Y.; Butt, A.; Swaminathan, R. (ouabain excretion), 1949
Serfaty, L. See Guéchot, J.
Seven, A.; Seymen, O.; Hatemi, S.; Hatemi, H.; Yiğit, G.; Candan, G. (vit. E, lipid peroxidn.), 1118
Sewing, K.-F. See Streit, F.; See Gonschior, A.-K.
Seymen, O. See Seven, A.
Shankaran, S. See Vreman, H. J.
Sharp, C. A.; Davie, M. W. J.; Worsfold, M.; Risteli, L.; Risteli, J. (Paget dis. procollagen, letter), 1121
Sharp, T. See Cuny, C.
Shaw, L. M. See Eder, A. F.; See Bernard, D. W.
—; Kaplan, B.; Kaufman, D. (immunosuppressive drug toxic effects), 1316
Shetty, H. U.; Holloway, H. W.; Schapiro, M. B. (*myo*-inositol in CSF), 298
ShiJue, C. See JianHua, M.
Shimada, H. See Miura, Y.
Shirey, T. See Malenfant, A.
Shultz, E. K. (neural networks), 496
Sicallac, P. See Granouillet, R.
Siekmeier, R.; Wülfroth, P.; Wieland, H.; Groß, W.; März, W. (LDL, smoking), 524
Siest, G. See Lecomte, E.
Silberberg, S. See Dudman, N. P. B.
Silberstein, L. E. See Stoerker, J.
Silkworth, J. B.; Brown, J. F. Jr. (environmental contaminant exposure), 1345
Sillekens, P.; van Deursen, P.; Frantzen, I.; Boele, S.; Melser, R.; Damen, M.; Cuypers, Th.; Kievits, T. (HCV RNA genotyping), 1889
Silverman, L. See Highsmith, W. E.
Simmonds, H. A. See Timms, P. M.
Simon, F. See Gérard, B.
Simson, M. B. See Bernard, D. W.
Sinatra, M. A. See Young, G. P.
Singh, N. P. See Petroziello, J. M.
—; Moore, M.; Niemeyer, D.; Mackrell, J.; DelVecchio, V. G. (p53 gene mutation detect.), 1894
Singh, P.; Moll III, F.; Lin, S. H.; Ferzli, C. (starburst dendrimers), 1567
Singh, R. See Ullman, E. F.
Singh, S. See Ullman, E. F.
Sklar, C. A. See Blank, R. D.
Skold, C. See Ullman, E. F.
Skovsgaard, T. See Sölétormos, G.
Skowronski, L. See Richie, J. P. Jr.
Slade, L. See Radike, E.; See Meixell, G.
Slavin, J. L. (phytoestrogens in milk), 841
Slobodianik, N. H.; Pallaro, A.; Rio, M. E.; Barbeito, S.; Strasnoy, I.; Franchello, A.; Casella, E.; Torales, M. R.; Giraudi, V.; Ramos, O. (proteins and IgA in AIDS patients), 471
Smirnov, I. P. See Haff, L.
Smith, C. H. See Ma, Z.
Smith, D. A. See Lott, J. A.
Smith, D. F.; Burke-Payne, J.; Actor, J. K.; Stults, N. L.; Pretto, C.; Eswaren, S.; Jennings, V.; Olsen, M.; Hunter, R. L. (mycobacterium and malaria detect. by biolum. hybridzn. IAs), 1894
Smith, F. A. See Westgard, J. O.
Smith, K. See Strobel, S.
Smith, K. M.; Kates, J. A. (regulatory hurdles), 1556
Smith, M. P. See Krause, B. R.
Smith, N. B. See Brooks, K. E.
Smith, S. J. See Barr, J. R.
Smith, T. H. See Nelson, P. S.
Smith-Kielland, A. See Mørland, H.
Snader, B. M. See Niemela, J. E.
Sniderman, A. D.; Cianflone, K. (apos, dyslipoproteinemia), 489
Snyder, P. J. See Guida, M.
Soldin, S. J. (book author: Biochemical Basis of Pediatric Disease), 485
Sölétormos, G.; Nielsen, D.; Schioler, V.; Skovsgaard, T.; Dombernowsky, P. (CA 15.3), 564
Somer, H. See Löfberg, M.
Soriano, T. F. See Cuny, C.
Spandra, B. See Fleetwood, M. K.
Spencer, C. A. (thyroglobulin and autoAbs), 661
—; Takeuchi, M.; Kazarosyan, M. (thyrotropin assays), 140
—; Takeuchi, M.; Kazarosyan, M. (thyroglobulin assays), 164
—; Takeuchi, M. ((what does "functional sensitivity" mean?, letter), 2051
Spiehler, V.; Fay, J.; Fogerson, R.; Schoendorfer, D.; Niedbala, R. S. (cocaine EIA), 34
Spitsbergen, M. P.; Whitney, S. E.; Wheeler, D.; Bryan, R.; Bhatt, R. S. (cycling probe assay), 1895
St. John, D. J. B. See Young, G. P.
St. Louis, P. See Randell, E. W.
Stalenhoef, A. F. H. See Demacker, P. N. M.
Stalling, F. See Forrey, A. W.
Stamey, T. A. (PSA sensitivity), 849; See Chen, Z.
Steffes, M. W.; Gillen, J. L.; Fuhrman, S. A. (lab. service to ICUs), 387
Stegmann, T. See Bohner, J.
Stein, J.; Jung, M.; Sziegoleit, A.; Zeuzem, S.; Caspary, W. F.; Lembcke, B. (pancreatic elastase), 222
—; Purschian, B.; Zeuzem, S.; Lembcke, B.; Caspary, W. F. (fecal CHOs), 309
Steinmetz, J. See Lecomte, E.
Stenman, U.-H. See Hedström, J.
Stephan, C. See Jung, K.
Stevenson, D. K. See Vreman, H. J.
Stigbrand, T. See Utgaard, J. O.
Stockigt, J. R. (monitoring thyroid dis.), 188
Stöckl, D. See Thienpont, L. M.
—; Libeer, J.-C.; Reinauer, H.; Thienpont, L. M.; De Leenheer, A. P. (proficiency testing), 469
Stoerker, J.; Hurwitz, C.; Rose, N. C.; Silberstein, L. E.; Highsmith, W. E. (Rh alleles), 356
Stoll, B. J. See Vreman, H. J.
Stone, M. J.; Chowdrey, P. E.; Miall, P.; Price, C. P. (Mg detn.), 1474
Stone, R. T. See Vreman, H. J.
Strasnoy, I. See Slobodianik, N. H.
Streit, F.; Christians, U.; Schiebel, H.-M.; Napoli, K. L.; Ernst, L.; Linck, A.; Kahan, B. D.; Sewing, K.-F. (sirolimus, HPLC), 1417

Strobel, S.; Smith, K.; Wolfert, R.; Rittenhouse, H. (PSA), 645
Stults, N. L. See Smith, D. F.
Stuyt, P. M. J. See Demacker, P. N. M.
Sugiyama, C. See Honda, S. A. A.
Suh, D. D.; Krauss, J. S.; Bures, K. (HbS and HbA, HPLC), 1113
Sullivan, B. M. See Oroskar, A. A.
Summers, R. H.; Herold, D. A.; Seely, B. L. (adrenal hyperplasia anal.), 1483
Suresh, M. R. See Jette, D. C.
Sußmann, S. See Bissé, E.
Swaminathan, R. See Semra, Y.
Swanson, J. R. See Green, T. R.
Swanson, P. See Luo, C. C.
Swayze, E. E. See Sanghvi, Y. S.
Sweetman, L. (newborn screening, MS-MS), 345
Switchenko, A. C. See Ullman, E. F.
Syrjälä, H. See Vuori, J.
Syvänen, A.-C. See Hietala, M.; See Paunio, T.; See Pastinen. T.
Szczepiorkowski, Z. M. See Hallaq, Y.
Sziegoleit, A. See Stein, J.
Tähtelä, R. See Löfberg, M.
Takahashi, K. See Ohta, M.
Takahashi, M.; Hoshino, H.; Kushida, K.; Kawana, K.; Inoue, T. (pentosidine, HPLC), 1439
Takeda, K. See Okabayashi, T. See Okabayashi, T.
Takemura, M. See Seishima, M.
Takeuchi, M. See Spencer, C. A.
Tautkus, G. See Meixell, G.
Taylor, K.; Elsey, T. S.; Thompson, S. P.; Maguire, G. A. (albumins, Ca interference), 332
Taylor, K. A. See Chmielewski, S. A.
Taylor, L. T. (book author: Analytical Supercritical Fluid Extraction), 2054
Taylor, P. J.; Jones, A.; Balderson, G. A.; Lynch, S. V.; Norris, R. L. G.; Pond, S. M. (tacrolimus, chromatog.), 279
Teissier, E.; Walters-Laporte, E.; Duhem, C.; Luc, G.; Fruchart, J.-C.; Duriez, P. (tocopherol in LDLs and HDLs), 430
Tenner, K. S.; Karst, L.; Thibodeau, S. N.; O'Kane, D. J. (Duchenne muscular dystrophy detect. by PCR), 1891
Terao, N. See Okabayashi, T. See Okabayashi, T.
Teruya, J. See Hallaq, Y.
Teulon, J.-M. See Delage, V.
Theunissen, P. H. M. H. See Kragten, J. A.
Thibodeau, S. N. See Tenner, K. S.
Thienpont, L. (estradiol workshop, letter), 1122; See Stöckl, D.
—; Van Landuyt, K. G.; Stöckl, D.; De Leenheer, A. P. (cholesterol), 531
Thijssen, J. H. H.; Gispen-de Wied, C. C.; van Heeswijk, G. M.; Veeman, W. (dexamethasone in saliva), 1238
Thögersen, A. M. See Nilsson, T. K.
Thomasson, H. R. See Dean, R. A.
Thompson, M. M. See McCann, M. T.
Thompson, S. P. See Taylor, K.
Thormann, W. See Zhang, C.-X.
Tiainen, P.; Puustinen, A.; Rosenberg, P. H.; Karhi, K. K. (glutathione transferase), 334
Tianshiu, L. See Yaping, Z.
Ticho, B. See Harris, N.
Tietz, N. W.; Rinker, A. D.; Morrison, S. R. (serum Fe), 109
Timms, P. M.; Simmonds, H. A.; Bold, A. M. (hypouricemia, letter), 985
Tlustos, L. See Hübl, W.
Toenhake-Dijkstra, H. See Demacker, P. N. M.
Tominaga, K.; Miura, Y.; Arakawa, T.; Kobayashi, K.; Mitsuhashi, M. (ELISA of mRNA with biotinylated mononucleotides), 1750
Top, B.; Lambrechts, A. C.; Perebolte, L.; van't Veer, L. J.; Rodenhuis, S.; Kievits, T. (breast tumor cell detect.), 1889
Topa, M. See Castaldo, G.
Torales, M. R. See Slobodianik, N. H.
Torjesen, P. A.; Bjoro, T. (Abs against testosterone, letter), 2047
Torrens, M. See de la Torre, R.
Tovar, I. See Lajarin, F.
Tozuka, M.; Hidaka, H.; Okumura, N.; Ichikawa, T.; Furihata, K.; Katsuyama, T. (IgA-l conjugated with LDH-5 isoenzyme), 1288
Trainor, D. A. See Percy, A. J.
Tran, L. See Cheung, J.
Treon, S. P.; Chabner, B. A. (high-dose methotrexate), 1322
Treskes, M. See van Duijnhoven, H. L. P.
Trijbels, J. M. F. See Keuzenkamp-Jansen, C. W.
Trinquier, S. See Rama, D.
Tripodi, A.; Mannucci, P. M. (activd. coagulation markers), 664
Trnovsky, J.; Weier, H.-U.; Ferrante, A.; McGrath, P. (chromosome sorting), 1897
Troncone, R. See Sacchetti, L.
Tsai, H.-F. See Hsieh, M.
Tsai, K.-J. See Liu, M.
Tsai, M. Y. (hyperhomocysteinemia), 492; See Garg, U. C.
Tseng, B. S.; Butler, I. J.; Olson, E. N. (myogenin gene sequence study), 1898
Tseng, R. W.; Anguiano, A. (Y chromosome sequencing), 1892
Tsuda, T. See Miida, T.
Tuan, R. S. See Mariani, B. D.
Tuchman, M. See McCann, M. T.
Tullis, A. See Forrey, A. W.
Turčáni, P. See Kuracka, L.
Turchi, S. See Clerico, A.
Turner, J. G. See Sadler, W. A.
Turner, W. E. See Barr, J. R.
Twite, D. B. See Gunter, E. W.
Tyson, J. E. See Vreman, H. J.
Ullén, A. See Utgaard, J. O.
Ullman, E. F. See Mehta, H. B.; See Patel, R.
—; Kirakossian, H.; Switchenko, A. C.; Ishkanian, J.; Ericson, M.; Wartchow, C. A.; Pirio, M.; Pease, J.; Irvin, B. R.; Singh, S.; Singh, R.; Patel, R.; Dafforn, A.; Davalian, D.; Skold, C.; Kurn, N.; Wagner, D. B. (lumin. O_2 channeling assay), 1518
Ungerer, J. P. J.; Bissbort, S. H. (pleural adenosine deaminases, letter), 1880
Uomoto, J. See Whinna, H. C.
Urade, Y. See Melegos, D. N.
Uretz, E. F. See Rosenson, R. S.
Usategui, M. See Laurino, J. P.
Utgaard, J. O.; Frengen, J.; Stigbrand, T.; Ullén, A.; Schmid, R.; Lindmo, T. (analyte binding assay read by flow cytometry), 1702
Väänänen, H. K. See Vuori, J.
Vacquier, J. See Cheung, J.
Vaks, J. E. (sample prepn.), 1074
Valdes, R. Jr. See Qazzaz, H. M. A. M.; See Jortani, S. A.
Valenti, G. See Denti, L.
Valentine, J. L. (book reviewer: Poisoning and Toxicology Handbook, 2nd ed.), 2054
van Baal, J. M. See Keuzenkamp-Jansen, C. W.
Van Cauter, E. See L'Hermite-Balériaux, M.
van den Bergh, F. A. J. T. M. See Vermes, I.
van den Hoek, M.-J. See Derkx, F. H. M.
van Deursen, P. See Sillekens, P.
van Dieijen-Visser, M. P. See Kragten, J. A.
van Duijnhoven, H. L. P. See Blankenstein, M. A.
—; Péquériaux, N. C. V.; van Zon, J. P. H. M.; Blankenstein, M. A. (PSA, cancer), 637
—; Treskes, M. (RBC volume interference), 76
van Eijsden, R.; Jelsma, T.; Heetebrij, R.; Boelens, Y.; Wiegant, J. (nucleic acid probe labeling), 1889
van Gool, J. M. G. See Derkx, F. H. M.
van Heeswijk, G. M. See Thijssen, J. H. H.
Van Houte, G. See Bernard, A.
van Kamp, G. J. See Hompes, P. G. A.
—; Bon, G. G.; Verstraeten, R. A.; Lynch, D.; Krikau, M.; Flückiger, J.; Ruibal, A.; Kenemans, P. (CA 15-3 assay evaln.), 28
Van Landuyt, K. G. See Thienpont, L. M.
van Nieuwenhoven, F. A. See Kragten, J. A.
van Zon, J. P. H. M. See van Duijnhoven, H. L. P.
Vandenberghe, A.; Latour, P.; Chauplannaz, G.; Chapon, F.; Pouget, J.; Dumas, A.; Laguenay, A.; Ollagnon, E.; Bost, M.; Duthel, S.; Chazot, G.; Boucherat, M. (Charcot–Marie–Tooth dis. diag.), 1021
Vanderbiesen, V. See Zhang, X.
Vanholder, R. See Zhang, X.
van't Veer, L. J. See Top, B.
Varela, J. M. See Ezquieta, B.
Vassar, M. J. See Wade, C. E.
Vassault, A. See Houbouyan, L.
Veeman, W. See Thijssen, J. H. H.
Velculescu, V. E.; El-Deiry, W. S. (*p*53 tumor suppressor gene), 858
Veldhuis, J. D. (ultrasensitive growth hormone assays), 1731
Vercellotti, G. M. (Fe economy), 657
Verebey, K. (Pb screening, letter), 984
Verkerk, R. See Maes, M.
Vermes, I.; van den Bergh, F. A. J. T. M. (alcohol abuse detect. by transferrin, letter), 2048
Verpooten, G. A. See Couttenye, M.-M.
Verstraeten, R. A. See van Kamp, G. J.; See Hompes, P. G. A.
Verter, J. See Vreman, H. J.
Verwimp, M. See Nabbe, A.
Vezon, G. See Merel, P.
Vierke, G. See Dibbelt, L.
Villard, C. See Pittet, J.-L.
Villena, V.
—; Navarro, J. A.; Benayas, C. G.; Encuentra, A. L.; Arenas, J. (pleural adenosine deaminases, letter), 1880
—; Navarro-Gonzálvez, J. A.; García-Benayas, C.; Manzanos, J. A.; Echave, J.; López-Encuentra, A.; Arenas Barbero, J. (adenosine deaminase in TB), 218
Vitai, M. See Góth, L.
Voelker, J. R. See Bowsher, R. R.
Vogt, W. See Braun, S. L.; See Heinemann, G.
Vold, B. S. See Mehta, H. B.
Volland, H. See Grassi, J.
von Pape, K.-W. See Bohner, J.
Voyta, J. C. See Bronstein, I.
Vreman, H. J.
—; Baxter, L. M.; Stone, R. T.; Stevenson, D. K. (CO breath anal.), 50
—; Verter, J.; Oh, W.; Fanaroff, A. A.; Wright, L. L.; Lemons, J. A.; Shankaran, S.; Tyson, J. E.; Korones, S. B.; Bauer, C. R.; Stoll, B. J.; Papile, L.-A.; Donovan, E. F.; Ehrenkranz, R. A.; Stevenson, D. K. (bilirubin variability), 869
Vuori, J.; Syrjälä, H.; Väänänen, H. K. (myoglobin/carbonic anhydrase), 107
Wachter, H. See Fuith, L. C.
Wada, H. G. See Gibbs, W.
Wade, C. E.; Dubick, M. A.; Vassar, M. J.; Perry, C. A.; Holcroft, J. W. (dextran, letter), 779
Wagner, D. B. See Ullman, E. F.
Walker, G. T.
—; Linn, C. P. (*M. tuberculosis* detect. by amplifn. and fluorescence polarizn.), 1604
—; Nadeau, J. G.; Linn, C. P.; Devlin, R. F.; Dandliker, W. B. (*M. tuberculosis* DNA detect.), 9
Walmsley, N. (book author: Primer of Chemical Pathology), 1887
Walsh, M. See Carville, D. G. M.
Walters-Laporte, E. See Teissier, E.
Wang, G.-R. See Liu, M.
Wartofsky, L. (thyroid dis. scope and impact), 121
Ward, G. See McWhinney, B. C.
Warner, A. (book reviewer: Handbook of Workplace Drug Testing), 485
Wartchow, C. A. See Ullman, E. F.
Waters, D. See Wu, A. H. B.
Watson, R. M. See Fisher, M. E.
Wauters, A. See Maes, M.
Weaver, L. G. See Parvin, C. A.
Weeckx, S. See Maes, M.
Wei, T. Q.; Bermes, E. W. Jr.; Jandreski, M. A. (β_2-Glycoprotein), 642
Weiblen, B. J. See Manak, M. M.
Weier, H.-U. See Trnovsky, J.
Weill, J. See Schellenberg, F.
Weinberg, D. S. (telepathology), 831
Weiss, N. S. (consequences of postmenopausal hormone therapy), 1342
Wen. L. T.; Fenwick, R. (HBV DNA quant.), 1891
Wen, M.-S. See Wu, J. H.

Wener, M. H. See Astion, M. L.
Werness, P.; Leonard, D.; Modlin, D.; Horsfall, K. (immunoanalyzer with random access), 1575
Weschler, W. See DiDomenico, N.
West, C. R. See Diver, M. J.
Western, L. See Patel, R.
Westgard, J. O. (book author: OPSpecs Manual: Operating Specifications for Precision, Accuracy, and Quality Control, Expanded Edition), 990; See Olafsdottir, E.
—; Smith, F. A.; Mountain, P. J.; Boss, S. (patient data algorithms assessment), 1683
Wheeler, D. See Spitsbergen, M. P.
Wheeler, M. J.; D'Souza, A.; Matadeen, J.; Croos, P. (testosterone, ACS:180), 1445
Whinna, H. C.; Krueger-Nielsen, S.; Uomoto, J; Raisys, V. (triglyceride reagent, letter), 778
Whitney, S. E. See Spitsbergen, M. P.
Whittaker, P. See Iqbal, S. J.
Wians, F. H. Jr. (correct PSA concns., letter), 1882
Wick, J. See Blassak, M.
Wiegant, J. See van Eijsden, R.
Wieland, H. See Siekmeier, R.; See Nauck, M.; See Bissé, E.
Wilcox, R. B. See Nelson, J. C.
Wild, D. (improving IA performance and convenience), 1137
Wilding, P. (cost-effective protocols for lab. testing), 347; (changing face of clin. lab.), 1899
Willems, D. See Peretz, A.
Willems, H. L. See Demacker, P. N. M.
Williams, K. C. See Berger, D. M.
Williams, R. D. (book reviewer: Mass Spectrometry in the Biological Sciences), 1728
Wilson, N. See Robins, S. P.
Wilson, P. W. F. See Contois, J. H.; See Lahoz, C.
Winger, L. A. See Self, C. H.
Winkler, M. See Gonschior, A.-K.; See Pasloske, B. L.
Winn-Deen, E. (book reviewer: Nonisotopic Probing, Blotting, and Sequencing, 2nd ed.), 1127
Wishart, D. S. See Jette, D. C.
Withold, W.; Schulte, U.; Reinauer, H. (bone ALP), 210
Witte, D. L. (overcoming challenges), 785
Woitge, H. W.; Seibel, M. J.; Ziegler, R. (bone ALP comparisons), 1796
Wolf, B. A. See Bernard, D. W.; See Eder, A. F.
Wolf, P. (software reviewer: Clinical Cases Computer Aided Learning: Thyroid Disorders), 118
Wolfe, J. See Fleetwood, M. K.
Wolfert, R. See Strobel, S.
Wong, R. See Eastman, J. W.
Wong, S. H. Y. (book reviewer: Analytical Supercritical Fluid Extraction), 2054
Worsfold, M. See Sharp, C. A.
Wright, L. L. See Vreman, H. J.
Wu, A. H. B.; Feng, Y. J.; Contois, J. H.; Azar, R.; Waters, D. (troponin, letter), 651
Wu, C.; Kenny, M. A. (Mg, ethanol ingestion), 625
Wu, J. See Lee, B.-L.
Wu, J. H.; Chern, M.-S.; Lo, S.-K.; Wen, M.-S.; Kao, J.-T. (apo B 3′ genotype), 927
Wu, K. See Gonzalez-Villaseñor, L. I.
Wu, L. See Meixell, G.; See Radike, E.
Wülfroth, P. See Siekmeier, R.
Wünsche, W. See Dibbelt, L.
Xie, L. See Dudman, N. P. B.
Xu, L. See Datta, P.
Yamaguchi, T. See Miida, T.
Yamaguchi, Y. See Kimura, S.
Yamaki, M. See Iwata, R.
Yamanishi, H.
—; Iyama, S.; Amino, N. (ferritin Fe interference), 2042
—; Iyama, S.; Fushimi, R.; Amino, N. (Fe, ferritin interference), 331
Yang, C.-Y. See Hsieh, M.
Yang, H. G. See Lee, B.-L.
Yang, M.; Hendrie, H. C.; Hall, K. S.; Oluwole, O. S. A.; Hodes, M. E.; Sahota, A. (DNA eluting), 1115
Yang, Y. See Dockter, J.
Yang, Z. See JianHua, M.
Yao, H. H.; Porter, W. H. (ethylene glycol, GC), 292
Yaping, Z.; Dongxing, Y.; Jixiang, C.; Tianshiu, L.; Huiqin, C. (I^- detn.), 2021
Yarmush, M. L. See Roth, C. M.
Yiğit, G. See Seven, A.
Yildiz, L.; Akçay, F.; Kaynar, H.; Bakan, N. (endothelin, smoking, letter), 483
YongKun, H. See JianHua, M.
YongPing, L. See JianHua, M.
Yoshimasa, T. See Iwata, R.
Yost, G. S. See Yuan, C.
Young, C. C. See Malenfant, A.
Young, G. P.; Sinatra, M. A.; St. John, D. J. B. (blood test sensitivity), 1107
Young, J. D. See Mackenzie, I. M. J.
Yu, H. See Hoffman, B. R.; See Ferguson, R. A.; See Diamandis, E. P.; See Melegos, D. N.
Yu, J. See Sassi, A. P.
Yuan, C.; Yost, G. S. (supercoiled DNA extn.), 1898
Yudkin, J. S. See Mohamed-Ali, V.
Zakut, H. See Avidor, B.
Zammit, S. See Ferguson, R. A.
Zaninotto, M.; Altinier, S.; Lachin, M.; Carraro, P.; Plebani, M. (cardiac troponin I), 1460
Zaragoza, R. See Lajarin, F.
Zarghami, N.; Diamandis, E. P. (PSA in breast tumors), 361
Zebelman, A. M. See Datta, P.
Zeuzem, S. See Stein, J.
Zhang, C.-X.; Aebi, Y.; Thormann, W. (amiodarone by capillary electrophoresis), 1805
Zhang, X.; Cornelis, R.; De Kimpe, J.; Mees, L.; Vanderbiesen, V.; De Cubber, A.; Vanholder, R. (As accumulation, renal dis.), 1231
Zhao, J. J.; Lemke, G. (ribozyme appln.), 1893
ZhiYun, N. See JianHua, M.
Ziegler, R. See Woitge, H. W.
Zoppi, F.; Brenna, S.; Fumagalli, C.; Marocchi, A. (dysHb discrimination, letter), 1300
Zuiderent, R. See Keuzenkamp-Jansen, C. W.
Zuppi, C. See Forni, F.

Volume 42, 1996
SUBJECT INDEX

KEY TO ABBREVIATIONS

A, abstract of meeting paper
CR, case report
CC, case conference
E, editorial
H, history
L, letter
O, opinion
R, review
S, symposium paper
SN, scientific note
SR, special report
TB, technical brief

AACC
award winners, 1996, 1129
task force on changing environment, 91
Abused drugs
advances in poison management (S), 1361
alum effect on methamphetamine screening tests (L), 1720
CHO-deficient transferrin to detect alcohol abuse (L), 2048
clin. evaln. of poisoned patient toxic syndromes (S), 1350
clin. studies of drug effects in humans (S), 1306
EIA validn. for qual. detect. of cocaine in sweat, 34
epidemiology of abused drugs: general population, ER drug-related episodes and arrestees (S), 1330
ester synthase present after liver and pancreatic injury, 24
ethanol ingestion: total and ionized Mg after, 625
false-neg. results with Emit amphetamine kit (L), 1726
false-pos. results for urine amphetamine and opiate IAs (L), 1725
lab. testing for recent alcohol consumption, 618
lipoprotein and apo profile changes induced by alcohol consumption and withdrawal, 1666
methamphetamine interference of alum (L), 338
nephelometric detn. of CHO-deficient transferrin, 551
thioridazine interference in identn. of phencyclidine (L), 1885
Accuracy
"correct" PSA conc. (L), 1882
evaln. of IAs on Technicon Immuno I, 1695
HbS influence on HbA quant. by HPLC (TB), 1113
homocysteine: light sensitivity of sulfonic acid derivative in assay of, 2028
lactate: 4 automated methods compared with capillary GC (TB), 1111
prep. of samples with equally spaced concs., 1074
problems and considerations in accuracy with NIST SRM 909a vials, 1832
ref. materials: how useful are they (E), 1733
Acetonitrile
digitalis-like factors: placenta radioreceptor assay with digoxin and ouabain, 270
Acetylcholinesterase
MAbs against C-terminal peptide of brain acetylcholinesterase, 19
Aciduria
GC-MS profiling of urinary organic acids, 1609
Acquired immunodeficiency syndrome
prealbumin, retinol-binding protein, and salivary IgA in children with (TB), 471
Adenosine triphosphatase. *See* ATPase
Adenosine deaminase
differentiating tuberculous and nontuberculous effusions, 218
in pleural effusions (L), 1880
Adrenal disease and function
phospholipid fatty acids in X-linked adrenoleukodystrophy (CR), 454
Age-related effects
ELISA: sol. Fas in elderly, 1911
growth hormone assays compared, 1789
IgA in diabetes: relation to age and complications, 1064
LDL oxidn. in smokers, 524
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
Albumins
Ca interference in meas. of urinary microalbumins (TB), 332
effect on lipoproteins with elevated fatty acids (TB), 1283
urine protein expert system evaln., 1214
Alcohol
CHO-deficient transferrin to detect alcohol abuse (L), 2048
lab. testing for recent alcohol consumption, 618
lipoprotein and apo profile changes induced by alcohol consumption and withdrawal, 1666
Alkaline phosphatase
acty. detd. in patients with bone dis., 210
analyte and label binding assay read by flow cytometry, 1702
bone metab. marker in corticosteroid treatment (TB), 102
comparison of total and bone-specific, 1796
hepatocellular carcinoma and cirrhosis differentiation, 1263
immunoadsorption assay compared with agglutinin assay for, 1970
IRMA for bone-specific (TB), 973
stds. required for quant. of skeletal (L), 480
Alum
effect on methamphetamine screening tests (L), 1720
Aluminum
HPLC with flourometric detect. of Al-lumogallion complex, 1405
Alzheimer disease
myo-inositol distribution in CSF and, 298
Amidolyase
Ca: *enzyme assay for*, 1202
Aminoglycosides
absorption by barrier gels in tubes (TB), 771
Amiodarone
3 labeled-Ab IAs of FT_3, 933
capillary electrophoresis of desethylamiodarone and, 1805
T_3: usage recommendations and anal. performance goals (S), 155
Ammonium
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
Ammonium persulfate
oxidizing reagent for urinary I⁻, 239
Amniotic fluid
evaln. of refractive-matched anomalous diffraction (RIMAD) for fetal lung maturation, 1861
MAbs against C-terminal peptide of brain acetylcholinesterase, 19 prostaglandin D synthase assay: immunofluorometry, 1984
prostaglandin D_2 synthase: fetal abnormalities, 1042
Amrinone
HPLC in patients on cephalosporin, 761
Amylase
trypsinogen: marker of acute pancreatitis in urine, 685
Amylin
diabetes pathogenesis? (E), 494
IA: amylin and amylin-like peptides, 576
Amyloidosis
preimplantation diag.: minisequencing of blastomere DNA, 1382
Analytical error
Abs against testosterone (L), 2047
ascorbic acid stability, repeatability, and reproducibility, 1257
avg. of normals patient data algorithms, 1683
bilirubin: errors in meas., 845
bilirubin interference with creatine, lactate, P, and uric acid (L), 988
BM/Hitachi 747-200 assay for fructosamine, 244
Ca interference in meas. of urinary microalbumins (TB), 332
cholesterol: meas. variability of LDL, 732
comments on NIST SRM 909a vials (L), 1878
dopamine influence on peroxidase-based assays (L), 1502
errors in meas. of bilirubin (L), 1880
false-neg. IA for troponin I and autoAbs (L), 2046
false-neg. results with Emit amphetamine kit (L), 1726
false-pos. results for urine amphetamine and opiate IAs (L), 1725
ferritin Fe interferes with meas. of serum Fe (TB), 2042
ferritin interference in meas. of Fe (TB), 331
heparin: anti-Xa acty. of low-molec. wt., 1223
6b-Hydroxycortisol interferes with IA of free cortisol (TB), 1290
hyperglycemia: interference in RBC volume meas. by Technicon analyzers, 76
hypertriglyceridemia: inaccuracy of Friedewald formula in (TB), 1491
interference with calcipotriol on IDS RIA for vit. D (L), 112
interference in detn. of total CK (L), 1501
interference by digoxin-like factors in neonates and pregnant women (TB), 974
K variations using tubes with gel separators (L), 1300
lipemia interference in hematology cell count (L), 987
metabolite and matrix interference in phenytoin IAs, 1645
Mg detn. based on activn. of isocitrate DHase, 1474
monoclonal Ig interference in PO_4 meas. (L), 1298
prep. of samples with equally spaced concs., 1074
PSA sensitivity reports mislead clinicians (O), 849
random access IA: evalg. interassay carryover on, 725
ref. materials: how useful are they (E), 1733
reproducibility of 1-h 50-g glucose challenge test, 255
reticulocyte quant. by Coulter MAXM VCS tech., 1930
thiocyanate and cyanide interference in glucose assay (CR), 449
thiocyanate on electrochem. biosensors for glucose (L), 1124
thiocyanate interference in Nova Stat Profile anal. (L), 483
thioridazine interference in identn. of phencyclidine (L), 1885
thyroglobulin ELISA: autoAb interference, 766
TSH assays: status and performance goals (S), 140
TSH: specimen carryover influence on assay for, 593
what does "functional sensitivity" mean? (L), 2051
Anemia
creatine: enzymatic meas. in RBC, 313
Fe: evalg. Fe economy (E), 657
Fe status: correlation or common sense, 718
Angiotensin
MAb sandwich assays for renin and prorenin, 1051
peptide research overlooked (L), 1500

two immunometric assay approaches for haptens (S), 1532
Animal studies
in vivo appln. and empirical design rules of (A), 1893
reporter genes in animal model (A), 1895
Antibiotics
amrinone: HPLC in patients on cephalosporin, 761
sirolimus quant. in kidney graft recipients by HPLC/electrospray MS, 1417
Antibodies
artificial Abs prepared by molec. imprinting (S), 1506
chemilum. IA for vascular endothelial growth factor, 1777
diabetes: radioimmunoprecipitation assay for glutamic acid decarboxylase Abs, 1975
diagnostic value of serum Abs in celiac dis., 1838
digoxin: Ab specificity effect on IAs, 373
b_2-Glycoprotein I in anti-cardiolipin calibrators (TB), 642
HIV epitope tails in prodn. of recombinant agglutination reagents (S), 1566
ref. calibrators for IgG Abs to b_2-glycoprotein I (TB), 1116
Starburst dendrimers: reagents in IAs (S), 1567
toward Ab mediated nucleic acid detect. (A), 1897
Antibodies, anticardiolipin
liposome IA for colorimetry of IgG anticardiolipin Abs, 874
Antibodies, antinuclear
antinuclear test: computer to monitor ability to interpret (S), 836
Antibodies, monoclonal
analyte and label binding assay read by flow cytometry, 1702
chemilum. IA for vascular endothelial growth factor, 1777
glutathione *S*-transferase Alpha 1-1 in gastrointestinal dis.: ELISA, 416
IA: amylin and amylin-like peptides, 576
IAs for small molecules: wash steps and multiple binding (S), 1527
immunoenzymometric assay for estrogen receptors, 1955
immunofluorometric assay for prostatic kallikrein (hK2), 1034
MAbs against C-terminal peptide of brain acetylcholinesterase, 19
MAb-based fluorometric assays in one-step format (S), 1513
MAb sandwich assays for renin and prorenin, 1051
precision profiles to eval. leukocyte differential, 1068
PSA epitope mapping with, 1961
thyroglobulin IRMA and autoAb interference, 258
urinary pyridinium cross-links, 1168
VIDAS D-dimer: ELISA meas. for, 410
Antichymotrypsin
anal. performance of PSA assays compared, 1026
IA for PSA complexes with a_2-macroglobulin, 545
PSA assay discrepancy in prostate cancer follow-up (CR), 637
Anticoagulants
actvd. coagulation markers usefulness (R), 664
titrating cardiovascular drugs (S), 1312
Antioxidants
acty. of resveratrol in red wine (L), 113
glutathione screening, 64
shortcomings of automated assay for (TB), 1712
Antiphospholipid syndrome
Abs against b_2-Glycoprotein I in anti-cardiolipin calibrators (TB), 642
Apolipoproteins
apo B 3N hypervariable repeat genotype: restriction fragment polymorphisms, 927
coronary artery dis.: preb$_1$-HDL increase in, 1992
HDL cholesterol: 3 methods for measg., 738
HDL cholesterol detd. by homogeneous assay, 424
isotope-diln.-MS quant. of apo A-I, 1676
LDL oxidn., antioxidants, and atherosclerosis (R), 498
LDL oxidn. in smokers, 524
lipoprotein cholesterol: comparing conventional methods with HPGC, 1996
phenotype-genotype discrepancies at E locus, 1817
ref. interval for apo A-1 detd. with immunoturbidimetric assay, 507
ref. interval for apo B detd. with immunoturbidimetric assay, 515
relation between no. of apo(a) kringle 4 repeats and isoform mobility, 436
serum lipids in anabolic steroid users (CR), 970
serum lipids and vit. E variability in serum concs., 1824
serum profile changes induced by alcohol consumption and withdrawal, 1666
Apoproteins
meas. for atherogenic dyslipoproteinemia (E), 489
Apoptosis
ELISA: sol. Fas in elderly, 1911
p53 tumor suppressor gene importance (R), 858
Arachidonate
stability in fasting and nonfasting patients (TB), 771
Arsenic
accumulation in renal dis., 1231
Arylsulfatase A
leukodystrophy: urine sulfatides and diag. of, 232
Ascites
pseudouridine discrimination of hepatocarcinoma and cirrhotic, 1843
Ascorbate (ascorbic acid)
LDL oxidn., antioxidants, and atherosclerosis (R), 498
RBC polyglutamyl folate enzymatic deconjugation, 1847
stability, intralab. repeatability, and interlab. reproducibility, 1257
Aspartylglucosaminuria
preimplantation diag.: minisequencing of blastomere DNA, 1382
screening for aspartylglucosaminuria mutations, 1398
Athena Society
role of clin. chem. in healthcare, 96
Atherosclerosis
apo B 3N hypervariable repeat genotype: restriction fragment polymorphisms, 927
coronary artery dis.: preb$_1$-HDL increase in, 1992
LDL oxidn., antioxidants, and atherosclerosis (R), 498
LDL oxidn. in smokers, 524
metal excretion and Mg retention in those treated with IV EDTA, 1938
vit. supplementation: ref. intervals for homocysteine and methylmalonic acid, 630
Atomic absorption spectroscopy
As accumulation in renal dis., 1231
hair Cd measd. by (TB), 1287
killer cell acty. detn. by, 319
Va quant. by electrothermal, 1275
ATPase
inhibit. of Na, K-ATPase by oleandrin and oleandrigenin: digoxin IA detect., 1654
salt intake effect on excretion of ouabain-like substance: RIA, 1949
Autoantibodies
calpastatin autoAbs: detect., mappings, ELISA for, 1250
diabetes: radioimmunoprecipitation assay for glutamic acid decarboxylase Abs, 1975
false-neg. IA for troponin I and autoAbs (L), 2046
incubation effects on ELISA for lipoproteins (TB), 1709
thyroglobulin ELISA: autoAb interference, 766
thyroglobulin meas. (E), 661
thyroperoxidase, thyroglobulin, and TSH receptor autoAbs: anal. and clin. performance goals (S), 160
Autoimmune disease
actvd. coagulation markers usefulness (R), 664
calpastatin autoAbs: detect., mappings, ELISA for, 1250
ELISA GAD_{65} autoAb assay: diabetes marker, 263
thyroid status in thyrotoxicosis (S), 174
thyroperoxidase, thyroglobulin, and TSH receptor autoAbs: anal. and clin. performance goals (S), 160
Avidin-biotin interaction
MAb sandwich assays for renin and prorenin, 1051
Beckman Conference
nineteenth, preface, 1305
Benzodiazepines
anal. of benzodiazepines by HPLC with solid-phase extn., 1412
Benzoylecgonine
EIA validn. for qual. detect. of cocaine in sweat, 34
Beta blockers
titrating cardiovascular drugs (S), 1312
Bilirubin
cord blood biochem. and idiopathic neonatal jaundice (TB), 1716
errors in meas. (E), 845
errors in meas. (L), 1880
interference with creatine, lactate, P, and uric acid (L), 988
interlab. variability, 869
Biotin-avidin interaction
COBAS AMPLICOR: DNA and RNA amplifn., 1915
Biotin-streptavidin interaction
a-globin mRNA measd. by ELISA and reverse transcription, 1750
HIV-1: fluorometric detect. of, 696
lumin. O_2 channeling assay (LOCI)^1 (S), 1518
RIA of C-telopeptides of collagen to assess bone resorption, 1639
Blood gases
matrix effects and quality control to monitor Po_2 meas., 392
Blood groups
heteroduplex generator in anal. of Rh blood group alleles, 356
Blood viscosity
blood viscosity and biochem. correlates in healthy adults, 1189
Bone
ALP acty. detd. in patients with bone dis., 210
ALP: IRMA for bone-specific (TB), 973
ALP marker in corticosteroid treatment (TB), 102
comparison of total and bone-specific ALP, 1796
health consequences of postmenopausal hormone therapy (S), 1342
MAbs for urinary pyridinium cross-links, 1168
meas. for hydroxyproline and deoxypyridinoline (TB), 2037
mole. diag. of orthopedic infections (A), 1890
procollagen blood concs. in Paget dis. of (L), 1121
procollagen: IA for NH_2-terminal propeptide of type I, 947
RIA of C-telopeptides of collagen to assess bone resorption, 1639
standardization of collagen crosslinks as biochem. markers, 1621
Book and videotape reviews
Analytical Supercritical Fluid Extraction (T. Taylor), 2054
Biochemical Basis of Pediatric Disease (S. J. Soldin, N. Rifai, J. M. B. Hicks), 485
Clinical Chemistry, 3rd ed. (W. J. Marshall), 1127
Cost Containment in the Clinical Laboratory (D. Evans, D. Frantz, V. Ng, C. Hogan, E. L. Gottfried, J. I. Mangels, R. Emrich, R. Harbeck), 1127
Handbook of Clinical Automation Robotics and Optimization (G. J. Kost, ed.), 1728
Handbook of Workplace Drug Testing (R. H. Liu and B. A. Goldberg, eds), 485

Mass Spectrometry in the Biological Sciences (A. L. Burlingame and S. A. Carr, eds.), 1728
Nonisotopic Probing, Blotting, and Sequencing (L. J. Kricka, ed.), 1127
OPSpecs Manual: Operating Specifications for Precision, Accuracy, and Quality control, Expanded Edition (J. O. Westgard), 990
Poisoning and Toxicology Handbook, 2nd ed. (J. B. Leikin and F. P. Paloucek), 2054
Primer of Chemical Pathology (E. S. C. Koay and N. Walmsley), 1887
Borrelia burgdorferi
detect. of OspA sequences by PCR (A), 1892
Brain
MAbs against C-terminal peptide of brain acetylcholinesterase, 19
Breast cancer
CA 15.3, CEA, and tissue polypeptide for breast cancer monitoring, 564
chemilum. IA for vascular endothelial growth factor, 1777
detect. of cells by NASBA amplifn. of cytokeratin 19 (A), 1889
immunoenzymometric assay for estrogen receptors of, 1955
PSA immunoacty. in women with breast cancer (L), 1721
PSA immunofluorometry and Immulite immunochemilum., 675
Breath analysis
CO: evaln. of end-tidal, 50
Bromide
automated assay for plasma, 1210
C-reactive protein
PSA concs. in acute illnesses, 1785
Cadmium
hair Cd measd. by AAS (TB), 1287
Calcitonin
ALP: IRMA for bone-specific (TB), 973
Calcium
enzyme assay for, 1202
evaln. of sampling and storage procedures (TB), 468
ion-selective electrode stability: AVL and Nova Mg and, 880
metal excretion and Mg retention in those treated with IV EDTA, 1938
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
Sarstedt Monovettes falsely increase total (L), 1722
vit. D quant. by RIA with ^{125}I tracer, 587
Calibration
homocysteine: light sensitivity of sulfonic acid derivative in assay of, 2028
lipase assay: standardization importance using calibrators, 1979
Calpastatin
calpastatin autoAbs: detect., mappings, ELISA for, 1250
Cancer
Abbott IMx CA 15-3 assay evaln., 28
ALP acty. detd. in patients with bone dis., 210
anal. performance of PSA assays compared, 1026
anal. stability: patient data statistics, 893
chemilum. IA for vascular endothelial growth factor, 1777
clin. studies of drug effects in humans (S), 1306
"correct" PSA conc. (L), 1882
DNA sequencing as tool in endocrine neoplasia type 2 and thyroid carcinoma (A), 1890
EIA for c-*erb*B-2 p185 and p53 in ovarian neoplasms (TB), 981
endocrine neoplasia: gradient gel electrophoresis, 598
enrichment of prostate-derived cells by density centrifugn. (L), 1881
genistein and daidzein concs. in human milk, 955
health consequences of postmenopausal hormone therapy (S), 1342
hepatocellular carcinoma and cirrhosis differentiation, 1263
immunofluorometric assay for prostatic kallikrein (hK2), 1034
immunological detect. of tumor cells and micrometastases (R), 1369
immunoluminometric assay for CA 72-4 (TB), 472
IRMA: for free PSA, 1243
K-*ras* Val-12 mutation in colorectal, 904
lab. testing for diag. and monitoring of thyroid dis. (S), 183
lipoproteins: prostate cancer and hormone effect on, 1176
procollagen: IA for NH_2-terminal propeptide of type I, 947
PSA assay discrepancy in prostate cancer follow-up (CR), 637
PSA concs. in acute illnesses, 1785
PSA epitope mapping with MAbs, 1961
PSA immunoreactivity in saliva (TB), 1110
PSA mRNA not always indicative of tumor cells (L), 1499
PSA mRNA and protein detect. in breast tumors, 361
PSA: phys. acty. releases, 691
PSA role in discordance across comm. assays (TB), 645
PSA screening using whole blood spotted on filter paper, 536
PSA sensitivity reports mislead clinicians (O), 849
PSA ultrasensitive assays (O), 853
pseudouridine discrimination of hepatocarcinoma and cirrhotic ascites, 1843
sequence-specific mutation detect. of K-*ras* using SSCP anal. (TB), 1717
standardization of cytokeratin-related tumor marker CYFRA21.1, 1634
thyroglobulin ELISA: autoAb interference, 766
thyroglobulin IRMA and autoAb interference, 258
Carbohydrates
near-infrared reflectance of fecal, 309
Carbon monoxide
breath anal. for end-tidal, 50
Carboplatin
biochem. markers of tubular function after receiving (L), 1498
Carcinoembryonic antigen
CA 15.3, CEA, and tissue polypeptide for breast cancer monitoring, 564
Carcinoid syndrome
validn. of HPLC-amperometric detect. to meas. serotonin, 1086
Cardiolipin
Abs against b_2-Glycoprotein I (TB), 642
Carotene
LDL oxidn., antioxidants, and atherosclerosis (R), 498
Case reports
anal. of patient with congenital adrenal hyperplasia, 1483
phospholipid fatty acids in X-linked adrenoleukodystrophy, 454
PSA assay discrepancy in prostate cancer follow-up, 637
purine nucleoside deficiency: liq. chromatog. of, 326
serum lipase without pancreatitis, 462
serum lipids in anabolic steroid users, 970
thiocyanate and cyanide interference in glucose assay, 449
Catalase
hypocatalasemia in hospital patients (L), 341
Celiac disease
diagnostic value of serum Abs in, 1838
sugar probe in serum: intestinal permeability testing, 445
Cell cycle
p53 tumor suppressor gene importance (R), 858
Centrifugation
axial centrifn., 402
enrichment of prostate-derived cells by density centrifugn. (L), 1881
evaln. of Du Pont axial sepn. system, 1467
Mg detn. based on activn. of isocitrate DHase, 1474
shortcomings of automated assay for antioxidants (TB), 1712
Cephalosporin
amrinone: HPLC in patients on cephalosporin, 761
Cerebrospinal fluid
HPLC: purine nucleotide products in CSF, 756
myo-inositol: distribution in Alzheimer dis., 298
prostaglandin D synthase assay: immunofluorometry, 1984
TNF-a: CSF shelf life and activn. energy, 670
Ceruloplasmin
signif. of haptoglobin polymorphism (R), 1589
Charcot–Marie–Tooth disease
DNA diagnostics for inherited neuropathies and (E), 995
molec. diag. of hereditary neuropathy and, 1021
Chemiluminescence
bacterial pathogen detect. by DNA amplifn. (A), 1894
chemilum. hybridzn.-ligation assays for DF508 and D1507 CF mutations, 14
detect. of molecules by fluorescent reporter groups and (S), 1573
detect. of single base mismatches using (A), 1893
detect. technology for reporter gene assays (S), 1542
folate: results of internatl. round robin for, 1689
Gen-Probe assay for *Chlamydia trachomatis* (A), 1890
growth hormone assays (E), 1731
IA for vascular endothelial growth factor, 1777
immunosensors: technology and opportunities in lab. med., 193
lumin. O_2 channeling assay (LOCI)$^{\text{I}}$ (S), 1518
multiple analyte detect. utilizing chemilum. DNA probe (A), 1894
testosterone: IA compared with neg. chem. ionization GC-MS, 749
Chemiluminescence immunoassay
endothelin-I: chemilum. EIA for, 1155
inhibin-A: two-site solid phase assay for, 1159
Chemotherapy
CA 15.3, CEA, and tissue polypeptide for breast cancer monitoring, 564
discovery and develop. of MMI linkage (A), 1897
metal excretion and Mg retention in those treated with IV EDTA, 1938
methotrexate: evaln. of clin. assays for measg., 39
p53 tumor suppressor gene importance (R), 858
Chlamydia trachomatis
COBAS AMPLICOR: DNA and RNA amplifn., 1915
Gen-Probe assay for (A), 1890
new approaches to diag. of (S), 809
Chloric acid
NH_4 persulfate: oxidizing reagent for urinary I^-, 239
Chloride
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
Cholecalciferol
vit. D: quant. by RIA with ^{125}I tracer, 587
Cholesterol
4 test systems evald. by isotope diln. GC-MS, 531
apo B 3N hypervariable repeat genotype: restriction fragment polymorphisms, 927
apos. in diag. and treatment of dyslipoproteinemia (E), 489
blood viscosity and biochem. correlates in healthy adults, 1189
coronary artery dis.: $preb_1$-HDL increase in, A-11
direct meas. of LDL (L), 781
HDL cholesterol: 3 methods for measg., 738
HDL cholesterol detd. by homogeneous assay, 424
hypertriglyceridemia: inaccuracy of Friedewald formula in (TB), 1491
LDL-cholesterol assay in hyperlipidemic population, 1182
LDL oxidn., antioxidants, and atherosclerosis (R), 498
LDL oxidn. in smokers, 524
lipoprotein cholesterol: comparing conventional methods with HPGC, 1996

lipoprotein implementation of recommendations from NCEP (L), 651
meas. variability of LDL, 732
microenzymatic assay of triglycerides, phospholipids and, 915
platelet meas. of Mg with variables, 744
ref. method for serum total cholesterol: enzymatic step (TB), 475
serum lipids in anabolic steroid users (CR), 970
serum lipids and vit. E variability in serum concs., 1824
variation in lipids and lipoproteins in fingerstick blood, 2002

Choline
microenzymatic assay of triglycerides, phospholipids and cholesterol, 915

Chorionic gonadotropin
IA with fluorescent Eu label and time-resolved fluorometry, 1196
lumin. O_2 channeling assay (LOCI)^J (S), 1518

Chromatography, anion-exchange
nephelometric detn. of CHO-deficient transferrin, 551
purine nucleoside deficiency: liq. chromatog. of (CR), 326
sulfite oxidase: screening with urinary thioSO_4/SO_3 ratios (L), 654

Chromatography, capillary-column
ethylene glycol and glycolic acid: gas chromatog. of, 293

Chromatography-cation-exchange
hemoglobinopathies: neonate HPLC screening, 704
identn. and quant. of Hbs A, F, S, and C by chromatog., 57

Chromatography, gel-filtration
IRMA: for free PSA, 1243
lipoprotein cholesterol: comparing conventional methods with, 1996
pentosidine urine quant. by HPLC with column switching, 1439

Chromatography, liquid
amrinone: HPLC in patients on cephalosporin, 761
anal. of benzodiazepines by HPLC with solid-phase extn., 1412
As accumulation in renal dis., 1231
ascorbic acid stability, repeatability, and reproducibility, 1257
detn. of ibuprofen pharmacokinetics in CF, 1812
folate: results of internatl. round robin for, 1689
Hb variant (Hb Chicago) (TB), 774
HbS influence on HbA quant. by (TB), 1113
hemoglobinopathies: neonate HPLC screening, 704
homocysteine: light sensitivity of sulfonic acid derivative in assay of, 2028
HPLC/EIA detect. of clenbuterol in human scalp (TB), 1869
HPLC with flourometric detect. of Al-lumogallion complex, 1405
HPLC screening method for cystinuria (TB), 1714
leukodystrophy: urine sulfatides and diag. of, 232
MAbs for urinary pyridinium cross-links, 1168
methotrexate: evaln. of clin. assays for measg., 39
monitoring whole-blood by HPLC with UV detect, 1943
proinsulins: IRMA compared with HPLC, 977
purine nucleotide products in CSF, 756
rhamnose, mannitol, and lactulose quant. in urine, 71
sirolimus quant. in kidney graft recipients by HPLC/electrospray MS, 1417
steroid hormone anal. using improved (TB), 979
steroid hormone anal. using improved HPLC (TB), 979
sugar probe in serum: intestinal permeability testing, 445
tacrolimus: electrospray MS-MS and, 279
validn. of HPLC-amperometric detect. to meas. serotonin, 1086

Chromatography, reversed-phase
amrinone: HPLC in patients on cephalosporin, 761
pentosidine urine quant. by HPLC with column switching, 1439
purine nucleoside deficiency: liq. chromatog. of (CR), 326
RBC polyglutamyl folate enzymatic deconjugation, 1847
a-tocopherol: quant. of LDL and HDL, 430

Chromatography, thin-layer
anal. of drugs in multiple urines (S), 1570

Chromium
killer cell acty. detn. by AAS, 319

Chromosomes
flow cytometric chromosome sorting after hybridzn. (A), 1897

Chymotrypsin
immunoreactive elastase: test of pancreatic function, 222
spectrofluorometric detn. of PABA and PASA by Tb-sensitized luminescence, 1659

Circadian rhythms
physiological variations in thyroid hormones (S), 135

Cisplatin
sensitizing tumor cells to (A), 1893

Clara cell protein
increased in firefighters (L), 1120

Clenbuterol
HPLC/EIA detect. in human scalp (TB), 1869

CLIA 88
review of personnel stds. (S), 790

Clinical chemistry
appln. of process capability indices to quality control (TB), 2035
changing environment for practice of (SR), 91
changing practice of (E), 5
future and role in healthcare (SR), 96
impact of converging technologies (R), 1735
logical observation identifier names and codes (LOINC) database (SR), 81
problems and considerations in accuracy with NIST SRM 909a vials, 1832

Clinical Chemistry Forum, 1995
proceedings of, 785

Clinical Chemist, The
343, 487, 656, 784, 991, 1129, 1304, 1504, 1730, 1888

Coagulation
actvd. coagulation markers usefulness (R), 664
DNA extn. from clotted blood (TB), 647
heparin: anti-Xa acty. of low-molec. wt., 1223
heparin monitoring by thromboplastin time using dry reagent (TB), 1488
VIDAS D-dimer: ELISA meas. for, 410
von Willebrand factor compared with plasminogen activator concs. (TB), 976

Cobalamin
methylmalonic acid quant. by GC-MS, 910

Collagen
MAbs for urinary pyridinium cross-links, 1168
meas. for hydroxyproline and deoxypyridinoline (TB), 2037
procollagen: IA for NH_2-terminal propeptide of type I, 947
RIA of C-telopeptides of collagen to assess bone resorption, 1639
standardization of collagen crosslinks as biochem. markers, 1621

Colorimetry
ferritin Fe interferes with meas. of serum Fe (TB), 2042
a-globin mRNA measd. by ELISA and reverse transcription, 1750
lipase assay: standardization importance using calibrators, 1979
liposome IA for colorimetry of IgG anticardiolipin Abs, 874
microenzymatic assay of triglycerides, phospholipids and cholesterol, 915
NH_4 persulfate: oxidizing reagent for urinary I^-, 239
PSA assay discrepancy in prostate cancer follow-up (CR), 637

Computers
antinuclear test: computer to monitor ability to interpret (S), 836
changing face of clin. lab. (E), 1899
impact of converging technologies (R), 1735
Internet: road to heaven or hell for clin. lab. (S), 827
PC-based IA simulation system (S), 1569
robotics and changing face of clin. lab. (R), 1901
sample retrieval and turnaround time with spreadsheet (S), 1571

Copper
hepatocellular carcinoma and cirrhosis differentiation, 1263
metal excretion and Mg retention in those treated with IV EDTA, 1938

Coronary artery disease
apo B 3N hypervariable repeat genotype: restriction fragment
polymorphisms, 927
cholesterol: 4 test systems evald. by isotope diln. GC-MS, 531
preb$_1$-HDL increase in, 1992

Coronary heart disease. *See* Heart disease and function

Corrections
488 (Konopka et al. 36:1068,1990)

Cortisol
effect on percentage of non-sex-hormone-bound steroid, 249
6b-Hydroxycortisol interferes with IA of free (TB), 1290
steroid hormone anal. using improved HPLC (TB), 979

Corticosteroids
saliva detn. of dexamethasone, 1238

Creatine
bilirubin interference with lactate, P, uric acid and (L), 988
enzymatic meas. in RBCs, 313

Creatine kinase
cardiac troponin T in those with high creatinine concs. but normal CK acty. (TB), 474
immunochromatog. for detect. of myoglobin and CK-MB (TB), 1292
interference in detn. of total CK (L), 1501
myocardial infarction: fluoroenzymometric method to meas. troponin I, 1460
sensitivity of CK-MB2, CK-MB, and myoglobin in myocardial infarction, 1454

Creatinine
cardiac troponin T in those with high creatinine concs. but normal CK acty. (TB), 474
Ektachem 250 testing of Na, K, Ca, urea, and (TB), 105
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855

Cryptosporidium
detect. of DNA of (A), 1891

Cyanide (cyanate)
concs. in chronic renal failure (L), 482

Cyclosporine
lumin. O_2 channeling assay (LOCI)^J (S), 1518
monitoring in posttransplant period (TB), 1294
monitoring whole-blood by HPLC with UV detect, 1943
toxic effects of immunosuppressive drugs (S), 1316

Cysteine
stability of glutathione and blood, 1100

Cystic fibrosis
chemilum. hybridzn.-ligation assays for DF508 and D1507 CF mutations, 14
HPLC detn. of ibuprofen pharmacokinetics in CF, 1812
nonradioactive mutation detect. (TB), 103
RT-PCR to quant. CFTR mRNA in endometrium, 1765

Cystinuria
HPLC screening method for cystinuria (TB), 1714

Cytochrome P-450
mutation detect. in *CYP21B* in steroid 21-hydroxylase deficiency (TB), 1108
reduced form of digoxin-like immunoreactive factor, 1092

Cytokines
chemilum. IA for vascular endothelial growth factor, 1777

EGR-1 suppresses transformation by inducing TGF-b1 (A), 1896
signif. of haptoglobin polymorphism (R), 1589
TNF-a: CSF shelf life and activn. energy, 670
TNF-a receptors interfere with detect. of TNF-a, 1450

Daidzein
genistein and daidzein concs. in human milk, 955

Dehydrogenases. *See also* specific dehydrogenases
lab. testing for recent alcohol consumption, 618
Mg detn. based on activn. of isocitrate DHase, 1474

Deoxypyridinoline
meas. for hydroxyproline and (TB), 2037

Dexamethasone
saliva detn. of, 1238
steroid hormone anal. using improved HPLC (TB), 979

Dextran
concs. in patients given hypertonic saline-dextran (L), 779

Diabetes
amylin as factor in pathogenesis of (E), 494
BM/Hitachi 747-200 assay for fructosamine, 244
ELISA GAD_{65} autoAb assay: diabetes marker, 263
glucose monitored at high altitude by Accu-Chek Advantage (L), 115
Hb A_{1c} measd. by latex particle agglutination (TB), 1874
IA: amylin and amylin-like peptides, 576
IgA in diabetes: relation to age and complications, 1064
pentosidine urine quant. by HPLC with column switching, 1439
reproducibility of 1-h 50-g glucose challenge test, 255

Digitalis
inhibit. of Na, K-ATPase by oleandrin and oleandrigenin: digoxin IA detect., 1654
reduced form of digoxin-like immunoreactive factor, 1092

Digoxin
Ab specificity effect on IAs for, 373
digitalis-like factors: placenta radioreceptor assay with ouabain and, 270
inhibit. of Na, K-ATPase by oleandrin and oleandrigenin: digoxin IA detect., 1654
interference by digoxin-like factors in neonates and pregnant women (TB), 974
lumin. O_2 channeling assay (LOCI)^J (S), 1518
nighttime dosing and therapeutic drug monitoring of, 45
reduced form of digoxin-like immunoreactive factor, 1092
titrating cardiovascular drugs (S), 1312

Dipstick methods
ultrafiltration discrepancies in myoglobin recovery from urine, 965

Dioxin
evalg. impact of exposure to environmental contaminants (S), 1345

DNA
amplifn. system for *M. tuberculosis* and *M. avium* complex (A), 1894
anal. by capillary electrophoresis and fluorescence (TB), 1106
bacterial pathogen detect. by amplifn. of (A), 1894
binding proteins, the Zn finger proteins (A), 1893
detect. of *Cryptosporidium* DNA in feces (A), 1891
detect. by Si sensor technology (A), 1896
DNA diagnostics for inherited neuropathies and Charcot–Marie–Tooth dis. (E), 995
DNA EIA for detect. deletions in spinal muscular atrophies (TB), 643
eluting from dried blood spots (TB), 1115
extn. from clotted blood (TB), 647
extn. of supercoiled DNA using XTRAX kit (A), 1898
"gas-phase cleavage of oligodeoxyribonucleotides (A), 1898
a-globin mRNA measd. by ELISA and reverse transcription, 1750
isolation method for fecal samples (A), 1897
strand displacement amplifn. and fluorescence polarizn. of *M. tuberculosis*, 1604
thymine dimer repair mediated by DNA double helix (A), 1898
whole blood extn. of (TB), 1285

DNA cloning
automation of molec. diagnostics (E), 7
detect. of immobilized amplicons by ELISA (S), 1547
Huntington dis.: amplifn. of CAG repeat (TB), 773
leptin: progress and directions for human (E), 843
strand displacement amplifn. and fluorescence polarizn. detect. of *M. tuberculosis* DNA, 9

DNA hybridization
chemilum. hybridzn.-ligation assays for DF508 and D1507 CF mutations, 14
DNA and RNA probe *in situ* hybridzn. (A), 1889
DNA sequence identn. using liposomes, 1206
HIV-1: fluorometric detect. of, 696
K-*ras* Val-12 mutation in colorectal cancer, 904
molec. diag. of hereditary neuropathy and Charcot–Marie–Tooth dis., 1021
mutation detect. in *CYP21B* in steroid 21-hydroxylase deficiency (TB), 1108
strand displacement amplifn. and fluorescence polarizn. (L), 1720

DNA probes. *See* Nucleic acid probes

DNA, recombinant
HIV epitope tails in prodn. of recombinant agglutination reagents (S), 1566

DNA sequencing
biolum. hybridzn. IAs for detect. of mycobacterium and malaria (A), 1894
calpastatin autoAbs: detect., mappings, ELISA for, 1250
chemilum. hybridzn.-ligation assays for DF508 and D1507 CF mutations, 14
detect. of sex-determining region of Y chromosome (A), 1892
DNA sequence identn. using liposomes, 1206
evolution of automated molec. diagnostics (E), 1367
LDL receptor gene: sequence variation detect., 1140
ligation-mediated PCR: mapping DNA damage (A), 1896
multiplex, fluorescent minisequencing to screen DNA variations, 1391
preimplantation diag.: minisequencing of blastomere DNA, 1382
screening for aspartylglucosaminuria mutations, 1398
sequence identn. of alpha thalassemia (A), 1892
as tool in endocrine neoplasia type 2 and thyroid carcinoma (A), 1890

Dopamine
influence on peroxidase-based assays (L), 1502

Drug assays
anal. of benzodiazepines by HPLC with solid-phase extn., 1412
artificial Abs prepared by molec. imprinting (S), 1506
capillary electrophoresis of amiodarone and desethylamiodarone, 1805
metab. of anabolic androgenic steroids (R), 1001
TLC: anal. of drugs in multiple urines (S), 1570

Drug monitoring
HPLC detn. of ibuprofen pharmacokinetics in CF, 1812
metabolite and matrix interference in phenytoin IAs, 1645
titrating cardiovascular drugs (S), 1312
whole-blood by HPLC with UV detect, 1943

Drug resistance
drug resistant mutants in HIV pos. patients (A), 1891

Drug treatment
advances in poison management (S), 1361

Drugs, antiarrhythmic
titrating cardiovascular drugs (S), 1312
capillary electrophoresis of amiodarone and desethylamiodarone, 1805

Drugs, anticonvulsant
metabolite and matrix interference in phenytoin IAs, 1645

Drugs, antidepressant
clin. evaln. of poisoned patient toxic syndromes (S), 1350

Drugs, antiinflammatory
clin. studies of drug effects in humans (S), 1306
HPLC detn. of ibuprofen pharmacokinetics in CF, 1812

Drugs, immunosuppressive
anal. of benzodiazepines by HPLC with solid-phase extn., 1412
tacrolimus metabolite patterns from liver and kidney transplants, 1426
tacrolimus: liq. chromatog.-electrospray MS-MS, 279
toxic effects of immunosuppressive drugs (S), 1316

Duchenne muscular dystrophy
carrier detect. by PCR (A), 1891

Dyslipoproteinemia
apos. in diag. and treatment of atherogenic (E), 489

Economics
changing face of clin. lab. (E), 1899
federal reimbursement to labs. (S), 817
how to evaluate and implement new technologies (S), 797
impact of cost cutting on labs. (S), 822
payment for new in vitro diagnostic technologies (S), 1558
robotics and changing face of clin. lab. (R), 1901

Editorials
apos: atherogenic dyslipoproteinemia diag. and treatment, 489
athletic drug testing and anabolic steroids, 999
automation of molec. diagnostics, 7
bilirubin: errors in meas., 845
changing face of clin. lab., 1899
cost-effective protocols for lab. testing, 347
diabetes: amylin as factor in pathogenesis of, 494
DNA diagnostics for inherited neuropathies and Charcot–Marie–Tooth dis., 995
evolution of automated molec. diagnostics, 1367
Fe: evalg. Fe economy, 657
folates: life and premature death with, 1579
growth hormone assays, 1731
homocysteinemia: lab. assessment and risk factor for occlusive vascular dis. (E), 492
IA performance and convenience improvement, 1137
Journal's new look and the changing practice of clin. chem., 5
leptin: progress and directions for human, 843
neural networks: lab. aid or sorcerer's apprentice?, 496
newborn screening by (MS-MS), 345
phytoestrogens and breast milk, 841
profession in an uncertain environment, 6
ref. materials: how useful are they, 1733
renin and prorenin methodology, 993
screening for hemoglobinopathies, 658
thyroglobulin meas., 661

Ektachem. *See* Multilayer film analysis

Elastase
immunoreactive elastase: test of pancreatic function, 222

Electrocardiogram
cardiac troponin T: marker for cardiac ischemia (S), 803
myocardial infarction: I. neural networks to diag., 604
myocardial infarction: II. neural networks to diag., 613

Electrochemical detection
immunosensors: technology and opportunities in lab. med., 193
sugar probe in serum: intestinal permeability testing, 445

Electrochemiluminescence
automated IA analyte detect. (S), 1576
TNF-a receptors interfere with detect. of TNF-a, 1450

Electrodialysis
purifn. of oligonucleotide-protein conjugates (A), 1897
Electrolytes
ion-selective electrode stability: AVL and Nova Mg and Ca, 880
point-of-care testing: impact on length of stay in emergency dept., 711
Electrophoresis, capillary
of amiodarone and desethylamiodarone and, 1805
DNA anal. by fluorescence and (TB), 1106
org. acid detn. in screening org. acidurias (TB), 477
serum protein sepn. by (L), 1886
Electrophoresis, gel
Au overstaining enhances electrophoresis of urine (TB), 1293
endocrine neoplasia: gradient gel electrophoresis, 598
media for high-resolution electrophoresis of PCR-fragments (A), 1897
nonisotopic detect. of $(CAG)_n$ repeats causing Huntington dis., 1601
PCR detn. of gene expression in limiting tissue samples, 227
Electrophoresis, pulsed-field
relation between no. of apo(a) kringle 4 repeats and isoform mobility, 436
Emergency medicine
epidemiology of abused drugs: general population, ER drug-related episodes and arrestees (S), 1330
pediatric poisonings (S), 1356
Endocrine disease and function
anal. of patient with congenital adrenal hyperplasia (CR), 1483
Ciba Corning ACS:180 testosterone evald., 1445
testosterone: IA compared with neg. chem. ionization GC-MS, 749
Endometriosis
CA-125 concs. as marker for (TB), 1871
Endothelin
chemilum. EIA for, 1155
increased endothelin-1 in heavy and light smokers (L), 483
two immunometric assay approaches for haptens (S), 1532
Environmental hazards
evalg. impact of exposure to environmental contaminants (S), 1345
Enzymatic methods
glutathione screening, 64
Enzyme activity
adenosine deaminase: differentiating tuberculous and nontuberculous
effusions, 218
creatine: enzymatic meas. in RBC, 313
ester synthase present after liver and pancreatic injury, 24
g-glutamyltransferase: evaln. as ref. material, 2008
prostaglandin D synthase assay: immunofluorometry, 1984
serum lipase without pancreatitis (CR), 462
Enzyme assay
Ca, 1202
LDH interference in assay of ethylene glycol (TB), 1489
Mg detn. based on activn. of isocitrate DHase, 1474
Enzyme immunoassay
Abbott IMx CA 15-3 assay evaln., 28
amylin and amylin-like peptides, 576
c-*erb*B-2 p185 and p53 in ovarian neoplasms (TB), 981
Chlamydia trachomatis: new approaches to diagnosis of (S), 809
DNA EIA for detect. deletions in spinal muscular atrophies (TB), 643
evaln. of IAs on Technicon Immuno I, 1695
HDL cholesterol detd. by homogeneous assay, 424
HPLC/EIA detect. of clenbuterol in human scalp (TB), 1869
immunoenzymometric assay for estrogen receptors, 1955
MAbs for urinary pyridinium cross-links, 1168
meas. of smallest analyte conc., 893
methotrexate: evaln. of clin. assays for measg., 39
ouabain: EIA compared to radioreceptor assay (TB), 648
PSA assay discrepancy in prostate cancer follow-up (CR), 637
rapid PTH assay: modification of Nichols PTH assay (L), 1498
tacrolimus metabolite patterns from liver and kidney transplants, 1426
thrombus precursor protein: marker in myocardial infarction (S), 1537
validn. for qual. detect. of cocaine in sweat, 34
Enzyme inhibitors
immunofluorometric assay for prostatic kallikrein (hK2), 1034
inhibit. of Na, K-ATPase by oleandrin and oleandrigenin: digoxin IA detect., 1654
MAb sandwich assays for renin and prorenin, 1051
methotrexate: evaln. of clin. assays for measg., 39
sensitizing tumor cells to cisplatin (A), 1893
variation in metalloproteinases and their inhibitors (TB), 2043
Enzyme-linked immunosorbent assay
calpastatin autoAbs: detect., mappings, ELISA for, 1250
detect. of immobilized amplicons by ELISA (S), 1547
GAD_{65} autoAb assay: diabetes marker, 263
glutathione *S*-transferase Alpha 1-1 in gastrointestinal dis.: ELISA, 416
growth hormone assays (E), 1731
IA for PSA complexes with a_2-macroglobulin, 545
incubation effects on ELISA for lipoproteins (TB), 1709
insulin-like growth factor-I, 1147
mRNA measd. by reverse transcription, 1750
retinol-binding protein: frozen storage of samples before ELISA (TB), 466
sol. Fas in elderly, 1911
thyroglobulin autoAb interference, 766
variation in metalloproteinases and their inhibitors (TB), 2043
VIDAS D-dimer: ELISA meas. for, 410
Enzymes
chemilum.: detect. technology for reporter gene assays (S), 1542
M. tuberculosis DNA strand displacement amplifn. and fluorescence polarizn., 1604
variation in metalloproteinases and their inhibitors (TB), 2043
Epidemiology
of abused drugs: general population, ER drug-related episodes and arrestees (S), 1330
CHO-deficient transferrin to detect alcohol abuse (L), 2048
clin. evaln. of poisoned patient toxic syndromes (S), 1350
clin. studies of drug effects in humans (S), 1306
diagnostic value of serum Abs in celiac dis., 1838
IgA in diabetes: relation to age and complications, 1064
modern concepts of primary thyroid gland failure (S), 179
phenotype-genotype discrepancies at apo E locus, 1817
ref. interval for apo A-1 detd. with immunoturbidimetric assay, 507
ref. interval for apo B detd. with immunoturbidimetric assay, 515
scope and impact of thyroid dis. (S), 121
Erythrocytes
Fe marker to complement monitoring therapy: bowel dis., 1270
folates: life and premature death with (E), 1579
heteroduplex generator in anal. of Rh blood group alleles, 356
hyperglycemia interference in RBC volume meas. by Technicon analyzers, 76
hypocatalasemia in hospital patients (L), 341
lipemia interference in hematology cell count (L), 987
polyglutamyl folates enzymatic deconjugation, 1847
purine nucleoside deficiency: liq. chromatog. of (CR), 326
reticulocyte quant. by Coulter MAXM VCS tech., 1930
stability of cysteine and blood glutathione, 1100
Erythropoiesis
Fe status: correlation or common sense, 718
Estradiol
cortisol: effect on percentage of non-sex-hormone-bound steroid, 249
meeting report: internatl. workshops (L), 1122
Estrogen
health consequences of postmenopausal hormone therapy (S), 1342
immunoenzymometric assay for receptors of, 1955
Ethanol
ethanol ingestion: total and ionized Mg after, 625
isotope GC-MS meas. of, 367
lab. testing for recent alcohol consumption, 618
salivary reagent stick measures serum (L), 985
Ethylene glycol
gas chromatog. of glycolic acid and, 293
LDH interference in assay of (TB), 1489
Exercise
PSA: phys. acty. releases, 691
Fatty acids
albumin effect on lipoproteins with elevated (TB), 1283
arachidonate: stability in fasting and nonfasting patients (TB), 771
cardiac autopsies: fatty acid-binding protein and myoglobin detn. (L), 337
ester synthase present after liver and pancreatic injury, 24
LDL oxidn., antioxidants, and atherosclerosis (R), 498
phospholipid fatty acids in X-linked adrenoleukodystrophy (CR), 454
Ferritin
Fe status: correlation or common sense, 718
ferritin Fe interferes with meas. of serum Fe (TB), 2042
interference in meas. of Fe (TB), 331
total Fe-binding capacity in evaln. of Fe status (L), 2053
Fertility and infertility
MAb sandwich assays for renin and prorenin, 1051
RT-PCR to quant. CFTR mRNA in endometrium, 1765
Fetal status
evaln. of refractive-matched anomalous diffraction (RIMAD) for fetal lung maturation, 1861
heteroduplex generator in anal. of Rh blood group alleles, 356
MAbs against C-terminal peptide of brain acetylcholinesterase, 19
prostaglandin D synthase assay: immunofluorometry, 1984
prostaglandin D_2 synthase: fetal abnormalities, 1042
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
Fetoprotein
hepatocellular carcinoma and cirrhosis differentiation, 1263
IA with fluorescent Eu label and time-resolved fluorometry, 1196
Fibrinogen
VIDAS D-dimer: ELISA meas. for, 410
Flow cytometry
analyte and label binding assay read by, 1702
chromosome sorting after hybridzn. (A), 1897
precision profiles to eval. leukocyte differential, 1068
Fluorescence
DNA anal. by electrophoresis and laser-induced (TB), 1106

immunosensors: technology and opportunities in lab. med., 193
microenzymatic assay of triglycerides, phospholipids and cholesterol, 915
Fluorescence polarization
M. tuberculosis DNA strand displacement amplifn. and, 9
M. tuberculosis DNA strand displacement amplifn. and, 1604
Fluorescence polarization immunoassay
metabolite and matrix interference in phenytoin IAs, 1645
methamphetamine: strand displacement amplifn. and (L), 1720
methotrexate: evaln. of clin. assays for measg., 39
Fluorescent microparticle assay
PSA: assay discrepancy in prostate cancer follow-up (CR), 637
Fluorometry
detn. of mRNA with oligo(dT), 1758
HIV-1: fluorometric detect. of, 696
MAb-based fluorometric assays in one-step format (S), 1513
platelet meas. of Mg with variables, 744
PSA: assay discrepancy in prostate cancer follow-up (CR), 637
quant. of urinary xanthurenic acid, 397
RT-PCR combined with fluorometry for detect. of BCR-ABL mRNA, 1924
a-tocopherol: quant. of LDL and HDL, 430
Fluorometry, time-resolved
IA with fluorescent Eu label and time-resolved fluorometry, 1196
Folic acid, folate
life and premature death with (E), 1579
material choice for quality control of (L), 652
RBC polyglutamyl folate enzymatic deconjugation, 1847
results of internatl. round robin for, 1689
vit. supplementation: ref. intervals for homocysteine and methylmalonic acid, 630
Follicle-stimulating hormone
inhibin-A: two-site solid phase chemilum. IA for, 1159
Forensic medicine
epidemiology of abused drugs: general population, ER drug-related episodes and arrestees (S), 1330
role of clin. toxicologist in court (S), 1337
signif. of haptoglobin polymorphism (R), 1589
Fragile X syndrome
amplifn. and automated detect. of trinucleotide repeats (A) in, 1890
dynamic mutations pose challenge for lab. (OV), 1582
Free radicals
shortcomings of automated assay for antioxidants (TB), 1712
signif. of haptoglobin polymorphism (R), 1589
smoking effect on pentane excretion in alveolar breath, 303
Friedewald equation
cholesterol: meas. variability of LDL, 732
lipoprotein cholesterol: comparing conventional methods with HPGC, 1996
Fructosamine
BM/Hitachi 747-200 assay for, 244
Gas chromatography
ethylene glycol and glycolic acid detn. by, 293
lactate: 4 automated methods compared with capillary (TB), 1111
smoking effect on pentane excretion in alveolar breath, 303
Gas chromatography-mass spectrometry
cholesterol: 4 test systems evald. by isotope diln. GC-MS, 531
EIA validn. for qual. detect. of cocaine in sweat, 34
ester synthase present after liver and pancreatic injury, 24
ethanol: isotope GC-MS meas. of ethyl-d_5 alcohol, 367
metab. of anabolic androgenic steroids (R), 1001
methylmalonic acid quant. by GC-MS, 910
myo-inositol: distribution in CSF and Alzheimer dis., 298
Pb: electron-capture neg. chem. ionization GC/MS, 286
profiling of urinary organic acids, 1609
testosterone: IA compared with neg. chem. ionization GC-MS, 749
Gemfibrozil
LDL oxidn. inhibit. by gemfibrozil metabolite (TB), 644
Genes
apo B 3N hypervariable repeat genotype: restriction fragment polymorphisms, 927
chemilum.: detect. technology for reporter gene assays (S), 1542
detect. of sex-determining region of Y chromosome (A), 1892
DNA binding proteins, the Zn finger proteins (A), 1893
EIA for c-*erb*B-2 p185 and p53 in ovarian neoplasms (TB), 981
evolution of automated molec. diagnostics (E), 1367
K-*ras* Val-12 mutation in colorectal cancer, 904
lab. testing for diag. and monitoring of thyroid dis. (S), 183
LDL receptor gene: sequence variation detect., 1140
molec. diag. of hereditary neuropathy and Charcot–Marie–Tooth dis., 1021
multiplex, fluorescent minisequencing to screen DNA variations, 1391
p53 tumor suppressor gene importance (R), 858
PCR detn. of gene expression in limiting tissue samples, 227
PCR-sequence study of myogenin gene in congenital myopathies (A), 1898
phenotype-genotype discrepancies at apo E locus, 1817
porphyria: R325X mutation in hydroxymethylbilane synthase gene (TB), 106
preimplantation diag.: minisequencing of blastomere DNA, 1382
Genetic disorders
anal. of patient with congenital adrenal hyperplasia (CR), 1483
CF mutations: chemilum. hybridzn.-ligation assays for DF508 and D1507, 14
CF: nonradioactive mutation detect. (TB), 103
DNA diagnostics for Charcot–Marie–Tooth dis. (E), 995
DNA EIA for detect. deletions in spinal muscular atrophies (TB), 643
dynamic mutations pose challenge for lab. (OV), 1582
endocrine neoplasia: gradient gel electrophoresis, 598
G1691A mutation of coagulation factor V by PCR (TB), 329
Hbs A. F. S. and C: identn. and quant. of by chromatog., 57
homocystinuria diag. from newborn blood spots by MS-MS, 349
HPLC screening method for cystinuria (TB), 1714
Huntington dis.: amplifn. of CAG repeat (TB), 773
hypouricemia in purine nucleoside phosphorylase deficiency (L), 985
LDL receptor gene: sequence variation detect., 1140
leukodystrophy: urine sulfatides and diag. of, 232
methylmalonic acid quant. by GC-MS, 910
molec. diag. of hereditary neuropathy and Charcot–Marie–Tooth dis., 1021
molec. diag. of Machado-Joseph dis. (A), 1889
mutation detect. in *CYP21B* in steroid 21-hydroxylase deficiency (TB), 1108
neonate hemoglobinopathies (E), 658
newborn screening by (MS-MS) (E), 345
nonisotopic detect. of $(CAG)_n$ repeats causing Huntington dis., 1601
p53 tumor suppressor gene importance (R), 858
phospholipid fatty acids in X-linked adrenoleukodystrophy (CR), 454
porphyria: R325X mutation in hydroxymethylbilane synthase gene (TB), 106
preimplantation diag.: minisequencing of blastomere DNA, 1382
purine nucleoside deficiency: liq. chromatog. of (CR), 326
screening for aspartylglucosaminuria mutations, 1398
Southern transfer protocol for confirmation of Huntington dis. (TB), 1711
Genetic variation
apo B 3N hypervariable repeat genotype: restriction fragment polymorphisms, 927
detect. of nucleic acid targets with enzyme-labeled probes (A), 1895
drug resistant mutants in HIV pos. patients (A), 1891
dynamic mutations pose challenge for lab. (OV), 1582
EIA for c-*erb*B-2 p185 and p53 in ovarian neoplasms (TB), 981
evolution of automated molec. diagnostics (E), 1367
heteroduplex generator in anal. of Rh blood group alleles, 356
K-*ras* Val-12 mutation in colorectal cancer, 904
LDL receptor gene: sequence variation detect., 1140
molec. diag. of hereditary neuropathy and Charcot–Marie–Tooth dis., 1021
molec. diagnostics: mass spectrometer approach (A), 1898
multiplex, fluorescent minisequencing to screen DNA variations, 1391
mutation detect. in *CYP21B* in steroid 21-hydroxylase deficiency (TB), 1108
p53 gene mutation detect. by fluorophore-enhanced PCR (A), 1894
p53 gene mutation detect. by nonisotopic PCR (A), 1894
p53 tumor suppressor gene importance (R), 858
preimplantation diag.: minisequencing of blastomere DNA, 1382
relation between no. of apo(a) kringle 4 repeats and isoform mobility, 436
screening for aspartylglucosaminuria mutations, 1398
sequence-specific mutation detect. of K-*ras* using SSCP anal. (TB), 1717
signif. of haptoglobin polymorphism (R), 1589
thymine dimer repair mediated by DNA double helix (A), 1898
Genetics
phenotype-genotype discrepancies at apo E locus, 1817
Genistein
daidzein and genistein concs. in human milk, 955
Geriatric chemistry
ELISA: sol. Fas in elderly, 1911
Globins
mRNA measd. by ELISA and reverse transcription, 1750
Glucose
monitored at high altitude by Accu-Chek Advantage (L), 115
problems and considerations in accuracy with NIST SRM 909a vials, 1832
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
reproducibility of 1-h 50-g glucose challenge test, 255
thiocyanate and cyanide interference in glucose assay (CR), 449
thiocyanate interference on electrochem. biosensors for glucose (L), 1124
Glutamic acid decarboxylase
diabetes: radioimmunoprecipitation assay for GAD Abs, 1975
ELISA GAD_{65} autoAb assay: diabetes marker, 263
Glutathione
concs. in large-scale study, 64
stability of cysteine and blood, 1100
Glycerol
microenzymatic assay of triglycerides, phospholipids and cholesterol, 915

Glycohemoglobin
BM/Hitachi 747-200 assay for fructosamine, 244
Glycoproteins
ref. calibrators for IgG Abs to b_2- (TB), 1116
Glycosides
reduced form of digoxin-like immunoreactive factor, 1092
Growth hormone
assays for (E), 1731
assays compared, 1789
ELISA: insulin-like growth factor-I, 1147
Hair
Cd measd. by AAS (TB), 1287
Fe marker to complement monitoring therapy: bowel dis., 1270
Haptoglobin
relation between IgA conc. and (L), 1722
Healthcare
changing environment for practice of clin. chem. (SR), 91
clin. chem. future and role in (SR), 96
federal reimbursement to labs. (S), 817
how to evaluate and implement new technologies (S), 797
impact of cost cutting on labs. (S), 822
Internet: road to heaven or hell for clin. lab. (S), 827
logical observation identifier names and codes (LOINC) database (SR), 81
point-of-care testing impact on healthcare delivery (L), 2052
review of personnel stds. (S), 790
scope and impact of thyroid dis. (S), 121
why is lab. afterthought for managed care organizations (S), 813
Heart disease and function
blood viscosity and biochem. correlates in healthy adults, 1189
cardiac troponin I and T in chronic myopathy (TB), 2039
cardiac troponin T: marker for cardiac ischemia (S), 803
coronary artery dis.: preb$_1$-HDL increase in, 1992
endothelin-I: chemilum. EIA for, 1155
folates: life and premature death with (E), 1579
inhibit. of Na, K-ATPase by oleandrin and oleandrigenin: digoxin IA detect., 1654
IRMA kit for measg. atrial natriuretic peptides, 1627
LDL oxidn., antioxidants, and atherosclerosis (R), 498
LDL oxidn. inhibit. by gemfibrozil metabolite (TB), 644
LDL-cholesterol assay in hyperlipidemic population, 1182
lipoprotein and apo profile changes induced by alcohol consumption and withdrawal, 1666
lipoprotein cholesterol: comparing conventional methods with HPGC, 1996
ref. interval for apo A-1 detd. with immunoturbidimetric assay, 507
ref. interval for apo B detd. with immunoturbidimetric assay, 515
renin and prorenin methodology, 993
thrombus precursor protein: marker in myocardial infarction (S), 1537
troponin I and LDH isoenzyme sensitivity in myocardial infarction, 1770
troponin T as marker in acute myocarditis (L), 340
troponins and rhabdomyolysis (L), 1120
vit. supplementation: ref. intervals for homocysteine and methylmalonic acid, 630
Heavy metals
metal excretion and Mg retention in those treated with IV EDTA, 1938
Hematocrit
point-of-care testing: impact on length of stay in emergency dept., 711
Hemodialysis
biosensors for monitoring urea during dialysis, 1079
FT_4 concs. measd. by equil. dialysis in renal failure, 1616
pentosidine urine quant. by HPLC with column switching, 1439
Hemoglobin
breath anal. for end-tidal CO, 50
discrimination among dysHBs (L), 1300
Fe status: correlation or common sense, 718
Hb A_{1c} detn. by (L), 2046
HbS influence on HbA quant. by HPLC (TB), 1113
identn. and quant. of Hbs A, F, S, and C by chromatog., 57
signif. of haptoglobin polymorphism (R), 1589
stool sampling delay and fecal occult blood test (TB), 1107
Hemoglobin variants
Hb A_{1c} measd. by latex particle agglutination (TB), 1874
hemoglobinopathies: neonate HPLC screening, 704
identn. and quant. of Hbs A, F, S, and C by chromatog., 57
liq. chromatog.: (Hb Chicago) (TB), 774
neonate hemoglobinopathies (E), 658
Hemolysis
breath anal. for end-tidal CO, 50
Hemopexin
signif. of haptoglobin polymorphism (R), 1589
Hemorrhage
dextran concs. in patients given hypertonic saline-dextran (L), 779
Heparin
anti-Xa acty. of low-molec. wt., 1223
monitoring by thromboplastin time using dry reagent (TB), 1488
Hepatitis B virus and disease
quant. of PCR-amplified HBV DNA (A), 1891
Hepatitis C virus and disease
COBAS AMPLICOR: DNA and RNA amplifn., 1915
detect. of HCV RNA with transcription-mediated amplifn. (A), 1891
HCV and HIV RNA targets detect. by RT-PCR (A), 1895
hyaluronan and procollagen markers for liver fibrosis in hepatitis C, 558
quant. and genotyping of (A), 1889
RNA U-capture for HGV/HGBV-C PCR detect. (A), 1895
Hepatitis G virus and disease
detect. of RNA sequences in HCV pos. donors (A), 1892
RNA U-capture for HGV/HGBV-C PCR detect. (A), 1895
Hirschsprung disease
gradient gel electrophoresis to diag. endocrine neoplasia, 598
Homeostasis
actvd. coagulation markers usefulness (R), 664
Homocysteine
fluorometric quant. of urinary xanthurenic acid, 397
light sensitivity of sulfonic acid derivative in assay of, 2028
vit. supplementation: ref. intervals for methylmalonic acid and, 630
Homocysteinemia
lab. assessment and risk factor for occlusive vascular dis. (E), 492
Homocystinuria
diag. newborn blood spots by MS-MS, 349
Hormones
ELISA: insulin-like growth factor-I, 1147
Kone Quartus random access IA evaln. (TB), 335
leptin: RIA of, 942
lipoproteins: prostate cancer and hormone effect on, 1176
phytoestrogens and breast milk (E), 841
saliva detn. of dexamethasone, 1238
Human chorionic gonadotropin
analyte and label binding assay read by flow cytometry, 1702
Human immunodeficiency virus
drug resistant mutants in HIV pos. patients (A), 1891
fluorometric detect. of, 696
HCV and HIV RNA targets detect. by RT-PCR (A), 1895
NASBA for quant. of HIV-1 RNA (A), 1889
probe hybridzn. assay for subtyping (A), 1891
RNase resistant stds. for HIV diagnostics (A), 1890
Huntington disease
amplifn. of CAG repeat (TB), 773
dynamic mutations pose challenge for lab. (OV), 1582
nonisotopic detect. of $(CAG)_n$ repeats causing, 1601
Southern transfer protocol for confirmation of (TB), 1711
Hyaluronan
marker for liver fibrosis in hepatitis C, 558
Hydrocarbons
smoking effect on pentane excretion in alveolar breath, 303
Hydroxyproline
meas. for deoxypyridinoline and (TB), 2037
Hyperbilirubinemia
breath anal. for end-tidal CO, 50
Hypercholesterolemia
LDL-cholesterol assay in hyperlipidemic population, 1182
LDL receptor gene: sequence variation detect., 1140
lipoprotein cholesterol: comparing conventional methods with HPGC, 1996
Hyperglycemia
interference in RBC volume meas. by Technicon analyzers, 76
Hyperparathyroidism
comparison of total and bone-specific ALP, 1796
Hypertension
MAb sandwich assays for renin and prorenin, 1051
salt intake effect on excretion of ouabain-like substance: RIA, 1949
validn. of HPLC-amperometric detect. to meas. serotonin, 1086
Hyperthyroidism
T_3: usage recommendations and anal. performance goals (S), 155
Hypertriglyceridemia
inaccuracy of Friedewald formula in (TB), 1491
lipoprotein cholesterol: comparing conventional methods with HPGC, 1996
Ibuprofen
HPLC detn. of ibuprofen pharmacokinetics in CF, 1812
Immunoassay
3 labeled-Ab IAs of FT_3, 933
anal. performance of free and total T_4 assays (S), 146
artificial Abs prepared by molec. imprinting (S), 1506
chemilum. IA for vascular endothelial growth factor, 1777
Ciba Corning ACS:180 testosterone evald., 1445
digoxin: Ab specificity effect on, 373
electrochemilum.: automated IA analyte detect. (S), 1576
ELISA GAD_{65} autoAb assay: diabetes marker, 263
ELISA: insulin-like growth factor-I, 1147
with fluorescent Eu label and time-resolved fluorometry, 1196
FT_4 concs. measd. by equil. dialysis in renal failure, 1616
Hb A_{1c} measd. by latex particle agglutination (TB), 1874
6b-Hydroxycortisol interferes with IA of free cortisol (TB), 1290
immunoanalyzer with random access to chemilum. and nephelometric assays (S), 1575
immunosensors: technology and opportunities in lab. med., 193
improvement in performance and convenience (E), 1137

inhibit. of Na, K-ATPase by oleandrin and oleandrigenin: digoxin IA detect., 1654
liposome IA for colorimetry of IgG anticardiolipin Abs, 874
lumin. O_2 channeling assay (LOCI)^{I} (S), 1518
MAbs against C-terminal peptide of brain acetylcholinesterase, 19
meas. of smallest analyte conc., 893
metabolite and matrix interference in phenytoin IAs, 1645
PC-based IA simulation system (S), 1569
procollagen: IA for NH_2-terminal propeptide of type I, 947
PSA complexes with a_2-macroglobulin, 545
PSA epitope mapping with MAbs, 1961
PSA screening using whole blood spotted on filter paper, 536
reduced form of digoxin-like immunoreactive factor, 1092
ref. calibrators for IgG Abs to b_2-glycoprotein I (TB), 1116
Starburst dendrimers: reagents in IAs (S), 1567
testosterone: IA compared with neg. chem. ionization GC-MS, 749
TNF-a receptors interfere with detect. of TNF-a, 1450
TSH assays: status and performance goals (S), 140
two immunometric assay approaches for haptens (S), 1532
ultrafiltration discrepancies in myoglobin recovery from urine, 965

Immunoassay, random access
evalg. interassay carryover on, 725
immunoanalyzer with random access to chemilum. and nephelometric assays (S), 1575
Kone Quartus evaln. (TB), 335

Immunochemiluminescence
PSA: immunofluorometry and Immulite immunochemilum., 675

Immunochemiluminometric assay
growth hormone assays compared, 1789
PSA: assay discrepancy in prostate cancer follow-up (CR), 637
thyroglobulin assays: status and performance goals (S), 164

Immunochromatography
detect. of myoglobin and CK-MB (TB), 1292

Immunoenzymometric assay
for estrogen receptors, 1955
troponin I immunoenzymometric assay in triathlon (TB), 2033

Immunofluorescence
antinuclear test: computer to monitor ability to interpret (S), 836
Chlamydia trachomatis: new approaches to diagnosis of (S), 809

Immunofluorometric assay
analyte and label binding assay read by flow cytometry, 1702
IA: amylin and amylin-like peptides, 576
prostaglandin D synthase assay using, 1984
prostatic kallikrein(hK2), 1034
PSA: immunofluorometry and Immulite immunochemilum., 675
PSA mRNA and protein detect. in breast tumors, 361
trypsinogen: marker of acute pancreatitis in urine, 685

Immunoglobulins
IgA in diabetes: relation to complications, 1064
Ig A-8 conjugated with LDH-5-isoenzyme (TB), 1288
prealbumin, retinol-binding protein, and salivary IgA in AIDS patients (TB), 471
ref. calibrators for IgG Abs to b_2-glycoprotein I (TB), 1116
relation between IgA conc. and haptoglobin type (L), 1722

Immunology
calpastatin autoAbs: detect., mappings, ELISA for, 1250
diagnostic value of serum Abs in celiac dis., 1838
heteroduplex generator in anal. of Rh blood group alleles, 356
immunological detect. of tumor cells and micrometastases (R), 1369
killer cell acty. detn. by AAS, 319
neopterin concs. in vaginal secretions (TB), 1495
signif. of haptoglobin polymorphism (R), 1589

Immunoluminometric assay
immunoluminometric assay for CA 72-4 (TB), 472

Immunometric assay
IAs for small molecules: wash steps and multiple binding (S), 1527
thyroglobulin assays: status and performance goals (S), 164
TSH assays: status and performance goals (S), 140
two approaches for hapten assay (S), 1532

Immunoradiometric assay
ALP acty. detd. in patients with bone dis., 210
ALP: IRMA for bone-specific (TB), 973
for free PSA, 1243
growth hormone assays compared, 1789
kit for measg. atrial natriuretic peptides, 1627
MAb sandwich assays for renin and prorenin, 1051
proinsulins: IRMA compared with HPLC (TB), 977
PSA: assay discrepancy in prostate cancer follow-up (CR), 637
renin and prorenin methodology (E), 993
thyroglobulin assay and autoAb interference, 258

Immunosensors
technology and opportunities in lab. med. (R), 193

Immunosuppression
p53 tumor suppressor gene importance (R), 858

Immunoturbidimetric assay
Hb A_{1c} detn. by (L), 2046
ref. interval for apo A-1 detd. with, 507
ref. interval for apo B detd. with immunoturbidimetric assay, 515

Infection
COBAS AMPLICOR: DNA and RNA amplifn., 1915
GeneStar: gastrointestinal bacterial pathogens (A), 1895
M. tuberculosis DNA strand displacement amplifn. and fluorescence polarizn., 9
M. tuberculosis DNA strand displacement amplifn. and fluorescence polarizn., 1604

Inflammation
antisense for modulation of inflammatory responses (A), 1893
HPLC detn. of ibuprofen pharmacokinetics in CF, 1812
signif. of haptoglobin polymorphism (R), 1589
TNF-a receptors interfere with detect. of TNF-a, 1450
TNF-a: CSF shelf life and activn. energy, 670

Inhibin
two-site solid phase chemilum. IA for, 1159

Insulin
Coat-A-Count RIA (L), 777
ELISA: insulin-like growth factor-I, 1147

Insulin-like growth factor
ELISA, 1147

Interferometry
immunosensors: technology and opportunities in lab. med., 193

Interlaboratory performance
Abbott IMx CA 15-3 assay evaln., 28
ascorbic acid stability, repeatability, and reproducibility, 1257
bilirubin: interlab. variability, 869
folate: results of internatl. round robin for, 1689
heparin: anti-Xa acty. of low-molec. wt., 1223

Intermethod comparison
3 labeled-Ab IAs of FT_3, 933
anal. performance of PSA assays compared, 1026
bilirubin: errors in meas., 845
Ca: enzyme assay for, 1202
cardiac troponin I and T in chronic myopathy (TB), 2039
cholesterol: 4 test systems evald. by isotope diln. GC-MS, 531
cholesterol: meas. variability of LDL, 732
Ciba Corning ACS:180 testosterone evald., 1445
comparison of total and bone-specific ALP, 1796
diagnostic value of serum Abs in celiac dis., 1838
digoxin: Ab specificity effect on IAs, 373
evaln. of IAs on Technicon Immuno I, 1695
ferritin interference in meas. of Fe (TB), 331
folate: results of internatl. round robin for, 1689
FT_4 concs. measd. by equil. dialysis in renal failure, 1616
g-glutamyltransferase: evaln. as ref. material, 2008
growth hormone assays (E), 1731
growth hormone assays compared, 1789
HDL cholesterol: 3 methods for measg., 738
HPLC with fluorometric detect. of Allumogallion complex, 1405
hyperglycemia: interference in RBC volume meas. by Technicon analyzers, 76
identn. and quant. of Hbs A, F, S, and C by chromatog., 57 immunoadsorption assay compared with agglutinin assay for ALP, 1970
immunoreactive elastase: test of pancreatic function, 222
ion-selective electrode stability: AVL and Nova Mg and Ca, 880
IRMA compared with HPLC, 977
lactate: 4 automated methods compared with capillary GC (TB), 1111
LDL-cholesterol assay in hyperlipidemic population, 1182
lipase assay: standardization importance using calibrators, 1979
lipid detn. by Fourier transform infrared spectrometry, 2015
methotrexate: evaln. of clin. assays for measg., 39
NH_4 persulfate: oxidizing reagent for urinary I^-, 239
phenotype-genotype discrepancies at apo E locus, 1817
precision profiles to eval. leukocyte differential, 1068
procollagen: IA for NH_2-terminal propeptide of type I, 947
PSA: assay discrepancy in prostate cancer follow-up (CR), 637
reticulocyte quant. by Coulter MAXM VCS tech., 1930
testosterone: IA compared with neg. chem. ionization GC-MS, 749
thyroglobulin assays: status and performance goals (S), 164
thyroid status in thyrotoxicosis (S), 174
troponin I and LDH isoenzyme sensitivity in myocardial infarction, 1770

Intestinal disease and function
Fe marker to complement monitoring therapy: bowel dis., 1270

Iodine
NH_4 persulfate: oxidizing reagent for urinary I^-, 239
spectrophotometric detn. of urinary I^-: flow-injection anal., 2021

Ion-capture assay
folate: results of internatl. round robin for, 1689

Ion-selective electrodes
ethanol ingestion: total and ionized Mg after, 625
immunosensors: technology and opportunities in lab. med., 193
stability: AVL and Nova Mg and Ca, 880

Iron
evalg, Fe economy (E), 657
Fe status: correlation or common sense, 718
ferritin interference in meas. of (TB), 331
ferritin Fe interferes with meas. of serum Fe (TB), 2042
hair marker to complement monitoring therapy: bowel dis., 1270
pediatric poisonings (S), 1356
serum transferrin in evaln. of Fe status (L), 2053
signif. of haptoglobin polymorphism (R), 1589
when is serum Fe really serum Fe? (TB), 109

Isoenzymes
adenosine deaminase in pleural effusions (L), 1880
ALP acty. detd. in patients with bone dis., 210

cardiac troponin T marker for cardiac ischemia (S), 803
comparison of total and bone-specific ALP, 1796
glutathione *S*-transferase Alpha 1-1 in gastrointestinal dis.: ELISA, 416
hepatocellular carcinoma and cirrhosis differentiation, 1263
immunoadsorption assay compared with agglutinin assay for ALP, 1970
LDH isoenzyme utilizn. (L), 1723
myocardial infarction: neural networks to diag., 613
sensitivity of CK-MB2, CK-MB, and myoglobin in myocardial infarction, 1454
serum lipase without pancreatitis (CR), 462
troponin I immunoenzymometric assay in triathlon (TB), 2033

Isoflavinoids
genistein and daidzein concs. in human milk, 955

Isoprostanes
LDL oxidn., antioxidants, and atherosclerosis (R), 498

Kallikrein
immunofluorometric assay for prostatic kallikrein(hK2), 1034

Kidney disease and function
As accumulation in renal dis., 1231
biosensors for monitoring urea during dialysis, 1079
cardiac troponins in chronic renal failure (L), 114
cyanate concs. in chronic renal failure (L), 482
FT_4 concs. measd. by equil. dialysis in renal failure, 1616
pentosidine urine quant. by HPLC with column switching, 1439
ref. intervals for 10 biochem. markers in fetal urine, 1855
renal function effect on NO concs., 440
sirolimus quant. in kidney graft recipients by HPLC/electrospray MS, 1417
thiocyanate concs. in patients receiving nitroprusside (L), 1878
troponin T and I after coronary artery grafting (L), 781
ultrafiltration discrepancies in myoglobin recovery from urine, 965
urine protein expert system evaln., 1214

Kits
extn. of supercoiled DNA using XTRAX (A), 1898
isolation kit method for fecal samples (A), 1897

Laboratory management
advances in poison management (S), 1361
appln. of process capability indices to quality control (TB), 2035
ascorbic acid stability, repeatability, and reproducibility, 1257
avg. of normals patient data algorithms, 1683
axial centrifn., 402
cardiac troponin T marker for cardiac ischemia (S), 803
changing environment for practice of clin. chem. (SR), 91
changing face of clin. lab. (E), 1899
Chlamydia trachomatis: new approaches to diagnosis of (S), 809
cost-effective protocols for lab. testing, 347
delivering clin. lab. services to ICUs, 387
dynamic mutations pose challenge for lab. (OV), 1582
evaln. of Du Pont axial sepn. system, 1467
evolution of automated molec. diagnostics (E), 1367
FDAs impact on lab. performance (S), 786
Fe status: correlation or common sense, 718
federal reimbursement to labs. (S), 817
how to evaluate and implement new technologies (S), 797
impact of converging technologies (R), 1735
impact of cost cutting on labs. (S), 822
Internet: road to heaven or hell for clin. lab. (S), 827
ISO 9001 benefits and pitfalls: successful certification (S), 1561
lab. testing for diag. and monitoring of thyroid dis. (S), 183
logical observation identifier names and codes (LOINC) database (SR), 81
meeting report: estradiol internatl. workshops (L), 1122
myocardial infarction: I. neural networks to diag., 604
myocardial infarction: II. neural networks to diag., 613
neural networks: lab. aid or sorcerer's apprentice? (E), 496
payment for new in vitro diagnostic technologies (S), 1558
point-of-care testing: impact on length of stay in emergency dept., 711
precision profiles to eval. leukocyte differential, 1068
prep. of samples with equally spaced concs., 1074
problems and considerations in accuracy with NIST SRM 909a vials, 1832
random access IA: evalg. interassay carryover on, 725
regulatory hurdles in bringing diagnostic device to market (S), 1556
review of personnel stds. (S), 790
robotics and changing face of clin. lab. (R), 1901
sensitivity of CK-MB2, CK-MB, and myoglobin in myocardial infarction, 1454
Shewhart *p* chart: monitoring anal. performance of clin. chem. lab, 1478
telepathology to improve patient care (S), 831
why is lab. afterthought for managed care organizations (S), 813

Lactate/lactic acid
4 automated methods compared with capillary GC (TB), 1111
bilirubin interference with P, uric acid and (L), 988
Paramax triglyceride reagent: lactate and LDH interferences (L), 778

Lactate dehydrogenase
evaln. of Du Pont axial sepn. system, 1467
hepatocellular carcinoma and cirrhosis differentiation, 1263
Ig A-8 conjugated with LDH-5-isoenzyme (TB), 1288
isoenzyme utilizn. (L), 1723
LDH interference in assay of ethylene glycol (TB), 1489
Paramax triglyceride reagent: lactate interferences (L), 778
troponin I and LDH isoenzyme sensitivity in myocardial infarction, 1770

Lactulose
quant. in urine by HPLC for intestinal permeability, 71
sugar probe in serum: intestinal permeability testing, 445

Lead
electron-capture neg. chem. ionization GC/MS, 286
metal excretion and Mg retention in those treated with IV EDTA, 1938
screening children for (L), 983

Lecithin
coronary artery dis.: $preb_1$-HDL increase in, 1992

Leptin
progress and directions for human (E), 843
RIA of, 942

Leucovorin
methotrexate: concepts in use of high-dose therapy (S), 1322

Leukemia
6-mercaptopurine: detect. and identn. of, 380
methotrexate: concepts in use of high-dose therapy (S), 1322
RT-PCR combined with fluorometry for detect. of BCR-ABL mRNA, 1924

Leukocytes
g-glutamyltransferase: evaln. as ref. material, 2008
precision profiles to eval. meas. of, 1068

Leukodystrophy
phospholipid fatty acids in X-linked adrenoleukodystrophy (CR), 454
urine sulfatides and diag. of, 232

Leukotrienes
two immunometric assay approaches for haptens (S), 1532

Li-Fraumeni syndrome
p53 tumor suppressor gene importance (R), 858

Lidocaine
HPLC of lidocaine metabolites and (TB), 330

Ligase chain reaction
Chlamydia trachomatis: new approaches to diagnosis of (S), 809

Lipase
lipase assay: standardization importance using calibrators, 1979
serum lipase without pancreatitis (CR), 462

Lipemia
interference in hematology cell count (L), 987

Lipid peroxidation
smoking effect on pentane excretion in alveolar breath, 303
vit. E supplementation in hyperthyroidism (TB), 1118

Lipids
blood viscosity and biochem. correlates in healthy adults, 1189
detn. by Fourier transform infrared spectrometry, 2015
ester synthase present after liver and pancreatic injury, 24
phenotype-genotype discrepancies at apo E locus, 1817
ref. interval for apo A-1 detd. with immunoturbidimetric assay, 507
serum lipids and vit. E variability in serum concs., 1824
variation in lipids and lipoproteins in fingerstick blood, 2002

Lipocalins
prostaglandin D synthase assay: immunofluorometry, 1984
prostaglandin D_2 synthase: fetal abnormalities, 1042

Lipoproteins
albumin effect on lipoproteins with elevated fatty acids (TB), 1283
apo B 3N hypervariable repeat genotype: restriction fragment polymorphisms, 927
apos. in diag. and treatment of dyslipoproteinemia (E), 489
cholesterol: meas. variability of LDL, 732
cigarette consumption and Lp(a) concs. (L), 479
coronary artery dis.: $preb_1$-HDL increase in, 1992
HDL cholesterol detd. by homogeneous assay, 424
HDL cholesterol: 3 methods for measg., 738
implementation of recommendations from NCEP (L), 651
incubation effects on ELISA for (TB), 1709
LDL-cholesterol assay in hyperlipidemic population, 1182
LDL-cholesterol: direct meas. of (L), 781
LDL oxidn., antioxidants, and atherosclerosis (R), 498
LDL oxidn. inhibit. by gemfibrozil metabolite (TB), 644
LDL oxidn. in smokers, 524
LDL receptor gene: sequence variation detect., 1140
lipoprotein cholesterol: comparing conventional methods with HPGC, 1996
microenzymatic assay of triglycerides, phospholipids and cholesterol, 915
prostate cancer and hormone effect on, 1176
serum lipids in anabolic steroid users (CR), 970
serum lipids and vit. E variability in serum concs., 1824
serum profile changes induced by alcohol consumption and withdrawal, 1666
a-tocopherol: quant. of LDL and HDL, 430
variation in lipids and lipoproteins in fingerstick blood, 2002

Liposomes
DNA sequence identn. using liposomes, 1206
IA for colorimetry of IgG anticardiolipin Abs, 874
Lithium
false Li readings from cadavers by flame photometry (L), 1302
Liver disease and function
comparison of total and bone-specific ALP, 1796
cord blood biochem. and idiopathic neonatal jaundice (TB), 1716
ester synthase present after liver and pancreatic injury, 24
glutathione *S*-transferase Alpha 1-1 in gastrointestinal dis.: ELISA, 416
hepatocellular carcinoma and cirrhosis differentiation, 1263
HPLC of lidocaine metabolites and (TB), 330
hyaluronan and procollagen markers for liver fibrosis in hepatitis C, 558
lipoprotein and apo profile changes induced by alcohol consumption and withdrawal, 1666
lumin. O_2 channeling assay (LOCI)^{I} (S), 1518
pseudouridine discrimination of hepatocarcinoma and cirrhotic ascites, 1843
Liver transplantation
tacrolimus: liq. chromatog.-electrospray MS-MS, 279
Luminescence
reporter genes in animal model (A), 1895
Lung disease and function. *See* Pulmonary disease and function
Lymphocytes
killer cell acty. detn. by AAS, 319
Lysosomal storage disease
leukodystrophy: urine sulfatides and diag. of, 232
Lysozyme
adenosine deaminase: differentiating tuberculous and nontuberculous effusions, 218
Machado-Joseph disease
molec. diag. of (A), 1889
Macroglobulin
IA for PSA complexes with a_2-macroglobulin, 545
PSA concs. in acute illnesses, 1785
Magnesium
detn. based on activn. of isocitrate DHase, 1474
ethanol ingestion: total and ionized Mg after, 625
ion-selective electrode stability: AVL and Nova Mg and Ca, 880
metal excretion and Mg retention in those treated with IV EDTA, 1938
platelet meas. of Mg with variables, 744
Malabsorption
immunoreactive elastase: test of pancreatic function, 222
near-infrared reflectance of fecal CHOs, 309
Malaria
biolum. hybridzn. IAs for detect. of mycobacterium and (A), 1894
Malondialdehyde
LDL oxidn. in smokers, 524
Mannitol
quant. in urine by HPLC for intestinal permeability, 71
sugar probe in serum: intestinal permeability testing, 445
Markers, biological
actvd. coagulation markers usefulness (R), 664
CA-125 concs. as marker for endometriosis (TB), 1871
carboplatin: markers of tubular function after receiving (L), 1498
cardiac troponin T: marker for cardiac ischemia (S), 803
EIA for c-*erb*B-2 p185 and p53 in ovarian neoplasms (TB), 981
ELISA GAD_{65} autoAb assay: diabetes marker, 263
Fe marker to complement monitoring therapy: bowel dis., 1270
hyaluronan and procollagen markers for liver fibrosis in hepatitis C, 558
lab. testing for diag. and monitoring of thyroid dis. (S), 183
LDH isoenzyme utilizn. (L), 1723
myocardial infarction: fluoroenzymometric method to meas. troponin I, 1460
myoglobin/carbonic anhydrase III ratio (TB), 107
PSA epitope mapping with MAbs, 1961
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
thrombus precursor protein: marker in myocardial infarction (S), 1537
troponin T as marker in acute myocarditis (L), 340
trypsinogen: marker of acute pancreatitis in urine, 685
Mass spectrometry
athletic drug testing and anabolic steroids, 999
homocystinuria diag. from newborn blood spots by MS-MS, 349
isotope-diln.-MS quant. of apo A-I, 1676
molec. diagnostics: mass spectrometer approach (A), 1898
newborn screening by (MS-MS) (E), 345
tacrolimus: liq. chromatog.-electrospray MS-MS, 279
Ti identn. and meas. by ICP-MS and ICP-OES in spleen (TB), 1875
Meningitis
TNF-a: CSF shelf life and activn. energy, 670
Menopause
RIA of C-telopeptides of collagen to assess bone resorption, 1639
Menstrual cycle
inhibin-A: two-site solid phase chemilum. IA for, 1159
RT-PCR to quant. CFTR mRNA in endometrium, 1765
Mercury
metal excretion and Mg retention in those treated with IV EDTA, 1938
Metabolic disorders
comparison of total and bone-specific ALP, 1796
cord blood biochem. and idiopathic neonatal jaundice (TB), 1716
GC-MS profiling of urinary organic acids, 1609
lipid detn. by Fourier transform infrared spectrometry, 2015
spectrofluorometric detn. of PABA and PASA by Tb-sensitized luminescence, 1659
standardization of collagen crosslinks as biochem. markers, 1621
Metabolism
anabolic androgenic steroids (R), 1001
ethanol: isotope GC-MS meas. of ethyl-d_5 alcohol, 367
homocystinuria diag. from newborn blood spots by MS-MS, 349
lab. testing for recent alcohol consumption, 618
leptin: progress and directions for human (E), 843
lipoproteins: prostate cancer and hormone effect on, 1176
MAbs for urinary pyridinium cross-links, 1168
org. acid detn. in screening org. acidurias (TB), 477
phytoestrogens and breast milk (E), 841
purine nucleoside deficiency: liq. chromatog. of (CR), 326
reduced form of digoxin-like immunoreactive factor, 1092
renal function effect on NO concs., 440
tacrolimus metabolite patterns from liver and kidney transplants, 1426
Methamphetamine
interference of alum (L), 338
Methanol
lab. testing for recent alcohol consumption, 618
Methotrexate
concepts in use of high-dose therapy (S), 1322
evaln. of clin. assays for measg., 39
6-mercaptopurine: detect. and identn. of, 380
Methylmalonic acid
quant. by GC-MS, 910
vit. supplementation: ref. intervals for homocysteine and, 630
Microglobulins
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
Microsomes
reduced form of digoxin-like immunoreactive factor, 1092
Milk
genistein and daidzein concs. in human, 955
prostaglandin D synthase assay: immunofluorometry, 1984
Mitochondria
DNA ref. std. for qual. control, medical diag., and mutational detect. (A), 1892
Monitoring therapy
amrinone: HPLC in patients on cephalosporin, 761
anal. of benzodiazepines by HPLC with solid-phase extn., 1412
CA 15.3, CEA, and tissue polypeptide for breast cancer monitoring, 564
digoxin: nighttime dosing and therapeutic drug monitoring of, 45
digoxin: Ab specificity effect on IAs, 373
methotrexate: concepts in use of high-dose therapy (S), 1322
modern concepts of primary thyroid gland failure (S), 179
spectrophotometric detn. of urinary I⁻: flow-injection anal., 2021
T_3 usage recommendations and anal. performance goals (S), 155
tacrolimus: liq. chromatog.-electrospray MS-MS, 279
thyroglobulin ELISA: autoAb interference, 766
Multianalyte testing
anal. stability: patient data statistics, 888
chemilum.: detect. technology for reporter gene assays (S), 1542
Ektachem 250 testing of Na, K, Ca, urea, and creatinine (TB), 105
electrochemilum.: automated IA analyte detect. (S), 1576
evaln. of Du Pont axial sepn. system, 1467
evaln. of IAs on Technicon Immuno I, 1695
GeneStar: gastrointestinal bacterial pathogens (A), 1895
IA performance and convenience improvement (E), 1137
IA for PSA complexes with a_2-macroglobulin, 545
IAs for small molecules: wash steps and multiple binding (S), 1527
microenzymatic assay of triglycerides, phospholipids and cholesterol, 915
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
urine protein expert system evaln., 1214
Multilayer film analysis
bilirubin: errors in meas. (E), 845
Muscle
cardiac troponin I and T in chronic myopathy (TB), 2039
troponin I immunoenzymometric assay in triathlon (TB), 2033
Myalgia
clin. studies of drug effects in humans (S), 1306
***Mycobacterium avium* complex**
amplifn. system for *M. tuberculosis* and *M. avium* complex (A), 1894
***Mycobacterium* tuberculosis**
amplifn. and fluorescence polarizn. detect. of *M. tuberculosis* DNA, 9
amplifn. and fluorescence polarizn. of DNA of *M. tuberculosis*, 1604
amplifn. system for *M. tuberculosis* and *M. avium* complex (A), 1894
biolum. hybridzn. IAs for detect. of malaria and (A), 1894
COBAS AMPLICOR: DNA and RNA amplifn., 1915
PCR amplifn. of IS6110 in *M.tuberculosis* (A), 1895
PCR amplifn. of IS6110 in *M. tuberculosis* (A), 1896
***myo*-inositol**
distribution in CSF and Alzheimer dis., 298

Myocardial infarction
cardiac troponin T: marker for cardiac ischemia (S), 803
fluoroenzymometric method to meas. troponin I, 1460
health consequences of postmenopausal hormone therapy (S), 1342
myoglobin/carbonic anhydrase III ratio (TB), 107
neural networks to diag.: clin. appln., 613
neural networks to diag.: methodology, 604
sensitivity of CK-MB2, CK-MB, and myoglobin in myocardial infarction, 1454
thrombus precursor protein: marker in (S), 1537
troponin I and LDH isoenzyme sensitivity in myocardial infarction, 1770
troponin I: prognostic value in chest pain (L), 651
troponin T and I after coronary artery grafting (L), 781
Myoglobin
cardiac autopsies: fatty acid-binding protein and myoglobin detn. (L), 337
immunochromatog. for detect. of myoglobin and CK-MB (TB), 1292
myocardial infarction: fluoroenzymometric method to meas. troponin I, 1460
myoglobin/carbonic anhydrase III ratio (TB), 107
sensitivity of CK-MB2, CK-MB, and myoglobin in myocardial infarction, 1454
ultrafiltration discrepancies in myoglobin recovery from urine, 965
Myotonic dystrophy
dynamic mutations pose challenge for lab. (OV), 1582
Myxedema
modern concepts of primary thyroid gland failure (S), 179
National Academy of Clinical Biochemistry Symposium
introduction, 119
National Cholesterol Education Program
lipoprotein: implementation of recommendations from (L), 651
NCCLS (National Committee of Clinical Laboratory Standards)
ref. materials: how useful are they (E), 1733
Near-infrared reflectance
fecal carbohydrates, 309
Neisseria gonorrhoeae
COBAS AMPLICOR: DNA and RNA amplifn., 1915
Neonates
breath anal. for end-tidal CO, 50
cord blood biochem. and idiopathic neonatal jaundice (TB), 1716
folates: life and premature death with (E), 1579
genistein and daidzein concs. in human milk, 955
hemoglobinopathies: neonate HPLC screening, 704
heteroduplex generator in anal. of Rh blood group alleles, 356
HIV-1: fluorometric detect. of, 696
homocystinuria diag. from newborn blood spots by MS-MS, 349
interference by digoxin-like factors in neonates and pregnant women (TB), 974
phytoestrogens and breast milk (E), 841
PSA in children from birth to age 18 years, 420
screening for hemoglobinopathies (E), 658
screening by (MS-MS) (E), 345
Neopterin
concs. in vaginal secretions (TB), 1495
Nephelometry
detn. of CHO-deficient transferrin, 551
immunoanalyzer with random access to chemilum. and nephelometric assays (S), 1575
Neural networks
lab. aid or sorcerer's apprentice? (E), 496
myocardial infarction: I. neural networks to diag., 604
myocardial infarction: II. neural networks to diag., 613
Neural tube defect
MAbs against C-terminal peptide of brain acetylcholinesterase, 19
Neurological disorders
HPLC: purine nucleotide products in CSF, 756
Neuropathy
IgA in diabetes: relation to age and complications, 1064
Newborns. *See* Pediatric chemistry; Neonates
Nitrate
renal function effect on NO concs., 440
Nitric oxide
renal function effect on concs. of, 440
Nitroprusside
thiocyanate and cyanide interference in glucose assay (CR), 449
Nucleic acid probes
COBAS AMPLICOR: DNA and RNA amplifn., 1915
detect. of molecules by fluorescent reporter groups and (S), 1573
detect. of nucleic acid targets with enzyme-labeled probes (A), 1895
detect. of single base mismatches using chemilum. hybridzn. (A), 1893
DNA and RNA probe *in situ* hybridzn. (A), 1889
multiple analyte detect. utilizing chemilum. (A), 1894
probe hybridzn. assay for subtyping HIV-1 (A), 1891
RT-PCR combined with fluorometry for detect. of BCR-ABL mRNA, 1924
RT-PCR to quant. CFTR mRNA in endometrium, 1765
Nucleic acids
NASBA extractor (A), 1896
toward Ab mediated nucleic acid detect. (A), 1897
Nutrition
antioxidant acty. of resveratrol in red wine (L), 113
leptin: progress and directions for human (E), 843
physiological variations in thyroid hormones (S), 135
phytoestrogens and breast milk (E), 841
Nutritional status
arachidonate: stability in fasting and nonfasting patients (TB), 771
near-infrared reflectance of fecal CHOs, 309
prealbumin, retinol-binding protein, and salivary IgA in children with AIDS (TB), 471
a-tocopherol: quant. of LDL and HDL, 430
vit. D: quant. by RIA with ^{125}I tracer, 587
vit. supplementation: ref. intervals for homocysteine and methylmalonic acid, 630
Oak Ridge Conference-1996
introduction, 1505
poster abstracts, 1889
Obesity
growth hormone assays compared, 1789
leptin: progress and directions for human (E), 843
leptin: RIA of, 942
Occupational disease
HPLC with fluorometric detect. of Al-lumogallion complex, 1405
Oligonucleotides
antisense for modulation of inflammatory responses (A), 1893
discovery and develop. of MMI linkage (A), 1897
electrodialysis purifn. of oligonucleotide-protein conjugates (A), 1897
fluorometric detn. of mRNA with oligo(dT), 1758
"gas-phase cleavage of oligodeoxyribonucleotides (A), 1898
a-globin mRNA measd. by ELISA and reverse transcription, 1750
3′-terminal labeling of (A), 1896
Oncogenes
sequence-specific mutation detect. of K-*ras* using SSCP anal. (TB), 1717
RT-PCR combined with fluorometry for detect. of BCR-ABL mRNA, 1924
Opinions
PSA sensitivity reports mislead clinicians, 849
PSA: ultrasensitive assays, 853
Osteoporosis
ALP: IRMA for bone-specific (TB), 973
pentosidine urine quant. by HPLC with column switching, 1439
Osteosarcoma
methotrexate: concepts in use of high-dose therapy (S), 1322
Ouabain
digitalis-like factors: placenta radioreceptor assay with digoxin and, 270
EIA compared to radioreceptor assay (TB), 648
inhibit. of Na, K-ATPase by oleandrin and oleandrigenin: digoxin IA detect., 1654
salt intake effect on excretion of ouabain-like substance: RIA, 1949
Overview
dynamic mutations pose challenge for lab., 1582
Paget disease
procollagen blood concs. in bone (L), 1121
Pancreas disease and function
ester synthase present after liver and pancreatic injury, 24
immunoreactive elastase: test of pancreatic function, 222
serum lipase without pancreatitis (CR), 462
spectrofluorometric detn. of PABA and PASA by Tb-sensitized luminescence, 1659
trypsinogen: marker of acute pancreatitis in urine, 685
Paraaminobenzoic acid
spectrofluorometric detn. of PABA and PASA by Tb-sensitized luminescence, 1659
Paraaminosalicylic acid
spectrofluorometric detn. of PABA and PASA by Tb-sensitized luminescence, 1659
Paramagnetic separation
chemilum. hybridzn.-ligation assays for DF508 and D1507 CF mutations, 14
Parathyroid hormone
rapid PTH assay: modification of Nichols PTH assay (L), 1498
Pediatric chemistry
amrinone: HPLC in patients on cephalosporin, 761
diagnostic value of serum Abs in celiac dis., 1838
evaln. of refractive-matched anomalous diffraction (RIMAD) for fetal lung maturation, 1861
folates: life and premature death with (E), 1579
GC-MS profiling of urinary organic acids, 1609
homocystinuria diag. from newborn blood spots by MS-MS, 349
immunoadsorption assay compared with agglutinin assay for ALP, 1970
LDL-cholesterol assay in hyperlipidemic population, 1182
pediatric poisonings (S), 1356
PSA in children from birth to age 18 years, 420
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
rhamnose, mannitol, and lactulose quant. in urine, 71
sugar probe in serum: intestinal permeability testing, 445
Pentosidine
urine quant. by HPLC with column switching, 1439
Peptides
actvd. coagulation markers usefulness (R), 664
endothelin-I: chemilum. EIA for, 1155
IA: amylin and amylin-like peptides, 576
IRMA kit for measg. atrial natriuretic peptides, 1627
RIA of C-telopeptides of collagen to assess bone resorption, 1639
trypsinogen: marker of acute pancreatitis in urine, 685
two immunometric assay approaches for haptens (S), 1532

Peroxisome disorders
phospholipid fatty acids in X-linked adrenoleukodystrophy (CR), 454
Pharmacokinetics
digoxin: nighttime dosing and therapeutic drug monitoring of, 45
ethanol: isotope GC-MS meas. of ethyl-d_5 alcohol, 367
HPLC detn. of ibuprofen pharmacokinetics in CF, 1812
methotrexate: concepts in use of high-dose therapy (S), 1322
pediatric poisonings (S), 1356
monitoring whole-blood by HPLC with UV detect, 1943
Phencyclidine
thioridazine interference in identn. of (L), 1885
Phenylketonuria
newborn screening by (MS-MS) (E), 345
Phenytoin
metabolite and matrix interference in phenytoin IAs, 1645
Phosphate
monoclonal Ig interference in PO_4 meas. (L), 1298
Phospholipids
microenzymatic assay of triglycerides, phospholipids and cholesterol, 915
phospholipid fatty acids in X-linked adrenoleukodystrophy (CR), 454
Phosphorus
bilirubin interference with lactate, uric acid and (L), 988
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
Photometry
variation in lipids and lipoproteins in fingerstick blood, 2002
Phytoestrogens
breast milk and (E), 841
Plasminogen
von Willebrand factor compared with plasminogen activator concs. (TB), 976
Platelets
validn. of HPLC-amperometric detect. to meas. serotonin, 1086
Point-of-care testing
heparin: monitoring by thromboplastin time using dry reagent (TB), 1488
impact on healthcare delivery (L), 2052
impact on length of stay in emergency dept., 711
variation in lipids and lipoproteins in fingerstick blood, 2002
Polychlorinated biphenyls
evalg. impact of exposure to environmental contaminants (S), 1345
Polymerase chain reaction
amplifn. and automated detect. of trinucleotide repeats (A) in Fragile X syndrome, 1890
amplifn. of IS6110 in *M. tuberculosis* (A), 1896
apo B 3N hypervariable repeat genotype: restriction fragment polymorphisms, 927
carrier detect. of Duchenne muscular dystrophy by PCR (A), 1891
chemilum. hybridzn.-ligation assays for DF508 and D1507 CF mutations, 14
Chlamydia trachomatis: new approaches to diagnosis of (S), 809
COBAS AMPLICOR: DNA and RNA amplifn., 1915
detect. of *Borrelia burgdorferi* OspA sequences by PCR (A), 1892
detect. of immobilized amplicons by ELISA (S), 1547
detect. of sex-determining region of Y chromosome (A), 1892
detn. of gene expression in limiting tissue samples, 227
DNA diagnostics for inherited neuropathies and Charcot–Marie–Tooth dis. (E), 995
DNA: eluting from dried blood spots (TB), 1115
DNA sequence identn. using liposomes, 1206
dynamic mutations pose challenge for lab. (OV), 1582
G1691A mutation of coagulation factor V by PCR (TB), 329
HCV and HIV RNA targets detect. by RT-PCR (A), 1895
HIV-1: fluorometric detect. of, 696
immunological detect. of tumor cells and micrometastases (R), 1369
K-*ras* Val-12 mutation in colorectal cancer, 904
LDL receptor gene: sequence variation detect., 1140
ligation-mediated PCR: mapping DNA damage (A), 1896
media for high-resolution electrophoresis of fragments from (A), 1897
mole. diag. of orthopedic infections (A), 1890
multiplex, fluorescent minisequencing to screen DNA variations, 1391
nonisotopic detect. of $(CAG)_n$ repeats causing Huntington dis., 1601
p53 gene mutation detect. by fluorophore-enhanced (A), 1894
p53 gene mutation detect. by nonisotopic (A), 1894
PCR amplifn. of IS6110 in *M.tuberculosis* (A), 1895
PCR-sequence study of myogenin gene in congenital myopathies (A), 1898
phenotype-genotype discrepancies at apo E locus, 1817
preimplantation diag.: minisequencing of blastomere DNA, 1382
PSA mRNA not always indicative of tumor cells (L), 1499
PSA mRNA and protein detect. in breast tumors, 361
quant. of PCR-amplified HBV DNA (A), 1891
RNA U-capture for HGV/HGBV-C PCR detect. (A), 1895
RT-PCR combined with fluorometry for detect. of BCR-ABL mRNA, 1924
RT-PCR to quant. CFTR mRNA in endometrium, 1765
screening for aspartylglucosaminuria mutations, 1398
sequence-specific mutation detect. of K-*ras* using SSCP anal. (TB), 1717
Polyols
distribution in CSF and Alzheimer dis., 298
Porphyria
R325X mutation in hydroxymethylbilane synthase gene (TB), 106
Potassium
myocardial infarction: I. neural networks to diag., 604
myocardial infarction: II. neural networks to diag., 613
salt intake effect on excretion of ouabain-like substance: RIA, 1949
variations using tubes with gel separators (L), 1300
Prednisolone
steroid hormone anal. using improved HPLC (TB), 979
Pregnancy
digitalis-like factors: placenta radioreceptor assay with digoxin and ouabain, 270
heteroduplex generator in anal. of Rh blood group alleles, 356
interference by digoxin-like factors in neonates and pregnant women (TB), 974
prostaglandin D synthase assay: immunofluorometry, 1984
prostaglandin D_2 synthase: fetal abnormalities, 1042
reproducibility of 1-h 50-g glucose challenge test, 255
screening for aspartylglucosaminuria mutations, 1398
Procollagen
hyaluronan and procollagen markers for liver fibrosis in hepatitis C, 558
IA for NH_2-terminal propeptide of type I, 947
procollagen blood concs. in Paget dis. of bone (L), 1121
Proficiency testing
avg. of normals patient data algorithms, 1683
matrix effects and quality control to monitor Po_2 meas., 392
review of personnel stds. (S), 790
serum from single donations: assessment of (TB), 469
Progesterone
IA with fluorescent Eu label and time-resolved fluorometry, 1196
RT-PCR to quant. CFTR mRNA in endometrium, 1765
Progestogen
health consequences of postmenopausal hormone therapy (S), 1342
Proinsulins
IRMA compared with HPLC, 977
Prorenin
MAb sandwich assays for renin and, 1051
methodology advances and declines (E), 993
Prostaglandins
immunofluorometry: prostaglandin D synthase assay, 1984
LDL oxidn., antioxidants, and atherosclerosis (R), 498
prostaglandin D_2 synthase: fetal abnormalities, 1042
signif. of haptoglobin polymorphism (R), 1589
Prostate-specific antigen
anal. performance of PSA assays compared, 1026
anal. stability: patient data statistics, 893
assay discrepancy in prostate cancer follow-up (CR), 637
in children from birth to age 18 years, 420
concs. in acute illnesses, 1785
"correct" PSA conc. (L), 1882
epitope mapping with MAbs, 1961
IA for PSA complexes with a_2-macroglobulin, 545
immunoacty. in women with breast cancer (L), 1721
immunofluorometric assay for prostatic kallikrein(hK2), 1034
immunofluorometry and Immulite immunochemilum., 675
immunological detect. of tumor cells and micrometastases (R), 1369
immunoreactivity in saliva (TB), 1110
IRMA: for free PSA, 1243
lyophilized PSA-ACT complex is stable (L), 1297
MAb-based fluorometric assays in one-step format (S), 1513
mRNA not always indicative of tumor cells (L), 1499
mRNA and protein detect. in breast tumors, 361
phys. acty. releases, 691
role in discordance across PSA assays (TB), 645
RT-PCR for PSA mRNA in prostatic adenocarcinoma (A), 1892
screening using whole blood spotted on filter paper, 536
sensitivity reports mislead clinicians (O), 849
ultrasensitive assays (O), 853
Prostatic acid phosphatase
PSA: phys. acty. releases, 691
Prostheses
Ti identn. and meas. by ICP-MS and ICP-OES in spleen (TB), 1875
Proteases
trypsinogen: marker of acute pancreatitis in urine, 685
Protein kinase C
PCR detn. of gene expression in limiting tissue samples, 227
Proteins
ELISA: insulin-like growth factor-I, 1147
ELISA: sol. Fas in elderly, 1911
isotope-diln.-MS quant. of apo A-I, 1676
PSA concs. in acute illnesses, 1785
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
serum protein sepn. by capillary electrophoresis (L), 1886
thrombus precursor protein: marker in myocardial infarction (S), 1537
urine protein expert system evaln., 1214
Protoporphyrin
Fe status: correlation or common sense, 718

Pseudouridine
discrimination of hepatocarcinoma and cirrhotic, 1843
Pulmonary disease and function
adenosine deaminase: differentiating tuberculous and nontuberculous effusions, 218
Clara cell protein increased in firefighters (L), 1120
evaln. of refractive-matched anomalous diffraction (RIMAD) for fetal, 1861
smoking effect on pentane excretion in alveolar breath, 303
Purines
HPLC: purine nucleotide products in CSF, 756
hypouricemia in purine nucleoside phosphorylase deficiency (L), 985
6-mercaptopurine: detect. and identn. of, 380
purine nucleoside deficiency: liq. chromatog. of (CR), 326
Pyridinoline
standardization of collagen crosslinks as biochem. markers, 1621
Quality control
anal. stability: patient data statistics, 888
antinuclear test: computer to monitor ability to interpret (S), 836
appln. of process capability indices to (TB), 2035
avg. of normals patient data algorithms, 1683
bilirubin: interlab. variability, 869
COBAS AMPLICOR: DNA and RNA amplifn., 1915
false Li readings from cadavers by flame photometry (L), 1302
FDAs impact on lab. performance (S), 786
folate: material choice for quality control of (L), 652
how to evaluate and implement new technologies (S), 797
IA performance and convenience improvement (E), 1137
impact of converging technologies (R), 1735
ISO 9001 benefits and pitfalls: successful certification (S), 1561
matrix effects and quality control to monitor Po_2 meas., 392
problems and considerations in accuracy with NIST SRM 909a vials, 1832
random access IA: evalg. interassay carryover on, 725
reticulocyte quant. by Coulter MAXM VCS tech., 1930
review of personnel stds. (S), 790
Shewhart *p* chart: monitoring anal. performance of clin. chem. lab, 1478
TSH: specimen carryover influence on assay for, 593
variation in lipids and lipoproteins in fingerstick blood, 2002
what does "functional sensitivity" mean? (L), 2051
why is lab. afterthought for managed care organizations (S), 813
Race-related effects
apo B 3N hypervariable repeat genotype: restriction fragment polymorphisms, 927
leptin: RIA of, 942
Radioassay
folate: results of internatl. round robin for, 1689
Radioimmunoassay
angiotensin peptide research overlooked (L), 1500
Coat-A-Count insulin RIA (L), 777
of C-telopeptides of collagen to assess bone resorption, 1639
diabetes: radioimmunoprecipitation assay for glutamic acid decarboxylase Abs, 1975
extn.-RIA for quant. plasma zalcitabine (TB), 462
growth hormone assays compared, 1789
leptin: RIA of, 942
saliva detn. of dexamethasone, 1238
salt intake effect on excretion of ouabain-like substance: RIA, 1949
thyroglobulin assays: status and performance goals (S), 164
vit. D: quant. by RIA with ^{125}I tracer, 587
Radioligand assay
immunoenzymometric assay for estrogen receptors, 1955
Random access analyzer
evaln. of IAs on Technicon Immuno I, 1695
Receiver-operating characteristics curve
ALP: acty. detd. in patients with bone dis., 210
anal. performance of PSA assays compared, 1026
CHO-deficient transferrin to detect alcohol abuse (L), 2048
comparison of total and bone-specific ALP, 1796
EIA validn. for qual. detect. of cocaine in sweat, 34
evaln. of refractive-matched anomalous diffraction (RIMAD) for fetal lung maturation, 1861
HPLC: purine nucleotide products in CSF, 756
hyaluronan and procollagen markers for liver fibrosis in hepatitis C, 558
myocardial infarction: neural networks to diag., 604
plot presentations (L), 986
pseudouridine discrimination of hepatocarcinoma and cirrhotic ascites, 1843
Receptor binding
immunoenzymometric assay for estrogen receptors, 1955
Reference interval
apo A-1 detd. with immunoturbidimetric assay, 507
apo B detd. with immunoturbidimetric assay, 515
creatine: enzymatic meas. in RBC, 313
immunoadsorption assay compared with agglutinin assay for ALP, 1970
nonthyroidal illness: diag. and monitoring of thyroid dis. (S), 188
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
vit. supplementation: ref. intervals for homocysteine and methylmalonic acid, 630
Reference material
bilirubin: errors in meas., 845
comments on NIST SRM 909a vials (L), 1878
g-glutamyltransferase: evaln. as ref. material, 2008
how useful are (E), 1733
isotope-diln.-MS quant. of apo A-I, 1676
mitochondrial DNA ref. std. for qual. control, medical diag., and mutational detect. (A), 1892
problems and considerations in accuracy with NIST SRM 909a vials, 1832
ref. calibrators for IgG Abs to b_2-glycoprotein I (TB), 1116
Reference methods
cholesterol: 4 test systems evald. by isotope diln. GC-MS, 531
HDL cholesterol: 3 methods for measg., 738
Pb: electron-capture neg. chem. ionization GC/MS, 286
serum total cholesterol: enzymatic step (TB), 475
when is a "ref. method" a "ref. method"? (L), 112
when is serum Fe really serum Fe? (TB), 109
Reference range
BM/Hitachi 747-200 assay for fructosamine, 244
folate: results of internatl. round robin for, 1689
Sarstedt Monovettes falsely increase total Ca (L), 1722
signif. of haptoglobin polymorphism (R), 1589
thyroperoxidase, thyroglobulin, and TSH receptor autoAbs: anal. and clin. performance goals (S), 160
Reference values
glutathione *S*-transferase Alpha 1-1 in gastrointestinal dis.: ELISA, 416
glutathione screening, 64
MAb sandwich assays for renin and prorenin, 1051
thrombus precursor protein: marker in myocardial infarction (S), 1537
Va: quant. by electrothermal AAS, 1275
validn. of HPLC-amperometric detect. to meas. serotonin, 1086
Refractive index
immunosensors: technology and opportunities in lab. med., 193
rhamnose, mannitol, and lactulose quant. in urine, 71
Renal. *See* Kidney
Renin
MAb sandwich assays for prorenin and, 1051
methodology advances and declines (E), 993
Respiratory distress syndrome
evaln. of refractive-matched anomalous diffraction (RIMAD) for fetal lung maturation, 1861
Retinol-binding protein
frozen storage of samples before ELISA (TB), 466
prealbumin, retinol-binding protein, and salivary IgA in children with AIDS (TB), 471
Reviews
actvd. coagulation markers usefulness, 664
immunological detect. of tumor cells and micrometastases, 1369
immunosensors: technology and opportunities in lab. med., 193
impact of converging technologies, 1735
LDL oxidn., antioxidants, and atherosclerosis, 498
metab. of anabolic androgenic steroids, 1001
p53 tumor suppressor gene importance, 858
robotics and changing face of clin. lab., 1901
signif. of haptoglobin polymorphism, 1589
Reye syndrome
clin. studies of drug effects in humans (S), 1306
Rhabdomyolysis
troponins and (L), 1120
Rhamnose
quant. in urine by HPLC for intestinal permeability, 71
Ribozyme
in vivo appln. and empirical design rules of (A), 1893
Risk factors
HDL cholesterol detd. by homogeneous assay, 424
hyperhomocysteinemia and occlusive vascular dis. (E), 492
LDL-cholesterol assay in hyperlipidemic population, 1182
lipoprotein and apo profile changes induced by alcohol consumption and withdrawal, 1666
ref. interval for apo A-1 detd. with, 507
ref. interval for apo B detd. with immunoturbidimetric assay, 515
serum lipids in anabolic steroid users (CR), 970
vit. supplementation: ref. intervals for homocysteine and methylmalonic acid, 630
RNA
detect. of HCV RNA with transcription-mediated amplifn. (A), 1891
detect. of RNA sequences in HCV pos. donors (A), 1892
NASBA for quant. of HIV-1 (A), 1889
quant. and genotyping of HCV (A), 1889
RNase resistant stds. for HIV diagnostics (A), 1890
RNA, messenger
detect. of cells by NASBA amplifn. of cytokeratin 19 (A), 1889
detect. by Si sensor technology (A), 1896
fluorometric detn. of mRNA with oligo(dT), 1758
a-globin mRNA measd. by ELISA and reverse transcription, 1750
immunological detect. of tumor cells and micrometastases (R), 1369
PCR detn. of gene expression in limiting tissue samples, 227
PSA mRNA and protein detect. in breast tumors, 361
RT-PCR combined with fluorometry for detect. of BCR-ABL mRNA, 1924
RT-PCR for PSA mRNA in prostatic adenocarcinoma (A), 1892

RT-PCR to quant. CFTR mRNA in endometrium, 1765
Robotics
changing face of clin. lab. (E), 1899
robotics and changing face of clin. lab. (R), 1901
Saliva
dexamethasone detn. in, 1238
prealbumin, retinol-binding protein, and salivary IgA in children with AIDS (TB), 471
PSA: immunoreactivity in (TB), 1110
reagent stick measures serum ethanol (L), 985
Sample handling
aminoglycosides: absorption by barrier gels in tubes (TB), 771
Abs against testosterone (L), 2047
axial centrifn., 402
Ca: evaln. of sampling and storage procedures (TB), 468
delivering clin. lab. services to ICUs, 387
digoxin: nighttime dosing and therapeutic drug monitoring of, 45
evaln. of Du Pont axial sepn. system, 1467
IRMA kit for measg. atrial natriuretic peptides, 1627
pentosidine urine quant. by HPLC with column switching, 1439
phenotype-genotype discrepancies at apo E locus, 1817
preanal. considerations in testing thyroid function (S), 125
proficiency testing: serum from single donations: assessment of (TB), 469
ref. materials: how useful are they (E), 1733
retinol-binding protein: frozen storage of samples before ELISA (TB), 466
sample retrieval and turnaround time with spreadsheet (S), 1571
standardization of cytokeratin-related tumor marker CYFRA21.1, 1634
stool sampling delay and fecal occult blood test (TB), 1107
TNF-a: CSF shelf life and activn. energy, 670
TSH: specimen carryover influence on assay for, 593
variation in lipids and lipoproteins in fingerstick blood, 2002
variation in metalloproteinases and their inhibitors (TB), 2043
whole blood extn. of DNA (TB), 1285
Sample preparation
digitalis-like factors: placenta radioreceptor assay with digoxin and ouabain, 270
IAs for small molecules: wash steps and multiple binding (S), 1527
lyophilized PSA-ACT complex is stable (L), 1297
PCR detn. of gene expression in limiting tissue samples, 227
prep. of samples with equally spaced concs., 1074
RBC polyglutamyl folate enzymatic deconjugation, 1847
TLC: anal. of drugs in multiple urines (S), 1570
validn. of HPLC-amperometric detect. to meas. serotonin, 1086
San Diego Conference Poster Abstracts 1996, 1889
Screening
diagnostic value of serum Abs in celiac dis., 1838
PSA epitope mapping with MAbs, 1961
fluorometric quant. of urinary xanthurenic acid, 397
HDL cholesterol detd. by homogeneous assay, 424
hemoglobinopathies: neonate HPLC screening, 704
homocystinuria diag. from newborn blood spots by MS-MS, 349
HPLC screening method for cystinuria (TB), 1714
hypouricemia in purine nucleoside phosphorylase deficiency (L), 985
neonate hemoglobinopathies (E), 658
newborn screening by (MS-MS) (E), 345
Pb in children (L), 983
PSA: screening using whole blood spotted on filter paper, 536
Screening, drug
alum effect on methamphetamine screening tests (L), 1720
athletic drug testing and anabolic steroids (E), 999
false-neg. results with Emit amphetamine kit (L), 1726
false-pos. results for urine amphetamine and opiate IAs (L), 1725
glutathione: large-scale study, 64
nonthyroidal illness: diag. and monitoring of thyroid dis. (S), 188
Screening, genetic
HIV-1: fluorometric detect. of, 696
screening for aspartylglucosaminuria mutations, 1398
Sensors
biosensors for monitoring urea during dialysis, 1079
thiocyanate interference on electrochem. biosensors for glucose (L), 1124
Serotonin
lab. testing for recent alcohol consumption, 618
validn. of HPLC-amperometric detect. to meas., 1086
Sex-and age-related effects
ELISA: sol. Fas in elderly, 1911
leptin: RIA of, 942
modern concepts of primary thyroid gland failure (S), 179
physiological variations in thyroid hormones (S), 135
vit. supplementation: ref. intervals for homocysteine and methylmalonic acid, 630
Sex-related effects
immunoadsorption assay compared with agglutinin assay for ALP, 1970
PSA: immunoreactivity in saliva (TB), 1110
Sex-related differences
platelet meas. of Mg with variables, 744
PSA in children from birth to age 18 years, 420
Sickle cell disease
hemoglobinopathies: neonate HPLC screening, 704
liq. chromatog.: (Hb Chicago) (TB), 774
Sirolimus (rapamycin)
monitoring whole-blood by HPLC with UV detect, 1943
quant. in kidney graft recipients by HPLC/electrospray MS, 1417
Smoking
cigarette consumption and Lp(a) concs. (L), 479
effect on pentane excretion in alveolar breath, 303
increased endothelin-1 after (L), 483
LDL oxidn. in smokers, 524
Sodium
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
salt intake effect on excretion of ouabain-like substance: RIA, 1949
Sodium pump
detect., 1654
inhibit. of Na, K-ATPase by oleandrin and oleandrigenin: digoxin IA reduced form of digoxin-like immunoreactive factor, 1092
Software reviews
Astute Statistics Add-in for Microsoft Excel for Windows, 1887
Clinical Cases Computer Aided Learning: Thyroid disorders, 118
Mosby's Diagnostic and Laboratory Tests Infobase, 118
Special reports
changing environment for practice of clin. chem., 91
clin. chem. future and role in healthcare, 96
logical observation identifier names and codes (LOINC) database, 81
Spectrofluorometry
spectrofluorometric detn. of PABA and PASA by Tb-sensitized luminescence, 1659
Spectrometry
immunosensors: technology and opportunities in lab. med., 193
lipid detn. by Fourier transform infrared, 2015
Ti identn. and meas. by ICP-MS and ICP-OES in spleen (TB), 1875
Spectrophotometry
automated assay for plasma, 1210
detn. of urinary I⁻: flow-injection anal., 2021
liposome IA for colorimetry of IgG anticardiolipin Abs, 874
Sphingomyelin
phospholipid fatty acids in X-linked adrenoleukodystrophy (CR), 454
Spinal cord
DNA EIA for detect. deletions in spinal muscular atrophies (TB), 643
Sports medicine
athletic drug testing and anabolic steroids (E), 999
metab. of anabolic androgenic steroids (R), 1001
serum lipids in anabolic steroid users (CR), 970
troponin I immunoenzymometric assay in triathlon (TB), 2033
Standardization
anal. performance of free and total T_4 assays (S), 146
changing face of clin. lab. (E), 1899
cholesterol: 4 test systems evald. by isotope diln. GC-MS, 531
collagen crosslinks as biochem. markers, 1621
cytokeratin-related tumor marker CYFRA21.1, 1634
g-glutamyltransferase: evaln. as ref. material, 2008
heparin: anti-Xa acty. of low-molec. wt., 1223
homocysteine: light sensitivity of sulfonic acid derivative in assay of, 2028
importance in lipase assays by using calibrators, 1979
isotope-diln.-MS quant. of apo A-I, 1676
problems and considerations in accuracy with NIST SRM 909a vials, 1832 ref. interval for apo A-1 detd. with immunoturbidimetric assay, 507
ref. interval for apo B detd. with immunoturbidimetric assay, 515
relation between no. of apo(a) kringle 4 repeats and isoform mobility, 436
robotics and changing face of clin. lab. (R), 1901
stds. of lab practice symposium on thyroid-function testing (S), 119
stds. required for quant. of skeletal ALP (L), 480
thyroglobulin assays: status and performance goals (S), 164
thyroperoxidase, thyroglobulin, and TSH receptor autoAbs: anal. and clin. performance goals (S), 160
TSH assays: status and performance goals (S), 140
Statistics
anal. stability: patient data statistics, 888
analyte and label binding assay read by flow cytometry, 1702
blood viscosity and biochem. correlates in healthy adults, 1189
CA 15.3, CEA, and tissue polypeptide for breast cancer monitoring, 564
EIA validn. for qual. detect. of cocaine in sweat, 34
hepatocellular carcinoma and cirrhosis differentiation, 1263
IA: meas. of smallest analyte conc., 893
isotope-diln.-MS quant. of apo A-I, 1676
lipid detn. by Fourier transform infrared spectrometry, 2015
lipoprotein cholesterol: comparing conventional methods with HPGC, 1996
lipoproteins: prostate cancer and hormone effect on, 1176
matrix effects and quality control to monitor Po_2 meas., 392
myocardial infarction: neural networks to diag., 604
near-infrared reflectance of fecal CHOs, 309
preanal. condition effect on FT_4 and T_3 (L), 1124
precision profiles to eval. leukocyte differential, 1068

prep. of samples with equally spaced concs., 1074
PSA: screening using whole blood spotted on filter paper, 536
random access IA: evalg. interassay carryover on, 725
renal function effect on NO concs., 440
reproducibility of 1-h 50-g glucose challenge test, 255
sensitivity of CK-MB2, CK-MB, and myoglobin in myocardial infarction, 1454
Shewhart *p* chart: monitoring anal. performance of clin. chem. lab, 1478
tacrolimus metabolite patterns from liver and kidney transplants, 1426
vit. E supplementation in hyperthyroidism (TB), 1118

Steroid hormones
PSA in children from birth to age 18 years, 420
steroid hormone anal. using improved HPLC (TB), 979

Steroids
athletic drug testing and anabolic (E), 999
metab. of anabolic androgenic (E), 1001
mutation detect. in *CYP21B* in steroid 21-hydroxylase deficiency (TB), 1108

Sulfite oxidase
screening with urinary thiosulfate/sulfate ratios (L), 654

Sweat
EIA validn. for qual. detect. of cocaine in, 34

Systemic lupus erythematosus
actvd. coagulation markers usefulness (R), 664

Tachykinins
two immunometric assay approaches for haptens (S), 1532

Tacrolimus
liq. chromatog.-electrospray MS-MS of, 279
metabolite patterns from liver and kidney transplants, 1426

Telemedicine
telepathology to improve patient care (S), 831

Testosterone
Abs against (L), 2047
Ciba Corning ACS:180 testosterone evald., 1445
cortisol: effect on percentage of non-sex-hormone-bound steroid, 249
IA compared with neg. chem. ionization GC-MS, 749
metab. of anabolic androgenic steroids (R), 1001
serum lipids in anabolic steroid users (CR), 970

Thalassemia
HbS influence on HbA quant. by HPLC (TB), 1113
sequence identn. of alpha (A), 1892

Thalidomide
clin. studies of drug effects in humans (S), 1306

Therapeutic drug monitoring
role of clin. toxicologist in court (S), 1337
sirolimus quant. in kidney graft recipients by HPLC/electrospray MS, 1417
tacrolimus metabolite patterns from liver and kidney transplants, 1426
toxic effects of immunosuppressive drugs (S), 1316

Thiocyanate
concs. in patients receiving nitroprusside (L), 1878
interference on electrochem. biosensors for glucose (L), 1124
interference in Nova Stat Profile anal. (L), 483

Thioridazine
interference in identn. of phencyclidine (L), 1885

Thiouric acid
6-mercaptopurine: detect. and identn. of, 380

Thrombocytopenia
amrinone: HPLC in patients on cephalosporin, 761

Thrombosis
actvd. coagulation markers usefulness (R), 664

Thyroglobulin
autoAb meas. (E), 661
lab. testing for diag. and monitoring of thyroid dis. (S), 183
thyroglobulin assays: status and performance goals (S), 164
thyroglobulin IRMA and autoAb interference, 258

Thyroid disease and function
gradient gel electrophoresis to diag. endocrine neoplasia, 598
lab. testing for diag. and monitoring of thyroid dis. (S), 183
modern concepts of primary thyroid gland failure (S), 179
nonthyroidal illness: diag. and monitoring of thyroid dis. (S), 188
preanal. considerations in testing thyroid function (S), 125
scope and impact of thyroid dis. (S), 121
stds. of lab practice symposium on thyroid-function testing (S), 119
T_3: usage recommendations and anal. performance goals (S), 155
thyroglobulin assays: status and performance goals (S), 164
thyroglobulin autoAb meas. (E), 661
thyroglobulin ELISA: autoAb interference, 766
thyroglobulin IRMA and autoAb interference, 258
thyroid status in thyrotoxicosis (S), 174
thyroperoxidase, thyroglobulin, and TSH receptor autoAbs: anal. and clin. performance goals (S), 160
troponin I in hypothyroidism (TB), 1494
vit. E supplementation in hyperthyroidism (TB), 1118

Thyroid hormones
physiological variations in (S), 135
thyroid status in thyrotoxicosis (S), 174

Thyroid-stimulating hormone (thyrotropin)
lab. testing for diag. and monitoring of thyroid dis. (S), 183
lumin. O_2 channeling assay (LOCI)^{J} (S), 1518
modern concepts of primary thyroid gland failure (S), 179
nonthyroidal illness: diag. and monitoring of thyroid dis. (S), 188
physiological variations in thyroid hormones (S), 135
preanal. considerations in testing thyroid function (S), 125
specimen carryover influence on assay for, 593
thyroglobulin assays: status and performance goals (S), 164
thyroid status in thyrotoxicosis (S), 174
TSH assays: status and performance goals (S), 140
what does "functional sensitivity" mean? (L), 2051

Thyroxine
anal. performance of free and total T_4 assays (S), 146
concs. measd. by equil. dialysis in renal failure, 1616
magnum automated T-uptake assay (L), 342
modern concepts of primary thyroid gland failure (S), 179
preanal. condition effect on FT_4 and T_3 (L), 1124
preanal. considerations in testing thyroid function (S), 125
two immunometric assay approaches for haptens (S), 1532

Titanium
Ti identn. and meas. by ICP-MS and ICP-OES in spleen (TB), 1875

Tocopherol
LDL oxidn., antioxidants, and atherosclerosis (R), 498
quant. of LDL and HDL, 430

Toxicology
advances in poison management (S), 1361
anal. of benzodiazepines by HPLC with solid-phase extn., 1412
As accumulation in renal dis., 1231
clin. evaln. of poisoned patient toxic syndromes (S), 1350
dysHbs discrimination (L), 1300
ethylene glycol and glycolic acid: gas chromatog. of, 293
evalg. impact of exposure to environmental contaminants (S), 1345
health consequences of postmenopausal hormone therapy (S), 1342
HPLC with fluorometric detect. of Al-lumogallion complex, 1405
inhibit. of Na, K-ATPase by oleandrin and oleandrigenin: digoxin IA detect., 1654
methotrexate: concepts in use of high-dose therapy (S), 1322
nephelometric detn. of CHO-deficient transferrin, 551
Pb: electron-capture neg. chem. ionization GC/MS, 286
pediatric poisonings (S), 1356
role of clin. toxicologist in court (S), 1337
thiocyanate concs. in patients receiving nitroprusside (L), 1878
thiocyanate and cyanide interference in glucose assay (CR), 449
titrating cardiovascular drugs (S), 1312
toxic effects of immunosuppressive drugs (S), 1316

Transferases
ELISA: glutathione *S*-transferase Alpha 1-1 in gastrointestinal dis., 416
g-glutamyltransferase: evaln. as ref. material, 2008
hepatocellular carcinoma and cirrhosis differentiation, 1263

Transferrin
CHO-deficient transferrin to detect alcohol abuse (L), 2048
nephelometric detn. of CHO-deficient, 551
total Fe-binding capacity in evaln. of Fe status (L), 2053

Transplantation
ALP: acty. detd. in patients with bone dis., 210
CsA monitoring in posttransplant period (TB), 1294
sirolimus quant. in kidney graft recipients by HPLC/electrospray MS, 1417
tacrolimus metabolite patterns from liver and kidney transplants, 1426
toxic effects of immunosuppressive drugs (S), 1316

Triglycerides
blood viscosity and biochem. correlates in healthy adults, 1189
cholesterol: meas. variability of LDL, 732
HDL cholesterol: 3 methods for measg., 738
LDL-cholesterol assay in hyperlipidemic population, 1182
LDL oxidn. in smokers, 524
microenzymatic assay of triglycerides, phospholipids and cholesterol, 915
Paramax reagent: lactate and LDH interferences (L), 778
serum lipids and vit. E variability in serum concs., 1824
variation in lipids and lipoproteins in fingerstick blood, 2002

Triiodothyronine
3 labeled-Ab IAs of FT_3, 933
FT_4 concs. measd. by equil. dialysis in renal failure, 1616
nonthyroidal illness: diag. and monitoring of thyroid dis. (S), 188
physiological variations in thyroid hormones (S), 135
preanal. condition effect on FT_4 and (L), 1124
usage recommendations and anal. performance goals (S), 155

Troponins
cardiac troponin I in hypothyroidism (TB), 1494
cardiac troponin I and LDH isoenzyme sensitivity in myocardial infarction, 1770
cardiac troponin I and T in chronic myopathy (TB), 2039
cardiac troponin T as marker in acute myocarditis (L), 340
cardiac troponin T marker for cardiac ischemia (S), 803
cardiac troponin T in those with high creatinine concs. but normal CK acty. (TB), 474

cardiac troponins in chronic renal failure (L), 114
coronary artery bypass grafting and (L), 781
false-neg. IA for troponin I and autoAbs (L), 2046
myocardial infarction: fluoroenzymometric method to meas. troponin I, 1460
prognostic value in chest pain (L), 651
rhabdomyolysis and (L), 1120
troponin I immunoenzymometric assay in triathlon (TB) 2033

Trypsinogen
marker of acute pancreatitis in urine, 685

Tryptophan
clin. studies of drug effects in humans (S), 1306

Tuberculosis. *See also Mycobacterium tuberculosis*
adenosine deaminase: differentiating tuberculous and nontuberculous effusions, 218

Tumor markers
Abbott IMx CA 15-3 assay evaln., 28
CA 15.3, CEA, and tissue polypeptide for breast cancer monitoring, 564
CA-125 concs. as marker for endometriosis (TB), 1871
immunological detect. of tumor cells and micrometastases (R), 1369
immunoluminometric assay for CA 72-4 (TB), 472
IRMA: for free PSA, 1243
PSA concs. in acute illnesses, 1785
PSA immunofluorometry and Immulite immunochemilum., 675
serum lipase without pancreatitis (CR), 462
standardization of cytokeratin-related tumor marker CYFRA21.1, 1634

Tumor necrosis factor
CSF shelf life and activn. energy, 670
ELISA: sol. Fas in elderly, 1911
TNF-a receptors interfere with detect. of TNF-a, 1450

Tumor suppressor genes
p53 tumor suppressor gene importance (R), 858

Turbidimetry
lipase assay: standardization importance using calibrators, 1979

Tyrosinase
immunological detect. of tumor cells and micrometastases (R), 1369

Ultrafiltration
discrepancies in myoglobin recovery from urine, 965

Urea
biosensors for monitoring urea during dialysis, 1079
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855

Urease
biosensors for monitoring urea during dialysis, 1079

Uric acid
bilirubin interference with lactate, P, and (L), 988
HPLC: purine nucleotide products in CSF, 756

Urine
Au overstaining enhances electrophoresis of urine (TB), 1293
Ca interference in meas. of microalbumins (TB), 332
digitalis-like factors: placenta radioreceptor assay with digoxin and ouabain, 270
Ektachem 250 testing of Na, K, Ca, urea, and creatinine (TB), 105
false-pos. results for urine amphetamine and opiate IAs (L), 1725
fluorometric quant. of urinary xanthurenic acid, 397
GC-MS profiling of urinary organic acids, 1609
lab. testing for recent alcohol consumption, 618
leukodystrophy: urine sulfatides and diag. of, 232
meas. for hydroxyproline and deoxypyridinoline (TB), 2037
methamphetamine: interference of alum (L), 338
methotrexate: concepts in use of high-dose therapy (S), 1322
methylmalonic acid quant. by GC-MS, 910
NH_4 persulfate: oxidizing reagent for urinary I^-, 239
org. acid detn. in screening org. acidurias (TB), 477
pentosidine urine quant. by HPLC with column switching, 1439
prostaglandin D synthase assay: immunofluorometry, 1984
purine nucleoside deficiency: liq. chromatog. of (CR), 326
renal function: ref. intervals for 10 biochem. markers in fetal urine, 1855
rhamnose, mannitol, and lactulose quant. in urine, 71
RIA of C-telopeptides of collagen to assess bone resorption, 1639
salt intake effect on excretion of ouabain-like substance: RIA, 1949
spectrofluorometric detn. of PABA and PASA by Tb-sensitized luminescence, 1659
spectrophotometric detn. of urinary I^-: flow-injection anal., 2021
standardization of cytokeratin-related tumor marker CYFRA21.1, 1634
sulfite oxidase: screening with urinary thioSO_4/SO_4 ratios (L), 654
TLC: anal. of drugs in multiple urines (S), 1570
trypsinogen: marker of acute pancreatitis in, 685
ultrafiltration discrepancies in myoglobin recovery from urine, 965
urine protein expert system evaln., 1214
validn. of HPLC-amperometric detect. to meas. serotonin, 1086

Vanadium
quant. by electrothermal AAS, 1275

Variation, source of
3 labeled-Ab IAs of FT_3, 933
anal. performance of free and total T_4 assays (S), 146
bilirubin: interlab. variability, 869
cardiac troponin I and T in chronic myopathy (TB), 2039
evaln. of Du Pont axial sepn. system, 1467
folate: results of internatl. round robin for, 1689
GC-MS profiling of urinary organic acids, 1609
immunoadsorption assay compared with agglutinin assay for ALP, 1970
ion-selective electrode stability: AVL and Nova Mg and Ca, 880
lipids and lipoproteins in fingerstick blood, 2002
metabolite and matrix interference in phenytoin IAs, 1645
in metalloproteinases and their inhibitors (TB), 2043
platelet meas. of Mg with variables, 744
preanal. considerations in testing thyroid function (S), 125
PSA: ultrasensitive assays (O), 853
reproducibility of 1-h 50-g glucose challenge test, 255
serum lipids and vit. E variability in serum concs., 1824
stability of cysteine and blood glutathione, 1100
T_3: usage recommendations and anal. performance goals (S), 155
thyroglobulin ELISA: autoAb interference, 766
thyroglobulin IRMA and autoAb interference, 258

Vascular disease
homocysteinemia as risk factor for occlusive (E), 492

Venous thrombosis
G1691A mutation of coagulation factor V by PCR (TB), 329

Vitamin B_6
fluorometric quant. of urinary xanthurenic acid, 397

Vitamin B_{12}
methylmalonic acid quant. by GC-MS, 910

Vitamin D
interference with calcipotriol on IDS RIA for vit. D (L), 112
quant. by RIA with ^{125}I tracer, 587

Vitamin E
serum lipids and variability in serum concs., 1824
supplementation in hyperthyroidism (TB), 1118
a-tocopherol: quant. of LDL and HDL, 430

Vitamins
vit. supplementation: ref. intervals for homocysteine and methylmalonic acid, 630

von Willebrand factor
comparison with plasminogen activator concs. (TB), 976

Warfarin
titrating cardiovascular drugs (S), 1312

Wine
antioxidant acty. of resveratrol in red wine (L), 113

Xanthines
HPLC: purine nucleotide products in CSF, 756

Xanthurenic acid
fluorometric quant. of urinary xanthurenic acid, 397

Xenobiotics
evalg. impact of exposure to environmental contaminants (S), 1345

Zalcitabine
extn.-RIA for quant. plasma (TB), 462

Zinc
metal excretion and Mg retention in those treated with IV EDTA, 1938